

Chulalongkorn University

## Chula Digital Collections

---

Chulalongkorn University Theses and Dissertations (Chula ETD)

---

2023

### Development of duplex loop-mediated isothermal amplification (dLAMP) for detection of carbapenem antibiotic-resistant genes KPC and NDM

Nindi Syahputri Lubis  
*Faculty of Science*

Follow this and additional works at: <https://digital.car.chula.ac.th/chulaetd>



Part of the [Microbiology Commons](#)

---

#### Recommended Citation

Lubis, Nindi Syahputri, "Development of duplex loop-mediated isothermal amplification (dLAMP) for detection of carbapenem antibiotic-resistant genes KPC and NDM" (2023). *Chulalongkorn University Theses and Dissertations (Chula ETD)*. 10432.  
<https://digital.car.chula.ac.th/chulaetd/10432>

This Thesis is brought to you for free and open access by Chula Digital Collections. It has been accepted for inclusion in Chulalongkorn University Theses and Dissertations (Chula ETD) by an authorized administrator of Chula Digital Collections. For more information, please contact [ChulaDC@car.chula.ac.th](mailto:ChulaDC@car.chula.ac.th).

Development of duplex loop-mediated isothermal amplification  
(dLAMP) for detection of carbapenem antibiotic-resistant genes  
*KPC* and *NDM*

Miss Nindi Syahputri Lubis



A Thesis Submitted in Partial Fulfillment of the Requirements  
for the Degree of Master of Science in Microbiology and Microbial  
Technology  
Department of Microbiology  
Faculty Of Science  
Chulalongkorn University  
Academic Year 2023

การพัฒนาอุปกรณ์ไอโซเทอร์มอลแอมพลิฟิเคชันแบบคู่ (dLAMP) สำหรับการตรวจหา  
ยีน KPC และ NDM ที่ติดต่อயาคาร์บาเพแนม



วิทยานิพนธ์นี้เป็นส่วนหนึ่งของการศึกษาตามหลักสูตรปริญญาวิทยาศาสตรมหาบัณฑิต  
สาขาวิชาจุลชีววิทยาและเทคโนโลยีจุลินทรีย์ ภาควิชาจุลชีววิทยา  
คณะวิทยาศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย  
ปีการศึกษา 2566

Thesis Title	Development of duplex loop-mediated isothermal amplification (dLAMP) for detection of carbapenem antibiotic-resistant genes <i>KPC</i> and <i>NDM</i>
By	Miss Nindi Syahputri Lubis
Field of Study	Microbiology and Microbial Technology
Thesis Advisor	Associate Professor NARAPORN SOMBOONNA, Ph.D.

---

Accepted by the FACULTY OF SCIENCE, Chulalongkorn University in  
Partial Fulfillment of the Requirement for the Master of Science

..... Dean of the FACULTY OF  
SCIENCE  
(POLKIT SANGVANICH)

THESIS COMMITTEE

..... Chairman  
(Associate Professor CHULEE YOMPAKDEE, Ph.D.)  
..... Thesis Advisor  
(Associate Professor NARAPORN SOMBOONNA,  
Ph.D.)  
..... Examiner  
(CHONCHANOK MUANGNAPOH, Ph.D.)  
..... External Examiner  
(Anunchai Assawamakin, Ph.D.)

จุฬาลงกรณ์มหาวิทยาลัย  
CHULALONGKORN UNIVERSITY

นินติ ชยาปุตริ ลูบิส : การพัฒนาลูปเมดิเอเตดไอโซเทอร์มอลแอมพลิฟิเคชันแบบคู่ (dLAMP) สำหรับการตรวจหา ยีน *KPC* และ *NDM* ที่คือต่อยาคาร์บาเพเนม. ( Development of duplex loop-mediated isothermal amplification (dLAMP) for detection of carbapenem antibiotic-resistant genes *KPC* and *NDM*) อ.ที่ปรึกษาหลัก : นราพร สมบูรณ์นะ

การใช้ยาปฏิชีวนะอย่าง Carbapenems ถือเป็นทางเลือกสุดท้ายในการรักษาการติดเชื้อจากแบคทีเรียที่แกรมบวกและแกรมลบ ในปัจจุบันพบยีนที่ต้านการใช้ Carbapenems เพิ่มขึ้นในผู้ป่วย พบว่ามีหลายปัจจัยที่เกี่ยวข้อง เช่น การพักรักษาที่โรงพยาบาลเป็นเวลานาน, มีประวัติการใช้ยาปฏิชีวนะ, การรักษาด้วยยาปฏิชีวนะที่ไม่เหมาะสมหรือไม่เพียงพอ, และการปนเปื้อนจากการผ่าตัดหรือบาดแผลจากการผ่าตัด ในปี 2005 carbapenem-resistant genes (CR genes) ได้รับความสนใจเป็นอย่างมาก เนื่องจากยีนเหล่านี้มี plasmid หรือ transposons ที่สามารถถูกแพร่ไปยังเชื้อแบคทีเรียอื่นๆ ได้ *Klebsiella pneumoniae carbapenemase (KPC)* and *New delhi metallo-β-lactamase (NDM)* เป็นยีนในกลุ่ม CR ที่พบมากที่สุดทั้งในประเทศแถบเอเชียตะวันออกเฉียงใต้และทั่วโลก ยีนเหล่านี้มี 123 และ 43 ชนิดย่อย สำหรับ *KPC* และ *NDM* ตามลำดับ ดังนั้น ในงานวิจัยนี้มีวัตถุประสงค์เพื่อพัฒนาเทคนิคลูปเมดิเอเตดไอโซเทอร์มอลแบบยีนเดี่ยว (LAMP) และสองยีน (dLAMP) ร่วมกับสีย้อม HNB ที่มีความจำเพาะต่อยีน *KPC* และ *NDM* รวมถึงชนิดย่อยๆ ของสองยีน ที่มีการแพร่กระจายไปทั่วโลกมากที่สุดในกลุ่ม CR การตรวจจับสำหรับยีนเดี่ยวสามารถทำได้ในสภาวะที่เหมาะสม นั่นคือ 65 องศาเซลเซียส เป็นเวลา 55 นาที และเมื่อใช้ร่วมกับสีย้อม HNB สังเกตการเปลี่ยนแปลงของสีจากสีม่วง (ผลลบ) เป็นสีฟ้า (ผลบวก) ด้วยความเข้มข้นของ  $MgSO_4$  และ HNB ที่เหมาะสม นั่นคือ 6.5 มิลลิโมลาร์ และ 180 มิลลิโมลาร์ ตามลำดับ ซึ่งยืนยันผลด้วยการสังเกตการดูดกลืนของแสงที่ความยาวคลื่น 650 นาโนเมตร นอกจากนี้เมื่อตรวจจับด้วยเทคนิค PCR พบว่าไพรเมอร์ที่ออกแบบมีความจำเพาะต่อยีน *KPC* และ *NDM* และความไวของการทดสอบที่พัฒนาขึ้นในการตรวจจับทั้งสองยีนมีความไวสูงถึงสิบเท่าเมื่อเทียบกับ PCR สามารถอ่านผลได้ภายในเวลาไม่ถึงหนึ่งชั่วโมง



สาขาวิชา จุลชีววิทยาและเทคโนโลยีจุลินทรีย์  
ปีการศึกษา 2566

ลายมือชื่อนิสิต .....  
ลายมือชื่อ อ.ที่ปรึกษาหลัก .....

# # 6478005223 : MAJOR MICROBIOLOGY AND MICROBIAL TECHNOLOGY

KEYWORD Carbapenems, Carbapenem-resistant genes, *Klebsiella pneumoniae*  
D: Carbapenemase (KPC), New Delhi Metallo  $\beta$ -lactamase (NDM)

Nindi Syahputri Lubis : Development of duplex loop-mediated isothermal amplification (dLAMP) for detection of carbapenem antibiotic-resistant genes *KPC* and *NDM*. Advisor: Assoc. Prof. Dr. NARAPORN SOMBOONNA, Ph.D.

Carbapenems are regarded as a last-resort option for treating a wide range of Gram-positive and Gram-negative bacterial infections. Unfortunately, the prevalence of carbapenem-resistant genes has been on the rise among patients. Some factors contribute to this trend, including prolonged hospital stays, prior antibiotic usage, inappropriate or insufficient antibiotic treatment, and contamination through wounds or feces. The emergence of carbapenem-resistant (CR) genes gained significant attention, particularly after 2005. These CR genes are frequently carried on mobile genetic elements such as plasmids or transposons, enabling their transmission to other bacteria. *Klebsiella pneumoniae* carbapenemase (*KPC*) and *New delhi metallo- $\beta$ -lactamase* (*NDM*) stand out as the most prevalent CR genes, both in Southeast Asian countries and worldwide. These genes exhibit numerous subtypes, with 123 and 43 subtypes for *KPC* and *NDM*, respectively. Hence, in this study, our focus was on *KPC* and *NDM* as the most widespread CR genes that have been responsible for numerous global outbreaks in recent times. We developed universal primers for *KPC* and *NDM* genes, aiming to detect the subtypes using loop-mediated isothermal amplification (LAMP) techniques. Additionally, we developed a duplex-LAMP assay which is capable of simultaneously detecting both genes in a single reaction. As a result, the developed dLAMP can detect *KPC* and *NDM* in a single reaction using an optimum temperature and incubation time of 55 minutes at 65°C temperature. For visualization, using hydroxyl naphthol blue (HNB) which changed from violet (negative) to blue (positive). With optimum  $\text{MgSO}_4$  and HNB concentration, 6.5 mM, and 180 mM, showed the highest absorbance at 650 nm. The developed universal primers *KPC* and *NDM* proved to be specific only for detecting both genes using PCR. Furthermore, the sensitivity of developed dLAMP in the detection of both genes was ten times higher compared to traditional PCR with approximately 1 hour to determine the positive results of dLAMP.

Field of Study:	Microbiology and Microbial Technology	Student's Signature .....
Academic Year:	2023	Advisor's Signature .....

## ACKNOWLEDGEMENTS

I would like to express my most profound appreciation to my advisor Assoc. Prof. Naraporn Somboonna for her enthusiastic guidance during the planning, implementation, discussion, and study performance.

To my late Father Andi Sangkot Lubis, my Mother Nauliani Sinaga, My Sister Dr. Anisa Rilla Lubis, my brothers Nanda Syahputra Lubis and Chairul Zall Lubis, for your unconditional love and encouragement that sustained me during the challenging moments of this academic endeavor. Your belief in my abilities fueled my determination to see this project through to completion.

I gratefully acknowledge the assistance of Dr. Rungdawan Wongsamart, Natkamol Thoraneenitiyan, for teaching me from the simple thing, and all 2016 Laboratory members.

To my dear friends, Melvalia, Christian, Nando, David, Intan, Maliha, Chutima, Nico, and Luthfia, I am grateful for the camaraderie, intellectual discussions, and shared laughter that made the research process not only productive but enjoyable. Your support created a positive and motivating environment.

I extend my appreciation to the ASEAN-Non-ASEAN scholarship for providing financial support that facilitated the execution of this research. Your investment in academic pursuits is crucial for the advancement of knowledge.

Lastly, to anyone whose name may have inadvertently been omitted, please accept my sincere gratitude. This thesis stands as a collective effort, and I am fortunate to have had the support of such an exceptional network of individuals.

Nindi Syahputri Lubis

# TABLE OF CONTENTS

	<b>Page</b>
.....	iii
ABSTRACT (THAI) .....	iii
.....	iv
ABSTRACT (ENGLISH).....	iv
ACKNOWLEDGEMENTS.....	v
TABLE OF CONTENTS.....	vi
LIST OF TABLES .....	x
LIST OF FIGURES .....	xi
LIST OF ABBREVIATIONS .....	1
CHAPTER I INTRODUCTION.....	2
1.1 Background.....	2
1.2 Study objectives.....	6
1.3 Hypothesis .....	6
CHAPTER II LITERATURE REVIEW .....	7
2.1 Overview of antibiotic resistance and its global impact.....	7
2.1.1 Definition of antibiotic resistance and its mechanisms .....	7
2.1.2 Prevalence and consequences of antibiotic-resistant infections worldwide	
8	
2.1.3 The Economic and healthcare burden of antibiotic resistance .....	10
2.2 Carbapenem antibiotics and their significance in treating infections.....	11
2.2.1 Introduction to carbapenems and their mode of action .....	11
2.2.2 Clinical importance and spectrum of activity of carbapenem antibiotics	13
2.2.3 Challenges in using carbapenems due to the emergence of resistant strains	
14	
2.3 Carbapenem-resistant bacteria and the role of <i>KPC</i> and <i>NDM</i> genes.....	15
2.3.1 Overview of carbapenem-resistant bacteria and their clinical impact .....	15



2.3.2	Mechanisms of carbapenem resistance, with a focus on <i>KPC</i> and <i>NDM</i> genes	16
2.3.3	Epidemiology and prevalence of <i>KPC</i> - and <i>NDM</i> -producing bacteria	17
2.4	Current diagnostic methods for detecting carbapenem-resistant genes	19
2.4.1	Conventional phenotypic methods for carbapenem resistance detection	19
a.	Disk diffusion method	19
b.	Broth microdilution method	19
c.	Etest method	19
d.	Modified hodge test (MHT)	20
e.	Carba NP test	20
2.4.2	Molecular techniques, such as PCR and real-time PCR, for identifying <i>KPC</i> and <i>NDM</i> genes	20
2.4.3	Limitations and challenges of current diagnostic approaches	21
2.5	Loop-mediated isothermal amplification (LAMP) as a molecular diagnostic tool	23
2.5.1	Introduction to LAMP and its principles of operation	23
2.5.2	Advantages of LAMP over traditional PCR-based methods	25
2.5.3	Previous applications of LAMP in detecting antibiotic-resistant genes and its limitation	26
2.6	Duplex LAMP (dLAMP) for simultaneous detection of multiple genes	28
2.6.1	Explanation of duplex LAMP and its capacity to detect two target genes	28
2.6.2	Review of studies using dLAMP in various molecular diagnostic applications	29
2.6.3	Potential benefits of using dLAMP for simultaneous detection of <i>KPC</i> and <i>NDM</i> genes	29
2.7	Challenges and limitations of dLAMP in antibiotic-resistant gene detection	30
2.7.1	Factors affecting the specificity and sensitivity of dLAMP assays	30
2.7.2	Comparison of dLAMP with other multiplex detection methods	31
2.7.3	Strategies to overcome challenges and improve dLAMP performance	33
2.8	The LAMP end point detection	34

CHAPTER III MATERIALS AND METHODS .....	36
3.1 Instruments .....	36
3.2 Chemicals .....	37
3.3 Supplies .....	38
3.4 Kits	38
3.5 Sample collections .....	38
3.6 Primer design for universal <i>KPC</i> and <i>NDM</i> dLAMP .....	39
3.7 <i>KPC</i> and <i>NDM</i> PCR detection with specificity and sensitivity test.....	39
3.8 The detection of <i>KPC</i> and <i>NDM</i> genes using Single LAMP (sLAMP) .....	40
3.9 sLAMP optimization .....	41
3.10 The detection of <i>KPC</i> and <i>NDM</i> using duplex LAMP (dLAMP) .....	41
3.11 dLAMP optimization.....	41
a. The intensity value of dLAMP using ImageJ software .....	42
b. dLAMP product yield using spectrophotometer .....	42
3.12 MgSO <sub>4</sub> and HNB concentration optimization.....	42
3.14 Statistical analysis .....	43
CHAPTER IV RESULTS .....	44
4.1 Targeted DNA sequences of <i>KPCs</i> and <i>NDMs</i> carbapenem-resistant (CR) genes	44
4.2 Specificity check result of <i>KPCs</i> and <i>NDMs</i> DNA sequences .....	45
4.2.1 <i>KPCs</i> universal DNA sequences .....	45
4.2.2 <i>NDMs</i> universal DNA sequences .....	45
4.3 Universal LAMP primers for <i>KPC</i> and <i>NDM</i> .....	46
4.4 Detection of <i>KPC</i> and <i>NDM</i> genes using Polymerase-chained reaction (PCR)	47
4.5 The detection and optimization of <i>KPC</i> and <i>NDM</i> genes using Single LAMP	
(sLAMP).....	50
4.6 The detection and optimization of <i>KPC</i> and <i>NDM</i> using dLAMP.....	52
4.6.1 The intensity value of dLAMP.....	53
4.6.2 dLAMP product yield.....	55
4.6.3 MgSO <sub>4</sub> and HNB optimization.....	57

CHAPTER V DISCUSSION .....	63
5.1 Targeted DNA sequences of <i>KPCs</i> and <i>NDMs</i> carbapenem-resistant (CR) genes 63	
5.2 Specificity of <i>KPCs</i> and <i>NDMs</i> DNA sequences .....	63
5.3 The universal LAMP primers of <i>KPC</i> and <i>NDM</i> genes .....	63
5.4 Detection of <i>KPC</i> and <i>NDM</i> genes using Polymerase-chained reaction (PCR)	64
5.5 The detection and optimization of <i>KPC</i> and <i>NDM</i> genes using Single LAMP (sLAMP).....	66
CHAPTER VI CONCLUSION .....	69
REFERENCES .....	70
APPENDIX.....	1
A. Subtypes of <i>KPC</i> and <i>NDM</i> .....	1
B. Two-way ANOVA and Multiple comparisons of dLAMP optimization .....	12
C. List of clinical bacterial .....	43
VITA .....	45

## LIST OF TABLES

	<b>Page</b>
Table 1 The universal DNA sequences of KPC and NDM.....	44
Table 2 The list of LAMP primer sets of KPC and NDM .....	46
Table 3 The product yield of dLAMP optimization.....	53
Table 4 The intensity in dLAMP optimization .....	53
Table 5 Two-way ANOVA for the intensity value based on varied temperatures and incubation time.....	54
Table 6 Two-way ANOVA for dLAMP product yield based on varied temperatures and incubation.....	55
Table 7 The two-way ANOVA table result of MgSO <sub>4</sub> and HNB concentration optimization .....	57
Table 8 The one-way ANOVA of MgSO <sub>4</sub> on intensity .....	58
Table 9 The one-way ANOVA of MgSO <sub>4</sub> on product yield.....	58

## LIST OF FIGURES

	<b>Page</b>
Figure 1 Intrinsic mechanisms of resistance .....	7
Figure 2 Chemical structure of Penam and Carbapenem.....	12
Figure 3 The schematic pathway of loop-mediated isothermal amplification (LAMP) .....	24
Figure 4 The specificity of the universal KPC sequence .....	45
Figure 5 The specificity of the universal NDM sequence .....	46
Figure 6 The specificity of the universal primers KPC and NDM .....	47
Figure 7 KPC and NDM PCR detection .....	48
Figure 8 The PCR specificity using clinical bacterial samples.....	49
Figure 9 The PCR sensitivity test .....	50
Figure 10 The two-way ANOVA graph on analysis of sLAMP intensity for temperature optimization .....	51
Figure 11 The temperature and incubation time optimization in dLAMP.....	51
Figure 12 The possible optimum temperatures and incubation time of dLAMP .....	52
Figure 13 The graph summary of temperature and incubation time optimization in dLAMP .....	54
Figure 14 The two-way ANOVA graph for dLAMP intensity .....	55
Figure 15 The two-way ANOVA graph for dLAMP product yield .....	56
Figure 16 The absorbance value for MgSO <sub>4</sub> and HNB optimization .....	57
Figure 17 The reaction tube for MgSO <sub>4</sub> and HNB optimization .....	58
Figure 18 The graph summary of MgSO <sub>4</sub> and HNB concentration optimization .....	59
Figure 19 The varied MgSO <sub>4</sub> and HNB concentration on dLAMP gel electrophoresis result.....	59
Figure 20 The sensitivity of dLAMP KPC .....	60
Figure 21 The sensitivity of dLAMP NDM.....	61
Figure 22 The specificity of dLAMP .....	62

## LIST OF ABBREVIATIONS

CR	Carbapenem-Resistant
CR genes	Carbapenem-Resistant Genes
<i>KPC</i>	<i>Klebsiella pneumoniae</i> Carbapenemase
<i>NDM</i>	New delhi metallo- $\beta$ -lactamase
LAMP	Loop-mediated Isothermal Amplification
dLAMP	Duplex Loop-mediated Isothermal Amplification
HNB	Hydroxyl Naphthol Blue
PCR	Polymerase Chain Reaction
MgSO <sub>4</sub>	Magnesium Sulfate
HNB	Hydroxyl Naphthol Blue
UV-Vis	Ultraviolet-Visible (spectrophotometry)
mm	Millimeter
mM	Millimolar
°C:	Degrees Celsius
DNA	Deoxyribonucleic Acid
RNA	Ribonucleic Acid
PCR	Polymerase Chain Reaction
dNTPs	Deoxynucleotide Triphosphates

## CHAPTER I INTRODUCTION

### 1.1 Background

Antibiotic consumption and usage are increasing annually, provided that unnecessary consumption promotes the increase of antibiotic resistance (Brink, 2019; Browne et al., 2021; WHO, 2019). Carbapenems are derived from beta-lactam antibiotics. This antibiotic is highly effective against aerobic-anaerobic, Gram-positive (GPB), and Gram-negative bacteria (GNB) yet is respected as the last antibiotic treatment choice for severe infections (Falagas et al., 2014). Carbapenems are primarily resistant to  $\beta$ -lactamase hydrolysis, which shows as a “slow substrate” or act as  $\beta$ -lactamase inhibitors yet still target the penicillin-binding proteins (PBPs) of the bacterial cell wall (K. M. Papp-Wallace et al., 2011). Additionally, Carbapenem has a unique molecular structure of beta-lactam ring that provides high stability against  $\beta$ -lactamase, such as ampicillin, carbenicillin (*AmpC*), and extended-spectrum beta-lactamase (Meletis, 2016). The emergence of carbapenem-resistant (CR) genes has been reported, especially after 2005. The reports were particularly on GNB because of the ability of the outer layer structure of GNB pathogens to sense and repair yet protect their cells from being damaged by antibiotic exposure.

Moreover, these CR genes are commonly carried on mobile genetic elements like plasmid or transposon that can be transmitted to other bacteria (Breijyeh et al., 2020; Miller, 2016). For instance, a Carbapenem-resistant Enterobacteriaceae (CRE) outbreak in ICU patients in the USA cost approximately \$275 million, with a 25% attributable mortality in hospitals with a loss of 8841 lives and severe ill combined (Bartsch et al., 2017). General factors that promote CR genes include prolonged hospitalization, prior antibiotic use, inappropriate or inadequate antibiotic therapy,

and contact or object contamination with wounds or stools (Meletis, 2016). Note that the primary factors confer public pressure on CR gene evolution and spread, and the latter factor confers contact with CR gene source bacteria.

Effective mechanisms for CR include enzyme production, efflux pumps, and porin mutations. *Carbapenemase* is the enzyme produced by the pathogen after acquiring CR genes. This enzyme can hydrolyze Carbapenem antibiotics by breaking the  $\beta$ -lactam ring that makes Carbapenem antibiotics lose the ability to degrade the PBP of the bacteria cell wall. The efflux pump is a transporter that allows the bacteria to pump out the Carbapenem antibiotics from their cellular environment. The porin mutation, such as diminished porins, prevents the antibiotic from reaching the cellular environment. Other mechanisms include producing low-affinity PBPs (Armstrong et al., 2021). A high correlation between CR and multidrug (e.g., imipenem) resistance was also reported (Micek et al., 2015; Sader et al., 2019). The reason could be the assembly of resistance genes accumulation on a single plasmid that can be transmitted to other bacteria (Hiroshi Nikaido, 2009). To date, the three most prevalent CR genes that have been reported worldwide distribution are *Klebsiella pneumoniae* carbapenemase (*KPC*), New delhi metallo- $\beta$ -lactamase (*NDM*), and oxacillinase (*OXA*) (Brink, 2019). Of these, *KPCs* represent the most found CR gene cases, mainly in China, Vietnam, Thailand, the United States, Italy, and most regions of South America, with *KPC-2* being the most common gene type (Hernández-García et al., 2022). *NDMs* have been reported to cause outbreaks globally, including in Thailand, China, Australia, European countries, and Middle East countries, with more cases in Southeast Asian countries (Bonomo et al., 2018). *OXAs* have been reported to spread sporadically in China, Australia, American



regions, and Middle Eastern countries, but currently, the outbreaks registered mainly in European countries and narrower compared to *NDMs* and *KPCs* that show caused outbreaks and sporadically spread worldwide, particularly in Asian countries (Brink, 2019). Thus, we choose *KPCs* and *NDMs* in this research as the most prevalent CR genes that the spread and outbreaks happen worldwide. These three genes are known for their high genetic mobility (i.e., in plasmid). A single mutation can cause resistance to the Carbapenem antibiotic; for example, porin mutation, which can be lost or diminished, makes the antibiotics cannot enter the cell environment or production of Carbapenemase that can hydrolyze the carbapenem antibiotic (Armstrong et al., 2021; Bojer et al., 2012). The high mortality rates in CR cases in hospitals are due to the difficulty and rapidness of accurately detecting CR genes in patients to allow a successful choice of antibiotic therapy (Mangold et al., 2011).

Traditional CR gene detection will require bacterial culture such as the modified Hodge test (Bartolini et al., 2014), followed by the disc diffusion test (Sood, 2014). This method depends on appropriate bacterial culture media and conditions, which require labor and time, approximately 18-24 hours. Another CR assay is by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) (Ghebremedhin et al., 2016) and Carbapenem inhibition test (Kuchibiro et al., 2018). However, these methods are not possible for local application (requires expensive instrument) or still requires > 8 hours of assay time (Nordmann et al., 2011). For the carba NP test, the assay has disadvantages in the high cost of reference standard imipenem powder (> 317 USD for 100 mg), fresh preparation of reagents each time, and relatively poorer assay accuracy compared

with molecular genetic amplification detection methods like polymerase chain reaction (PCR) and loop-mediated isothermal amplification (LAMP) (Nordmann & Poirel, 2019). However, PCR is not rapid and may not be appropriate for resource-restricted and local settings (Carmeli et al., 2010).

Therefore, this study aimed to develop LAMP and demonstrate its effectiveness in possible local uses, which include simple, rapid, low price and accurate (Nakano et al., 2015; Poirier et al., 2021; Solanki et al., 2013; Yamamoto et al., 2015). Local rapid CR gene detection assay would help to select appropriate antibiotics for patients, reducing mortality rates and limiting the spread of further antimicrobial resistance (Brogan & Mossialos, 2016). LAMP utilizes a unique strand displacing *Bst* DNA polymerase enzyme and specially designed self-loop primers to allow a copy of target DNA to amplify to billions of copies within 1 hour at a constant temperature. The final product can be detected by turbidity, agarose gel electrophoresis, or combined with specific dyes or probes for visual or fluorescent color detection (Notomi et al., 2000). This technique has been used successfully to detect a variety of viral, bacterial, and fungal pathogens (Fan et al., 2022; Khan et al., 2018; Osterdahl et al., 2020; Rohatensky et al., 2018). Additionally, multiplex LAMPs in a single reaction have been demonstrated since 2015: (Nyan & Swinson, 2015) identifying six viruses in blood plasma. This study thereby designed universal *KPC* and *NDM* primers for dual LAMP (dLAMP) assay, will find optimal reaction recipe and conditions (incubation temperature and time for the maximum limit of detection) and determine the limit of detection and specificity of the developed dLAMP assay in laboratory references and infected mock samples. As too many primers could affect the assay sensitivity and specificity (Liu et al., 2017), our

developed dLAMP preliminary focus on the prevalent CR genes in Thailand and Southeast Asian countries and hopes our assay will offer an effective rapid, and inexpensive detection for outbreaking CR genes in this region and supports local and resource-restricted setting diagnoses. Moreover, as our developed dLAMP targets the presence of CR genes, the assay is not limited to specific microbial species. It can detect samples of any type (e.g., clinical samples and medical devices).

### 1.2 Study objectives

The objectives of this study are mentioned as follows:

1. To develop a universal *KPC* and *NDM* carbapenem-resistant (CR) gene detection assay using a duplex loop-mediated isothermal amplification (dLAMP) technique.
2. To determine the limit of detection and specificity of the developed dLAMP assay compared to PCR assay.

### 1.3 Hypothesis

The hypotheses of this study are mentioned as follows:


1. The developed dLAMP technique can detect the universal *KPC* and *NDM* CR genes.
2. The limit of detection (LOD) and specificity of the developed dLAMP assay have a high sensitivity and specificity compared to PCR method.

## CHAPTER II LITERATURE REVIEW

### 2.1 Overview of antibiotic resistance and its global impact

#### 2.1.1 Definition of antibiotic resistance and its mechanisms

Antibiotic resistance refers to the capability of microorganisms such as bacteria to withstand antibiotic actions that lead to reduced effectiveness or complete ineffectiveness in treating infections caused by these resistant strains (Davies & Davies, 2010). This phenomenon then poses a significant public health challenge as it shows the persistence and dissemination of challenging-to-treat conditions, resulting in increasing morbidity, mortality, and healthcare costs (Bush et al., 2011).



*Figure 1* Intrinsic mechanisms of resistance

Antibiotic resistance in bacteria can occur intrinsically (Figure 1) to certain antibiotics and also can be acquired via mutations in chromosomal genes and horizontal gene transfer (Blair et al., 2015). The intrinsic resistance in bacteria to a specific antibiotic is its ability to resist the effect of that antibiotic as the result of inherent structural or functional traits. One of the intrinsic-resistance examples in bacteria such as the absence of a susceptible target of specific antibiotics which then

supports the bacteria to inhibit the antibiotic effect such as the production of enoyl-ACP reductase enzyme by *fabI* allele in *Pseudomonas* that can inhibit triclosan effect in their cell environment. Recent studies also led to the discovery of many genes that play a role in inherent resistance in bacteria to various antibiotics, such as  $\beta$ -lactams, fluoroquinolones, and aminoglycosides. Additionally, intrinsic resistance in bacteria can be acquired or developed to resistance to antibiotics, which is mediated by several mechanisms; first, minimize the intracellular concentrations of the antibiotic because of poor penetration into the bacterium or of antibiotic efflux (Fernandez & Hancock, 2012); second, modify the antibiotic target by genetic mutation of the target (H. Nikaido, 2009); third, inactivate the antibiotic by hydrolysis or modification (Wright, 2011).

### 2.1.2 Prevalence and consequences of antibiotic-resistant infections worldwide

The antibiotic-resistant infections have already been a challenge worldwide due to the increasing over and misuse of antibiotics in human medicine and agriculture which have contributed to the emergence and spread of antibiotic-resistant bacteria (McKernan et al., 2021). The World Health Organization (WHO) stated that antimicrobial resistance (AMR) is one of the top 10 global public health threats, which require urgent multisectoral action. The misuse and overuse of antimicrobials are the main factors in the increasing AMR cases. Additionally, lack of clean water, knowledge of sanitation, and inadequate infection prevention and control also promote the spread of microbes, some of which can be resistant to antimicrobial treatment (WHO, 2021). Thus, the prevalence of AMR transmission is urgently needed.

As of September 2017, AMR infections continue to be a significant global health issue with a rising prevalence worldwide (CDC, 2021; Coque et al., 2023). The prevalence of AMR varies across regions and countries, but it affects all parts of the world. As a global health concern, AMR is a major public health concern in both developed and developing countries. It affects people of all ages and can occur in various settings, including healthcare facilities, communities, and agricultural settings. In hospital and healthcare settings, AMR infections are a common problem (CDC, 2021). Healthcare-associated infections (HAI) are caused by multidrug-resistant organisms (MDROs) which can lead to increased morbidity, mortality, and healthcare costs (Al-Tawfiq & Tambyah, 2014).

Furthermore, the rise of multidrug-resistant organisms has severely limited the treatment options available to physicians, leading to a rise in treatment failures and a resurgence of once-controlled infectious diseases. The spread of these resistant strains transcends national borders, facilitated by international travel and trade, necessitating global cooperation and surveillance (Laxminarayan et al., 2013). Consequently, the AMR extends beyond healthcare settings, affecting agriculture, food safety, and the environment. The widespread use of antibiotics in agriculture contributes to the development of resistant strains, which can then spread to humans through the food chain (McKernan et al., 2021). Additionally, antibiotic residues in the environment can further foster resistance development.

The prevalence and consequences of AMR infections demand a multifaceted approach. This includes promoting prudent and responsible antibiotic use, implementing infection prevention and control measures, enhancing surveillance systems, fostering research and development of new antibiotics and alternative

treatments, and advocating for global collaboration to combat this urgent public health threat (O'Neill, 2016). In conclusion, the global prevalence of antibiotic-resistant infections and their consequences underscore the need for immediate and concerted action. Effective strategies are essential to preserve the efficacy of existing antibiotics and ensure that future generations can rely on these life-saving medications in the face of evolving microbial challenges.

### 2.1.3 The Economic and healthcare burden of antibiotic resistance

Nowadays, AMR infections have become a burden on the economy and healthcare because it is difficult to treat and have already contributed to the increase of morbidity and mortality, they are also simultaneously adding high costs to the health systems. On the other hand, some reports through death analysis that are associated with AMR show unstraightforward information (Cassini et al., 2019). The effects of AMR pathogens can be manifested in different AMR infections is the reason for this phenomenon. For example such as methicillin-resistant *Staphylococcus aureus* (MRSA) commonly causes infection on the skin, wound, pneumonia, and bloodstream infection (Garoy et al., 2019), though other pathogens harboring other AMR might cause the same infections. Due to this reason, the actual impact of resistant infections on public health has been unfocused and underestimated in the population (CDC, 2019b).

The attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015 showed the health burden of five types of antibiotic-resistant bacteria. The report in 2015 estimated 671.689 infections with antibiotic-resistant bacteria, with 63%

associated with health care. The estimation for attributable death is approximately 33.110 cases, which is highest in infants and people aged 65 years older which has been increasing since 2007 in Italy and Greece (Cassini et al., 2019).

The intergovernmental economic organization, OECD has been working on reports for AMR since 2015 collaborating with CDC. The OECD estimated about 60.000 deaths from resistant infection every year in the USA and Europe. By 2050, the OECD estimated the AMR will cause 2.4 deaths in the same countries (OECD, 2018). Additionally, the long-term public health impact of this increment of morbidity and mortality of AMR is the rise of antibiotic resistance jeopardizes our ability to control infectious diseases and manage common medical procedures like surgeries, chemotherapy, and organ transplantation, as they heavily rely on effective antibiotics to prevent or treat infections (CDC, 2019a).

AMR infections require more extensive and expensive treatments, including longer hospital stays, additional diagnostic tests, and the use of costly second-line or last-resort antibiotics, which contribute to the escalation of healthcare expenditure (O'Neill, 2014). Moreover, the productivity loss might be the consequence of longer periods of illness, reduced workforce productivity, and missed days of work or school, which leads to economic losses for individuals and business (CDC, 2019a).

## 2.2 Carbapenem antibiotics and their significance in treating infections

### 2.2.1 Introduction to carbapenems and their mode of action

Carbapenems are a class of broad-spectrum antibiotics that belong to the beta-lactam group (K. M. Papp-Wallace et al., 2011). The carbapenems consist of  $\beta$ -lactams antibiotics with a unique structure that makes it different from penicillin by



having a carbon atom that replaces Sulphur at position I and by the presence of unsaturated bond between carbon atoms 2 and 3 in the 5-membered ring (Figure 2) (Moellering & Sentochnik).




Figure 2 Chemical structure of Penam and Carbapenam

Among many types of carbapenam antibiotics, imipenem is the representative of carbapenam and is known to be able to its ability to penetrate the cell envelope of Gram-negative bacilli and its high affinity for certain penicillin-binding protein (PBP) targets (Kahan et al., 1983). Additionally, imipenem also inhibits the synthesis of bacterial cell walls which is a vital component for the structural integrity and survival of bacteria. Furthermore, this mechanism will disrupt the growth and replication of a diverse array of pathogens. If imipenem is combined with cilastatin, a compound that prevents the carbapenam antibiotic breakdown by renal enzymes, will allow for extended dosing intervals and improved therapeutic outcomes (Drawz & Bonomo, 2010; Livermore, 1995).

Carbapenam antibiotics including imipenem have mode of action that makes them highly effective against the wide range of bacterial infections. As they belong to the beta-lactam class of antibiotics, their mechanism of action involves interfering with the synthesis of bacterial cell walls. By targeting an essential component of

bacterial cell walls called peptidoglycan, carbapenem antibiotic will inhibit the activity of enzymes known as penicillin-binding protein (PBPs), which are responsible for cross-linking the peptidoglycan chains, a process vital for maintaining the structural integrity of bacterial cell walls, these whole mechanisms known as inhibition of the bacterial cell wall synthesis. By inhibiting the PBPs, carbapenem prevents the proper formation of peptidoglycan, leading to the weakening pressure changes and ultimately burst due to the inability to maintain cell wall integrity. Furthermore, carbapenem also exhibit bactericidal or killing activity against broad spectrum of bacteria, including Gram-positive and Gram-negative species. This characteristic makes them particularly effective against severe and life-threatening infections (Brown & Wright, 2016; Fisher et al., 2005; Wright, 2016).

### 2.2.2 Clinical importance and spectrum of activity of carbapenem antibiotics

Carbapenem antibiotics hold significant various clinical importance due to their broad-spectrum activity and effectiveness against various bacterial infections. They are often considered critical antibiotics for treating severe or life-threatening infections when other antibiotics have failed or when the precise infecting organism is unknown. As carbapenem antibiotics have a broad-spectrum activity, it makes them effective against a wide range of bacteria, including Gram-positive and negative organisms. This versatility is especially valuable when treating severe infections where the causative bacteria may not be identified immediately (Bassetti et al., 2018; Papp-wallace et al., 2011; Patel & Bonomo, 2011).

Carbapenems are often reserved for specific clinical situations, such as hospital-acquired infections, multi-drug resistant infections, or immunocompromised

patients, thus they are called as reserve antibiotics. Their use is crucial in combating infections caused by resistant bacterial strains. Furthermore, due to their potency and ability to penetrate various tissues, carbapenems are indispensable for treating life-threatening infections like sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections (Papp-wallace et al., 2011; Tamma et al., 2017).

### 2.2.3 Challenges in using carbapenems due to the emergence of resistant strains

The emergence of resistance to carbapenem antibiotics poses significant challenges in the field of healthcare and antimicrobial therapy. Carbapenems, once considered reliable agents against a wide range of bacterial infections, are increasingly facing resistance, limiting their effectiveness. The high mortality rates caused by carbapenem resistant bacteria are associated with higher mortality rates compared to infections caused by susceptible strains. Patients with limited treatment options due to carbapenem resistance face a greater risk of poor outcomes (Tzouveleki et al., 2012). The limited treatment options are another challenge. Since carbapenem-resistant bacteria often exhibit resistance to multiple classes of antibiotics, leaving healthcare providers with limited or no effective treatment options. This can lead to the use of less effective or more toxic antibiotics (Patrice Nordmann et al., 2012).

Carbapenem-resistant bacteria are frequently associated with healthcare-associated infections, including those acquired in hospitals and long-term care facilities. These infections are often challenging to control and contain within healthcare settings (De Oliveira et al., 2020). Furthermore, the carbapenem-resistant bacteria can rapidly spread across geographic regions, creating a global health threat.

The international dissemination of resistant strains make containment and control efforts more complex (van Duin & Doi, 2018). Additionally, the overuse and misuse of carbapenem antibiotics in healthcare settings can contribute to the development and spread of resistance. Inappropriate prescribing practices can exert selective pressure on bacterial populations (Boucher et al., 2009). Finally, the carbapenem resistance genes can be transmitted between different species of bacteria through horizontal gene transfer mechanisms. This facilitates the rapid dissemination of resistance (Walsh & Toleman, 2012).

### 2.3 Carbapenem-resistant bacteria and the role of *KPC* and *NDM* genes

#### 2.3.1 Overview of carbapenem-resistant bacteria and their clinical impact

Carbapenem-resistant bacteria represent a growing global health concern due to their ability to resist treatment with carbapenem antibiotics, which are often considered the last line of defense against drug-resistant infections. These bacteria pose a substantial clinical impact by limiting treatment options and increasing the risk of healthcare-associated infections.

Carbapenem-resistant bacteria are microorganisms that have acquired mechanisms to resist the action of carbapenem antibiotics, which are a class of beta-lactam antibiotics known for their broad-spectrum activity. These bacteria can exhibit resistance through various mechanisms, including the production of Carbapenemases (enzymes that degrade carbapenems), efflux pumps, and alteration in cell wall permeability. Carbapenem resistance has been observed in a wide range of bacterial pathogens, including Enterobacteriaceae (e.g., *K. pneumoniae*, *Escherichia coli*) *Pseudomonas aeruginosa*, and *Acinetobacter baumannii*.

The limited treatment options are one of the clinical impacts of carbapenem resistant emergence. Carbapenems are often considered as last-resort antibiotics, and the emergence of resistance reduces the effectiveness of these critical drugs. This limitation in treatment options can lead to prolonged and more complicated infections (Pitout et al., 2015). Furthermore, the infections caused by carbapenem resistant bacteria are associated with higher mortality rates compared to infections caused by susceptible strains. Delayed or inadequate treatment can contribute to poor patient outcomes (Tzouveleki et al., 2014). Additionally, carbapenem-resistant bacteria are often linked to healthcare-associated infections, particularly in intensive care units and long-term care facilities. Their ability to persist in healthcare environments poses a significant challenge (Bassetti et al., 2019). The global spread of carbapenem-resistant carrying bacteria especially those carrying Carbapenemase genes have rapidly spread across countries and continents. This global dissemination complicates infection control efforts and surveillance (Davey et al., 2017). Finally, the emergence of carbapenem resistance underscores the importance of antibiotic stewardship programs to optimize antibiotic use, prevent the development of resistance, and preserve the effectiveness of existing antibiotics.

### 2.3.2 Mechanisms of carbapenem resistance, with a focus on *KPC* and *NDM* genes

Carbapenem resistance can occur through various mechanisms, but two prominent mechanisms involve the presence of Carbapenemase genes, specifically *KPC* and *NDM*. These genes encode enzymes that can hydrolyze carbapenem antibiotics, rendering them ineffective. The *KPC* or *K. pneumoniae* Carbapenemase is a class A Carbapenemase that confers resistance to carbapenem antibiotics, such as

imipenem and meropenem. *KPC* enzymes hydrolyze the beta-lactam ring of carbapenems then makes them inactivated. The *KPC*-producing bacteria, particularly *K. pneumoniae*, are associated with healthcare-associated infections and have spread globally, posing a significant clinical challenge (Yigit et al.). The *NDM* or New Delhi Metallo-beta-lactamase is a class B metallo-beta-lactamase that confers resistance to carbapenem antibiotics by binding and hydrolyzing them. *NDM* enzymes require metal ions (usually zinc) for their catalytic activity. *NDM*-producing bacteria have been identified in various species, including *Enterobacteriaceae* and *Pseudomonas aeruginosa*, and are associated with healthcare-associated infections and they have spread globally and are challenging to treat (Yigit et al.).

Besides Carbapenemase production, carbapenem resistance can also arise from other mechanisms including efflux pumps, porin loss or alterations, AmpC  $\beta$ -Lactamase, and mutation in penicillin-binding protein (PBPs) (Patrice Nordmann et al., 2012). Some bacteria may overexpress efflux pumps that actively remove carbapenems from the bacterial cell, reducing intracellular drug concentrations, others can modify or lose outer membrane porins, which serve as channels for antibiotic entry, and this will reduce carbapenem uptake into the bacterial cell. Furthermore, certain bacteria produce AmpC beta-lactamases, which can hydrolyze carbapenems to varying degrees. The mutations in PBPs can reduce the affinity of carbapenems for their target sites in the bacterial cell wall.

### 2.3.3 Epidemiology and prevalence of *KPC*- and *NDM*-producing bacteria

*KPC* and *NDM* are two prominent Carbapenemase enzymes that confer resistance to carbapenem antibiotics. The epidemiology and prevalence of *KPC*- and

*NDM*-producing bacteria have been a growing concern in recent years due to their global spread. The *KPC*-producing bacteria were initially identified in the United States in the early 2000s, primarily in *K. pneumoniae* strains. They have spread worldwide with significant outbreaks reported in various countries. *KPC*-producing bacteria are frequently associated with healthcare-associated infections, particularly in intensive care units and long-term facilities. Patients with prolonged hospitalization, exposure to broad-spectrum antibiotics, and invasive medical procedures are at higher risk of this resistant bacteria (Patrice Nordmann et al., 2012). The prevalence of *KPC*-producing bacteria varies by region. In some areas, the prevalence remains relatively low, while in others, it has become a significant concern. Surveillance and monitoring programs are essential to track the prevalence and spread of *KPC*-producing strains.

*NDM*-producing bacteria were first identified in New Delhi, India, in 2008. They belong to the class of Metallo-beta-lactamases and have rapidly spread globally. These bacteria have been found in both healthcare and community settings, making them a versatile and concerning threat (Walsh et al., 2011). The presence of *NDM* genes on mobile genetic elements facilitates their rapid dissemination. The prevalence of *NDM*-producing bacteria varies by region and as well influenced by factors such as antimicrobial use, infection control practices, and local epidemiology. These bacteria often coexist with other resistance mechanisms, making treatment challenging (Patel & Bonomo, 2011).

Both *KPC* and *NDM*-producing bacteria are associated with multidrug-resistant phenotypes, limiting treatment options, and increasing the risk of healthcare-associated infections. the global spread of these resistance mechanisms highlights the

importance of international collaboration in surveillance, infection control, and antimicrobial stewardship efforts to mitigate their impact (Patel & Bonomo, 2011).

## 2.4 Current diagnostic methods for detecting carbapenem-resistant genes

### 2.4.1 Conventional phenotypic methods for carbapenem resistance detection

Conventional phenotypic methods for detecting carbapenem resistance in bacteria involve various laboratory techniques that assess a bacterium's ability to resist the action of carbapenem antibiotics. These methods are essential for identifying resistance patterns in clinical isolates. The conventional phenotyping methods such as:

#### *a. Disk diffusion method*

This method involves testing the susceptibility of bacteria to carbapenem by placing antibiotic disks containing carbapenem drugs (e.g., imipenem or meropenem) onto an agar plate inoculated with the bacterial isolate. Zones of inhibition are measured to determine resistance or susceptibility (Fr, 2010).

#### *b. Broth microdilution method*

In this method, a series of twofold dilutions of carbapenem antibiotics are prepared in a liquid growth medium. Bacterial isolates are then exposed to these dilutions, and the minimum inhibitory concentration (MIC) is determined as the lowest concentration of antibiotic that inhibits visible growth (Fr, 2010).

#### *c. Etest method*

The Etest involves a plastic strip impregnated with a gradient of antibiotic concentrations. This strip is placed on an agar plate inoculated with



the test bacteria, and the intersection point of growth inhibition with the strip is used to determine the MIC (Kulengowski et al., 2019).

*d. Modified hodge test (MHT)*

The MHT is a qualitative test used to detect the production of Carbapenemases by Enterobacteriaceae. A carbapenem-susceptible *E. coli* strain is streaked across a streak of the test organism on agar plate, and the growth pattern is observed for an “enhanced” cloverleaf appearance (Fr, 2010).

*e. Carba NP test*

This test detects Carbapenemase activity by monitoring the hydrolysis of imipenem in the presence of a bacterial isolate. A color change due to the pH increase is indicative of Carbapenemase production (Patrice Nordmann et al., 2012).

2.4.2 Molecular techniques, such as PCR and real-time PCR, for identifying *KPC* and *NDM* genes

Molecular techniques like PCR (Polymerase-chained reaction) and real-time PCR (qPCR) are widely used for the detection and identification of specific resistance genes, including *KPC* and *NDM* genes in bacteria. These techniques provide highly sensitive and specific methods for identifying the presence of these genes. PCR-based detection such as PCR will amplify specific DNA sequences. For detection of both *KPC* and *NDM*, primers targeting both gene are used to amplify and confirm its presence in bacterial DNA (Cuzon et al., 2010; P. Nordmann et al., 2012; Yong et al., 2009). The real-time PCR (qPCR) allows the real-time monitoring of DNA

amplification. It uses specific primers and fluorescent probes to quantify the amount of *KPC* and *NDM* DNA in a sample (Kitchel et al., 2009).

#### 2.4.3 Limitations and challenges of current diagnostic approaches

While diagnostic approaches for the detection of carbapenem-resistant genes have advanced significantly, several limitations and challenges still exist in the current methods. These limitations can impact the accuracy, timeliness, and effectiveness of detecting carbapenem resistance genes in clinical and laboratory settings. These are some key limitation and challenges of the current diagnostic in detection of carbapenem resistant genes:

a) Limited specificity and sensitivity

Some molecular techniques may lack of specificity or sensitivity when detecting Carbapenemase genes, leading to false positive or false negative results (Ramirez et al., 2020).

b) Diverse resistance mechanisms

Carbapenem resistance can result from various mechanisms, including Carbapenemase production, porin loss, and efflux pump overexpression. Current diagnostic tests may not capture all mechanisms simultaneously (Patrice Nordmann et al., 2012).

c) Emerging resistance genes

New Carbapenemase genes continue to emerge, necessitating regular updates of diagnostic assays to include these variants (Kitchel et al., 2009).

d) Time-consuming methods

Traditional molecular methods can be time-consuming, delaying the reporting of resistant results (Kitchel et al., 2009).

e) Need for infrastructure and expertise

Advanced molecular techniques require specialized equipment and trained personnel, which may not be readily available on all healthcare settings (Patel & Bonomo, 2011).

f) Cost and resource constraints

The cost associated with implementing and maintaining molecular diagnostic tests may be a barrier, particularly in resource-limited settings (Bassetti et al., 2013).

g) Antibiotic stewardship implications

Rapid molecular diagnostic may lead to overuse or misuse of antibiotics if results are not interpreted and acted upon judiciously (Davey et al.).

Addressing these limitations and challenges in carbapenem-resistant gene detection is critical for the effective management of antibiotic resistance. Continued research and development of diagnostic assays that improve sensitivity, specificity, and turnaround time are essential to combat the global threat of carbapenem-resistant bacteria. Thus, in this research we plan to use loop mediated isothermal amplification (LAMP) method in solving these problems in identification of CR genes, *KPC* and *NDM*.

## 2.5 Loop-mediated isothermal amplification (LAMP) as a molecular diagnostic tool

### 2.5.1 Introduction to LAMP and its principles of operation

Loop-mediated isothermal amplification (LAMP) is a powerful molecular biology technique used for the rapid and specific amplification of DNA under isothermal conditions. Developed in the late 1990s, LAMP has gained popularity due to its simplicity, speed, and versatility in applications such as molecular diagnostics and pathogen detection. LAMP is a nucleic acid amplification method that was invented by Dr. Notomi and his colleagues in 2000 (Notomi et al., 2000) (figure 3). LAMP is designed to efficiently amplify a target DNA sequence with high specificity under isothermal conditions, typically at a single, constant temperature (usually around 60-65°C). This isothermal nature eliminates the need for a thermal cycler, making LAMP an attractive option for point-of-care testing and field applications.

LAMP amplifies DNA through a strand displacement mechanism and involves the use of four to six primers that specifically target different regions of the target DNA sequence. The LAMP reaction typically includes the following components (Goto et al., 2009; Mori & Notomi, 2009):

1. Target DNA: the DNA sample containing the target sequence to be amplified.
2. Forward and Backward Inner primers (FIP and BIP): these primers initiate DNA synthesis from the target DNA and create a stem-loop structure.
3. Forward and backward outer primers (F3 and B3): these primers further extend the DNA synthesis and assist in the formation of the stem-loop structure.
4. Loop primers (LF and LB, optional): these primers accelerate the amplification process by targeting loop regions within the stem-loop structure.

5. DNA polymerase with strand displacement activity: A DNA polymerase enzyme capable of strand displacement, such as Bst polymerase, is used to initiate and extend DNA synthesis within the stem-loop structure.

LAMP offers several advantages, including high specificity, rapid amplification (typically within 30-60 minutes), robustness against inhibitors, and the ability to detect low copy numbers of target DNA (Wong et al., 2018).




Figure 3 The schematic pathway of loop-mediated isothermal amplification (LAMP)

### 2.5.2 Advantages of LAMP over traditional PCR-based methods

Loop-mediated isothermal amplification (LAMP) offers several advantages over traditional PCR-based methods. These advantages have contributed to the growing popularity of LAMP in various applications, including molecular diagnostics, pathogen detection, and environmental testing. Here are some key advantages of LAMP over traditional PCR-based methods:

- 1) Isothermal amplification: LAMP operates at a constant temperature, typically around 60-65°C, eliminating the need for a thermal cycler. This simplifies instrument requirement and reduces energy consumption (Notomi et al., 2000).
- 2) Speed: LAMP can amplify DNA rapidly, typically within 30-60 minutes, compared to traditional PCR, which requires multiple temperature cycling steps and may take several hours (Parida et al., 2008).
- 3) Simplicity: LAMP uses a set of four to six primers to target multiple regions of the DNA, simplifying primer design compared to traditional PCR, which often requires optimization (Mori & Notomi, 2009).
- 4) Robustness: LAMP is more tolerant of inhibitory substances and can be used with complex sample matrices, making it suitable for point-of-care and field application (Poon et al., 2004).
- 5) High specificity: LAMP's use of multiple primers targeting different regions enhances specificity, reducing the likelihood of non-specific amplification (Goto et al., 2009).

- 6) Visual detection: LAMP results can be visually assessed by turbidity or color change without the need for specialized equipment, enhancing its applicability in resource-limited settings (Tomita et al., 2008).
- 7) Less prone to contamination: LAMP reaction are less prone to contamination because they are performed in closed tubes, reducing the risk of false-positive results (Nagamine et al., 2002).

These advantages have made LAMP a valuable tool in various fields, including infectious disease diagnosis, food safety testing, and environmental monitoring, where speed, simplicity, and robustness are essential for reliable results.

### 2.5.3 Previous applications of LAMP in detecting antibiotic-resistant genes and its limitation

LAMP has been utilized in various studies to detect antibiotic-resistant genes, including *KPC* and *NDM* genes. Its speed, simplicity, and high specificity make LAMP a valuable tool for the rapid detection of these resistance genes. The detection of *KPC* and *NDM* genes using LAMP in clinical isolates of *K. pneumoniae* showed that the LAMP assay demonstrated high sensitivity and specificity (Iwamoto et al., 2003; Poirier et al., 2021). Not only *KPC* and *NDM* genes, LAMP also been known to be able to detect other resistant genes such as *bla*CTX-M genes in Extended-spectrum beta-lactamase (ESBL)-Producing bacteria (Parida et al., 2008), identification of *mecA* gene in Methicillin-Resistant *Staphylococcus aureus* (MRSA) (Iwamoto et al., 2003), detection of *vanA* and *vanB* genes in Vancomycin-resistant Enterococci (VRE) (Kim et al., 2014), and identification of 16S rRNA Methyltransferase genes in aminoglycoside-resistant bacteria (Wu et al., 2009).

While LAMP is a powerful tool for detection of various genetic targets, including antibiotic-resistant genes like *KPC* and *NDM*, it has some limitations. To design a specific and efficient LAMP primers for some target genes, especially with high sequence variability might be challenging (Goto et al., 2009), risk of false positive due to primer dimer formation or nonspecific amplification particularly in sample matrices (Nagamine et al., 2002), the need for proper positive and negative controls with may not always be readily available or feasible to use in all settings (Mori & Notomi, 2009), sensitivity to inhibitors which commonly found in clinical or environmental samples that might lead to false negative results (Nagamine et al., 2002), limited multiplexing especially when designing primers for multiple genes (Cheng et al., 2014), and complexity of interpretation that might be subjective particularly when relying on visual inspection of color changes that lead to variability in result interpretation (Tomita et al., 2008).

Thus, to overcome these limitations, it is crucial to carefully design LAMP assays, incorporate appropriate controls, and validate the result using complementary methods when necessary. LAMP's advantages in terms of speed, simplicity, and isothermal operation make it a valuable tool but understanding its limitations is essential for reliable and accurate molecular diagnostic. In terms of overcoming the limited multiplexing in LAMP, in this research we design specific primers for 123 subtypes of *KPC* and 43 types of *NDM* based on conserved region from multiple sequence alignment (MSA) of each DNA sequence. Thus, we plan to use dLAMP or duplex loop-mediated isothermal amplification (dLAMP) in detection of *KPCs* and *NDMs* genes.



## 2.6 Duplex LAMP (dLAMP) for simultaneous detection of multiple genes

### 2.6.1 Explanation of duplex LAMP and its capacity to detect two target genes

Duplex loop-mediated isothermal amplification (dLAMP) is an advanced application of the LAMP technique that enables the simultaneous detection of two target genes in a single reaction. This approach is particularly valuable in various molecular biology and diagnostic applications where it is necessary to assess the presence of multiple genetic targets concurrently. dLAMP involves the design of specific primers for two different target genes of interest. These primers are included in the same LAMP reaction mixture. Each set of primers is designed to recognize and amplify a unique target gene, enabling the simultaneous amplification and detection of both genes in a single reaction tube (Hong et al., 2023; Parida et al., 2005).

The key component of dLAMP include two sets of specific primers which one set of primers is designed for the first target genes, and another set is designed for the second target gene. Each set consists of four to six primers that recognize distinct regions within the respective target genes. Isothermal amplification reaction is conducted at a constant temperature, typically around 60-65°C. Primers initiate DNA synthesis and create loop structures for each target gene, allowing for exponential amplification (Notomi et al., 2000). Detection of two target genes can be achieved through various means, including color changes, turbidity, or fluorescence, depending on the specific detection method used (Goto et al., 2009; Nyan & Swinson, 2015).

dLAMP offers several advantages when it comes to the simultaneous detection of two targets. It allows for the efficient and specific amplification of two different genetic targets within a single reaction tube. It simplifies the experimental setup by eliminating the need for running two separate reactions, reducing the time and

resources required. Conducting a single dLAMP reaction is often more cost-effective than running two separate reactions, moreover it saves time, making it suitable for applications where rapid detection of multiple genes is essential. Finally, dLAMP can conserve limited or precious sample material because it requires only one sample for testing (Gong et al., 2018; Jang, 2021; Jang et al., 2021; Jang et al., 2022; Kim et al., 2021; Osterdahl et al., 2020; Sattabongkot et al., 2014; Shao et al., 2011; Sharma et al., 2021; Sonaty, 2015; Tanner et al., 2012; Zhong et al., 2019).

#### 2.6.2 Review of studies using dLAMP in various molecular diagnostic applications

The dLAMP technique allows the simultaneous detection and amplification of multiple target DNA sequences in a single reaction. This approach is valuable in various molecular diagnostic applications for the detection of multiple pathogens or genetic markers. The application of dLAMP has been applied for simultaneous detection of multiple pathogenic microorganisms, such as bacteria and virus in clinical samples (Li & Macdonald, 2015), to detect and differentiate between different serotypes of dengue virus in clinical samples (Parida et al., 2005), simultaneous detection of bacterial pathogen causing diarrhea and offering a rapid results (Phaneuf et al., 2018), for the detection of multiple genes in environmental samples including antibiotic resistance genes in wastewater (Miłobedzka et al., 2022), and detection of multiple plasmodium species (Selvarajah et al., 2020).

#### 2.6.3 Potential benefits of using dLAMP for simultaneous detection of *KPC* and *NDM* genes

dLAMP has been developed as a technique for the simultaneous detection of two specific genes. and it is also potential in detection of *KPC* and *NDM* resistant

genes which may offer several potential benefits in molecular diagnostic. The concurrent detection of two specific resistance genes in a single reaction, providing a comprehensive assessment of antibiotic resistance (Yang et al., 2018) represent a simultaneous detection of multiple resistance genes. It also will give a rapid results because dLAMP typically offers faster results than traditional PCR-based methods, enabling quicker decision-making in clinical or epidemiological settings (Parida et al., 2008). This technique also offer high sensitivity and specificity which reducing the risk of false-positive or false-negative results (Mori & Notomi, 2009), additionally dLAMP can conserve resource as it requires only one reaction for the detection of multiple genes and minimizing reagent and sample consumption (Tomita et al., 2008). Other benefits such as dLAMP's isothermal nature and simplicity make it suitable for field applications where access to sophisticated laboratory equipment is limited (Nagamine et al., 2002) and simultaneous detection of multiple resistance genes using dLAMP can enhance diagnostic accuracy for effective patient management and infection control (Goto et al., 2009).

## 2.7 Challenges and limitations of dLAMP in antibiotic-resistant gene detection

### 2.7.1 Factors affecting the specificity and sensitivity of dLAMP assays

The specificity and sensitivity of dLAMP assays can be influenced by several factors. The specificity of dLAMP assays depends on the design of primers for the target genes. Proper primer design, including sequence selection and optimization is critical. Well-design primers that efficiently anneal to the target sequences can enhance sensitivity (Li & Macdonald, 2015). The primer concentration in dLAMP reactions can affect specificity. An optimal primer concentration ensures specific

amplification and also contributes to sensitivity and preventing non-specific amplification (Goto et al., 2009). The reaction temperature in dLAMP should be carefully controlled to ensure specific amplification of target genes, and optimizing the reaction temperature can impact sensitivity by influencing the efficiency of DNA amplification (Mori et al., 2001).

Another factors that affect the specificity and sensitivity of dLAMP assay is primer cross-reactivity which can occur if primers have unintended interactions with non-target sequences, furthermore minimizing cross-reactivity improves sensitivity by reducing false-positive results (Parida et al., 2008). Proper sample preparation techniques such as DNA extraction can enhance specificity by reducing the risk of sample contaminants interfering with assay and efficient sample preparation methods can maximize DNA recovery and consequently the sensitivity (Cheng et al., 2014). The prolonged reaction times may increase the risk of non-specific amplification thus it is essential to optimize the reaction time, and adequate reaction times ensure sufficient amplification, contributing to sensitivity (Nagamine et al., 2002). Finally, the contamination from previously amplified product or environmental sources can compromise specificity thus stringent contamination control measures is important and also equally vital for sensitivity, as it prevents the introduction of false-positive result (Mori & Notomi, 2009).

#### 2.7.2 Comparison of dLAMP with other multiplex detection methods

In this study, we design 2 sets of LAMP primers using primer explorer ver. 5. The primers were designed based on MSA (multiple sequences alignment) of 123 subtypes of *KPCs* and 43 subtypes of *NDMs*. In one single reaction, two target DNA

will mixed along with reagents and water, then incubated around 30-60 minutes at 60-65°C without thermal cycler, this is the difference between dLAMP with other multiplex detection method like mPCR (Gong et al., 2018; Jang, 2021; Jang et al., 2021; Jang et al., 2022; Jang et al., 2020; Kim et al., 2021; Kim et al., 2019; Liang et al., 2012; Liu et al., 2017; Mahony et al., 2013; Moonga et al., 2020; Osterdahl et al., 2020; Sharma et al., 2021; Tanner et al., 2012; Wong et al., 2018; Zhong et al., 2019). Additionally, in this running time of incubation, there will no temperature adjustment like in the PCR that makes dLAMP assay is rapid and easy to be performed in detection of one or more than one DNA target, yet again we can obtained the results within one hour without using gel electrophoresis, instead we can add the HNB dye and see the color changing from violet to sky blue for positive result (Goto et al., 2009).

If compared with other multiplex detection methods lie microarray-based method, dLAMP typically more cost-effective and straightforward to implement which microarray may require complex sample preparation and expensive equipment (Sauer & Kliem, 2010). The next-generation sequencing (NGS) requires longer data analysis times and may be cost-prohibitive for routine diagnostics while dLAMP provides results in a shorter time frame (Mardis, 2008) o e. Lateral flow assays may require reader devices for quantification while dLAMP offers the possibility of visual detection without the need of expensive reader devices (Goto et al., 2009). Lastly, digital PCR (dPCR) requires specialized equipment and may have a longer turnaround time while dLAMP generally accessible and cost-effective (Hindson et al., 2011).

### 2.7.3 Strategies to overcome challenges and improve dLAMP performance

To overcome challenges and improve the performance of dLAMP assays, several strategies can be employed. These strategies aim to enhance specificity, sensitivity, speed, and reliability. The primer design and optimization by carefully optimize and design the primer sequences which are critical for dLAMP specificity and sensitivity (Mori & Notomi, 2009). The use of loop primers can enhance the efficiency and speed of dLAMP reactions, leading to improved sensitivity (Nagamine et al., 2002). Next, the optimization of reaction buffer including salt concentrations and pH can enhance dLAMP performance (Goto et al., 2009). The temperature optimization is essential for specific and efficient dLAMP amplification (Mori et al., 2001). The isothermal heating devices can ensure consistent and accurate temperature control during dLAMP reactions (Kaneko et al., 2007).

The contamination control by implementing strict control measures to prevent false-positive results in dLAMP assay is very important points (Mori et al., 2001). By multiplexing strategies is consider as optimizing primer sets and reaction conditions to expand dLAMP multiplexing capabilities for the simultaneous detection of more than two targets (Cheng et al., 2014). The implementation of visual detection methods, such as colorimetric or turbidity-based indicators, to simplify result interpretation in dLAMP (Goto et al., 2020). Optimize dLAMP for field applications by using portable, battery-operated devices is a strategy for field-friendly application (Mori & Notomi, 2009). Finally, validation and quality control should be in place to ensure the reliability of dLAMP results (Mardis, 2008).

## 2.8 The LAMP end point detection

The sLAMP and dLAMP product can be detected through various methods such as the addition of color dye like HNB (Goto et al., 2020), paper-based or strip (Choopara, Suea-Ngam, et al., 2021) and the standard method in detection of LAMP product, gel electrophoresis. These techniques provide different means to determine and confirm the presence of the amplified product, allowing for flexibility in experimental design and application.

The dLAMP product detection by using paper-based such as strip methods which offers a practical and visual interpretable means of confirming the presence of amplified DNA (Choopara, Teethaisong, et al., 2021). These techniques leverage the specificity of the dLAMP reaction to generate detectable signals that are then visualized on a paper strip. The strip typically contains components such as primers, enzymes, and indicators that undergo specific color changes in the presence of the target DNA. This visual readout simplified the interpretation of results, making it accessible even in resource-limited settings. On the other hand, gel electrophoresis is a traditional yet highly effective method for LAMP detection. In this technique, the amplified DNA is separated based on size and charge as it migrates through a gel matrix under the influence of an electric field. The resulting banding patterns on the gel electrophoresis is valuable for assessing the overall success of the LAMP reaction and confirming the specificity of the amplification (El-Kholy et al., 2014).

However, its important to note that gel electrophoresis requires specialized equipment, is time-consuming, and may not be as well-suited rapid, on-site diagnostics compared to strip or paper-based methods. The choice between these methods often depends on the specific requirements of the experiments, the available

resources, and the desired level of sensitivity and precision in LAMP product detection. Alternatively, we want to use the hydroxyl naphthol blue (HNB) addition in our reaction to detect the LAMP product by visualization or naked-eyes.

The selection of HNB as the color dye in LAMP detection hold significance. This choice is not arbitrary, rather, it is driven by specific characteristics that make HNB suitable for this application. Elaborating on the reasons behind choosing HNB involves discussing its sensitivity, specificity, and compatibility with the LAMP reaction. These considerations contribute to the overall efficacy and reliability of the detection method (Goto et al., 2009).

Finally, the detection of our developed dLAMP product, especially when employing HNB as a color dye, encompasses multiple dimensions, from method selection to the chemical intricacies of the chosen dye. Understanding and explaining these aspects are crucial for researchers and practitioners working in the field of molecular biology and diagnostics.



## CHAPTER III MATERIALS AND METHODS

### 3.1 Instruments

Autoclave: Kokusan, Shizouka, Japan

Hot air oven: Memmert, Munich, Germany

Vortex mixer: VM-10 DAIHAN Scientific, Seoul, Korea

Micro-centrifuge: Hettich, Massachusetts, USA

Laminar flow: BossTech, Hampshire, USA

UV-Cabinet: BossTech, Hampshire, USA

Nanodrop spectrophotometer: Nanodrop2000, Thermo Scientific,  
Northumberland, UK

Freezer 4°C MISUBISHI, Tokyo, Japan

Deep freezer -20°C: Haier, Bangkok, Thailand

Agarose Gel Electrophoresis System: GE-100, Hangzhou Bioer Technology  
CO., LTD. Hangzhou, China

UV transilluminator: HANGZHOU BIOER TECHNOLOGY CO., LTD.

Gel Documentation Bio-Rad, California, USA

Micropipette: Eppendorf North America, New York, USA

Dry bath incubator: Hangzhou Allsheng Instruments Co., LTD. China.

DNA Thermal Cycler: T100T™ BIO-RAD, Bio-Rad laboratories LTD.,  
Bangkok, Thailand

Balance: VALOR 7000, OHAUS Instruments (Shanghai) Co., LTD. Shanghai,  
China

### 3.2 Chemicals

Double distilled water

0.5×TBE buffer (Tris/Borate/EDTA)

1.0×TBE buffer (Tris/Borate/EDTA)

70% ethanol

Agarose powder: AMRESCO, Ohio, USA

Ethidium Bromide: AMRESCO, Ohio, USA

Novel Juice: GeneDireX, BIO-HELIX, New Taipei City, Taiwan

OneMark 100 RTU: BIO-HELIX, New Taipei City, Taiwan

Deoxynucleotide (dNTP) solution mix: New England Biolabs Ipswich, UK

Betaine solution: Sigma-aldrich, St. Louis,, USA

10×TherPol reaction buffer: New England Biolabs Ipswich, UK

Magnesium sulfate (MgSO<sub>4</sub>): New England Biolabs Ipswich, UK

*Bst* DNA polymerase, Large fragment: New England Biolabs Ipswich, UK

Hydroxy naphthol blue (HNB): Fluka Analytical, Munich, Germany

### 3.3 Supplies

Microcentrifuge tubes: Biorline, Massachusetts, USA

Micropipette: Labnet International, Inc., New Jersey, USA

Blade

Cuvettes

### 3.4 Kits

EmeraldAmp® GT PCR Master mix: TAKARA BIO INC., Shiga, Japan

PureDireX® Quick Gel extraction kit: Invitrogen, New York, USA

GF-1 Nucleic acid extraction kit: Vivantis, Malaysia

GF-1 AmbiClean Kit (Gel&PCR): Vivantis, Malaysia

### 3.5 Sample collections

Samples included positive controls, negative controls and laboratory references. The positive control strains were obtained from a previous study (Kerdsin et al., 2019; Takeuchi et al., 2022); The *Enterobacter asburiae* strain KU-C1235 1 (GenBank: JAJAIX010000001.1) and *E. coli* strain ECS01 (GenBank: NC\_024954.1) both harboring *KPC* and *NDM* CR genes, respectively. The laboratory references, *K. pneumoniae* and *E. coli*, and negative strains were obtained from the previous study (Takeuchi et al., 2022).. All models will be extracted genomics using a DNA isolation

kit (Sangon, Shanghai, China) for reference samples or a DNeasy PowerSoil kit (Qiagen, Maryland, Germany) for clinical specimens.

### 3.6 Primer design for universal *KPC* and *NDM* dLAMP

123 DNA sequences of *KPC* and 43 sequences of *NDM* gene were downloaded from the NCBI GenBank database ([www.ncbi.nlm.nih.gov/pathogens/refgene/#blaKPC](http://www.ncbi.nlm.nih.gov/pathogens/refgene/#blaKPC) and [www.ncbi.nlm.nih.gov/pathogens/refgene/#blaNDM](http://www.ncbi.nlm.nih.gov/pathogens/refgene/#blaNDM), respectively). Multiple sequence alignments by MUSCLE for each gene were performed using Mega11: Molecular Evolutionary Genetics Analysis software (Tamura et al., 2021). The conserved region for each type of primer (including outer primers F3 and B3, inner primers FIP and BIP, and loop primers LF and LB) was designed using Primer explorer version 5 software (<http://primerexplorer.jp/lampv5e/index.html>). BLASTN confirmed the specificity of every primer against the non-redundant database (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>) and manual verification of multiple sequence alignments.

### 3.7 *KPC* and *NDM* PCR detection with specificity and sensitivity test

To confirm positive controls (*KPC* and *NDM* strains) in this study, we performed the PCR assay using F3 and B3 primers of both genes. The specificity and sensitivity of PCR was also conducted to confirm the limit of detection (LOD) and specificity of the designed universal primers of *KPC* and *NDM* in this study.

The PCR reaction in this study was using the F3 and B3 primers of each gene (10  $\mu$ M each), 12.5  $\mu$ L EmeraldAmp® GT PCR Master Mix (TakaRa Bio, Shiga,

Japan), and 50 ng DNA. The PCR reaction was conducted in two different tubes specifically for *KPC* and *NDM* genes. The cycling conditions were 95°C for 5 mins followed by 35 cycles of 94°C for 20 s, 61.4°C for 30 s, and 72°C for 1 min, with a final extension at 72°C for 5 mins. PCR product 200 bp, was determined by 2% gel electrophoresis.

In this step, we also conducted the PCR specificity using our developed universal LAMP primers (F3 and B3). The extracted DNA from twenty-one clinical bacterial obtained from the previous study (Takeuchi et al., 2022), was used as template for PCR specificity test. The ten-fold dilution of extracted DNA of both genes was used as the template in PCR sensitivity test.

### 3.8 The detection of *KPC* and *NDM* genes using Single LAMP (sLAMP)

The single LAMP reaction (15 µL total volume) comprises 0.2 µM each of F3 and B3 primers, 1.6 µM for FIP and BIP primers, 1.4 µM each of LF and LB primers, 1×ThermoPol Buffer (New England BioLabs, Massachusetts, USA), 8 mM MgSO<sub>4</sub>, 1.4 mM dNTP mix, 8 U Bst DNA polymerase (New England BioLabs), nuclease-free water, 0.5 M betaine and 50 ng DNA template (Choopara, Suea-Ngam, et al., 2021; Gong et al., 2018). The reaction was performed on a simple heat block. The LAMP product was analyzed by the 2% gel electrophoresis (Cambridge, UK). The appearance of band in the same temperature between both genes will be used as the estimation of the most suitable temperature and incubation time or the compromised condition of LAMP for both genes. This data then used to optimize dLAMP.

### 3.9 sLAMP optimization

The effectivity of sLAMP reaction was confirmed by the appearance of product band on the gel electrophoresis which then the intensity measured by ImageJ. The temperature and incubation times then ranged from 50-70°C and 30-55 minutes, respectively. The result then analyzed by two-way ANOVA to confirm the significance of different to obtained the optimum condition of sLAMP. The optimum condition of LAMP in detection of *KPC* and *NDM* is the basic understanding to find compromised condition when both genes used as templates in dLAMP reaction.

### 3.10 The detection of *KPC* and *NDM* using duplex LAMP (dLAMP)

The dLAMP reaction (25  $\mu$ L total volume) comprises 10  $\mu$ M of each F3 and B3, 40  $\mu$ M of FIP, BIP, LF, and LB of both *KPC* and *NDM* primer sets, 1.4 mM dNTP mix, 12U Bst DNA polymerase, 5.5 mM of MgSO<sub>4</sub>, 0.5 mM of betaine, 1x of isothermal buffer and distilled ddH<sub>2</sub>O. The incubation was performed using simple heat block. The dLAMP product was determined by 2% agarose gel electrophoresis.

### 3.11 dLAMP optimization

To optimize the dLAMP reaction, we ranging the temperature based on the compromised temperature of both genes in single LAMP (63, 65, 67, 69 and 71°C), the incubation time (45, 50, 55, 60, 65, and 70 minutes), MgSO<sub>4</sub> concentration (3.5, 4.5, 5.5, 6.5, and 7.5 mM), and HNB (80, 120, and 160  $\mu$ M) concentration, then the dLAMP product was determined by 2% agarose gel electrophoresis and the intensity value was analyzed by ImageJ software to compare the data then two-way ANOVA was performed to obtained the

significance difference between condition. Additionally, the specificity and sensitivity test were performed with reference positive and negative samples and using ten- fold serial dilution for sensitivity (Qin et al., 2021). The intensity was measured, and the intensity peak was plotted by using ImageJ software. Additionally, the dLAMP product was measured by using a spectrophotometer.

a. The intensity value of dLAMP using ImageJ software

To analyze the intensity value of gel electrophoresis of dLAMP product we use ImageJ software and conduct the gel plotting to compare the intensity value. The plotting results from ImageJ were analyzed using two-way ANOVA along with dLAMP product yield as the data measurement in dLAMP optimization.

b. dLAMP product yield using spectrophotometer

To obtain the dLAMP product concentration, we analyzed 3 microlite of dLAMP product using Nanodrop spectrophotometer. The data obtained was then collected and analyzed using two-way ANOVA along with intensity value as the data measurement in dLAMP optimization.

### 3.12 MgSO<sub>4</sub> and HNB concentration optimization

It has been demonstrated that the concentration of MgSO<sub>4</sub> has an impact on the color change of Hydroxy naphthol blue (HNB) in dLAMP. To visualize the positive outcomes in the dLAMP (Choopara, Suea-Ngam, et al., 2021; Goto et al., 2009), we conducted optimization of both MgSO<sub>4</sub> (3.5-7.5 mM) and HNB (80-160 μm) concentrations. This optimization aimed to achieve the most distinct color change from violet to sky-blue, indicative of a positive result. Additionally, the blue color

associated with positive results was quantified by measuring the highest absorbance at 650 nm using a Uv-Visible spectrophotometer. Given that MgSO<sub>4</sub> concentration is known to influence intensity and product formation in the LAMP reaction (Dadas et al., 2013), we extended our investigation to analyze the effects of varied MgSO<sub>4</sub> concentrations on both 2% gel electrophoresis intensity and dLAMP product yield. The product was assessed using Uv-Visible spectroscopy and confirmed through gel electrophoresis. subsequently, the intensity of the gel electrophoresis bands was analyzed using ImageJ software.

### 3.13 Sensitivity and specificity of dLAMP

The sensitivity of dLAMP was conducted by using the tenfold dilution of positive control extracted DNA as the template to determine the limit of detection (LOD) of dLAMP and compare it to PCR. The reaction was incubated at 65°C for 55 minutes with the addition of HNB and analyzed using 2% gel electrophoresis. Additionally, the specificity of dLAMP was performed by using OXA-48 genes as the negative template. The reaction was incubated at 65°C for 55 minutes. The positive result will be shown by the band appearance and the blue-sky color reaction in dLAMP.

### 3.14 Statistical analysis

The data obtained from the sLAMP and dLAMP optimization (intensity value, dLAMP yield, and UV-visible absorbance) in this study was then analyzed using one-way and two-way ANOVA using GraphPad Prism 9 software. The multiple comparisons using Tukey were then conducted to obtain the significant difference between factors. The p-value less or equal to ( $\leq$ ) 0.05 was then used as a significantly different value in this research.



## CHAPTER IV RESULTS

### 4.1 Targeted DNA sequences of *KPCs* and *NDMs* carbapenem-resistant (CR) genes

The multiple sequence alignment was conducted to align 123 subtypes of *KPC* and 43 subtypes of *NDM* carbapenem-resistant (CR) genes. The DNA sequences obtained from 100% conserved region covered all subtypes of *KPC* and *NDM* CR genes. As a results, 854 bp of *KPC* and 813 bp (Table 1) of *NDM* DNA sequences were obtained from the software. Then to confirm the specificity of the DNA sequences, checking using BLASTN was conducted.

*Table 1* The universal DNA sequences of *KPC* and *NDM*

Genes	Targeted DNA sequences	Length
<i>KPC</i>	ATGTCACTGTATCGCCGTCTAGTTCTGCTGTCTTGCTTCATGGCCGCTGG CTGGCTTTTCTGCCACCGCGCTGACCAACCTCGTCGCGGAACCATTGCT AAACCTCGAACAGGACTTTGGCGGCTCCATCGGTGTGTACGCGATGGATA CCGGCTCAGGCGCAACTGTAAGTTACCGCGCTGAGGAGCGCTTCCCACT GTGCAGCTCATTCAAGGGCTTTCTTGCTGCCGCTGTGCTGGCTCGCAGCC AGCAGCAGGCCGGCTTGCTGGACACACCCATCCGTTACGGCAAAAATGC GCTGGTTCGGTGGTCACCCATCTCGGAAAAATATCTGACAACAGGCATG ACGGTGGCGGAGCTGTCCGCGGCCGCCGTGCAATACAGTGATAACGCCG CCGCAATTTGTTGCTGAAGGAGTTGGGCGGCCCGGGGCTGACGGC CTCATGCGCTCTATCGGCGATACCACGTTCCGTCTGGACCGCTGGGAGC CCGCCCCAGGCGATGCGCGGATACCTCATCGCCGCGCGCCGTGACGGA AAGCTTACAAAACTGACACTGGGCTCTGCACTGGCTGCGCCGACGCGG CGCAGTTTGTGATTGGCTAAAGGGAAACACGACCGGCAACCACCGCA TCCGCGCGGGTGCAGGAGACTGGGCGAGTCGGAGACAAAACCGGCAAC CTGCTATGCAAATGACTATGCCGTCTGCTGGCCACTGGGCGCGCACCTA TTGTGTTGGCCGCTTACACCCGGGCGCCTAACAAGGATGACAAGTACAG CGAGGCCGTCATCGCCGCTGCGGCTAGACTCGCGCTCGAGGGATTGGGC GTCAACGGGCAGTAA	854
<i>NDM</i>	ATGGAATTGCCAATATTATGCACCCGGTCGCGAAGCTGAGCACCGCATT AGCCGCTGCATTGATGCTGAGCGGGTGCATGCCCGGTGAAATCCGCCC ACGATTGGCCAGCAAATGGAAACTGGCGACCAACGGTTTGGCGATCTGG TTTCCGCCAGCTCGCACCCGAATGTCTGGCAGCACACTTCCATCTCGAC ATGCCGGGTTTCGGGGCAGTCGCTTCCAACGGTTTGTATCGTCAGGGATGG CGGCCGCGTGTGGTGGTCGATACCGCCTGGACCGATGACCAGACCGCC CAGATCCTCAACTGGATCAAGCAGGAGATCAACCTGCCGGTCGCGCTGG CGGTGGTGACTIONCAGCGCATCAGGACAAGATGGGCGGTATGGACGCGCT GCATGCGGCGGGGATTGCGACTTATGCCAATGCGTTGTCGAACCAGCTTG CCCCAGAGGGGATGGTTGCGGCGCAACACAGCCTGACTTTCGCCCGC CAATGGCTGGGTCGAACCAGCAACCGCGCCCAACTTTGGCCCGCTCAAG GTATTTTACCCCGGCCCGGCCACACCAGTGACAATATCACCGTTGGGAT CGACGGCACCGACATCGCTTTTGGTGGCTGCCTGATCAAGGACAGCAAG GCCAAGTCGCTCGGCAATCTCGGTGATGCCGACACTGAGCACTACGCCG CGTCAGCGCGCGCTTTGGTGCGGCGTTCCCAAGGCCAGCATGATCGTG ATGAGCCATTCCGCCCCCAATAGCCGCGCCGCAATCACTCATAAGGCCCG CATGGCCAACAAGCTGCGCTGA	813

## 4.2 Specificity check result of *KPCs* and *NDMs* DNA sequences

### 4.2.1 *KPCs* universal DNA sequences

The specificity checks of *KPC* DNA sequences using 5000 hit BLAST N from NCBI software showed that *KPC* DNA sequences showed 87.32% found in plasmid, 5.17% in chromosomes, and 7.51% clearly stated that it is *KPC* sequences that mostly found in 78.82% of *K. pneumoniae* among bacterial strains (Figure 4). It has also already been confirmed that every chromosome that listed harbored this DNA sequence are same sequence as the *KPC* DNA sequence.




Figure 4 The specificity of the universal *KPC* sequence

### 4.2.2 *NDMs* universal DNA sequences

The specificity check result showed that 74.20% of *NDM* DNA sequence is harbored in the plasmid, 9.84% in the chromosome, and 15.96% clearly stated that it is listed as the DNA sequence of *NDM* in the NCBI database. *K. pneumoniae* is the bacterial strain that mostly might harbored and already listed in NCBI as shown as 31.92% among many species (Figure 5).




Figure 5 The specificity of the universal NDM sequence

#### 4.3 Universal LAMP primers for *KPC* and *NDM*

The specific DNA sequences of *KPC* and *NDM* are then used as sequence templates to design LAMP primers consisting of outer primers (F3 and B3), inner primers (FIP and BIP), and two more optional loop primers (LF and LB). In total, we designed 2 sets of primers for *KPC* and *NDM* CR genes (Table 2).

After we designed the universal primers for *KPC* and *NDM*, we conducted a specificity test using hit 5000 BLAST N from NCBI software and the result showed similar results to the DNA sequences specificity check (Figure 6). Both sets of the primers (*KPC* and *NDM*) will bind to the DNA sequences or templates that are harbored or found in plasmids with *K. pneumoniae* (*KPC*) and *E. coli* (*NDM*) will be the most common species that might harbor this DNA sequence that represents as CR gene DNA sequences (Figure 4.3).

Table 2 The list of LAMP primer sets of *KPC* and *NDM*

Genes	Primers	Sequences
<i>KPC</i>	F3	TGGCTTTTCTGCCACCG
	B3	TGCGAGCCAGCACAGC
	FIP	TACACACCGATGGAGCCGCC-TTTT-CCTCGTCGCGGAACCAT

<i>NDM</i>	BIP	GGCTCAGGCGCAACTGTAAGT-TTTT-GCAGCAAGAAAGCCCTTGAA
	LF	AAAGTCCTGTTCGAGTTTAGC
	LB	GAGCGCTTCCCCTGT
	F3	GGCGACCAACGGTTTGG
	B3	CCTGCTTGATCCAGTTGAGG
	FIP	CGAAACCCGGCATGTCGAGATA-TTTT-TTTTCCGCCAGCTCGCAC
	BIP	GGCAGTCGCTTCCAACGGT-TTTT-TGGTCATCGGTCCAGGC
	LF	GAAGTGTGCTGCCAGACATTC
	LB	GCGTGCTGGTGGTCGATA




Figure 6 The specificity of the universal primers KPC and NDM

#### 4.4 Detection of *KPC* and *NDM* genes using Polymerase-chained reaction (PCR)

To confirm positive controls (*KPC* and *NDM* strains) in this study, we performed the PCR assay using F3 and B3 primers of both genes. The result showed the PCR product around 200 bp as in Figure 7.




Figure 7 KPC and NDM PCR detection

- a. Lane M: 100 bp DNA ladder bio-helix; lane 2-4: PCR (KPC primers with) ddH<sub>2</sub>O, NDM, OXA-48, and KPC template, respectively.
- b. Lane M: 100 bp DNA ladder bio-helix; lane 2-4: PCR (NDM primers with) ddH<sub>2</sub>O, KPC, OXA-48, and NDM template respectively

As for the specificity of the PCR using clinical bacterial DNA samples, we confirm that the PCR method using F3, and B3 of LAMP primers can identify the different subtypes of *NDM* gene with specificity 100% and no false negative result (Figure 8).




Figure 8 The PCR specificity using clinical bacterial samples

- a. Lane M: 100 bp DNA ladder bio-helix; Lane 4-15: clinical bacterial sample (*E. coli*) *NDM-1*, *NDM-4*, *NDM-5*, *NDM-1*, *NDM-1*, *NDM-7*, *NDM-7*, *NDM-4*, *NDM-4*, *NDM-1*, *NDM-1*, and *NDM-1* harboring gene, respectively.
- b. Lane M: 100 bp DNA ladder bio-helix; Lane 4-12: clinical bacterial sample (*K. pneumoniae*) *NDM-1*, *NDM-1*, *NDM-1*, *NDM-1*, *NDM-1*, *NDM-5*, *NDM-1*, *NDM-1*, and *NDM-1* harboring gene, respectively.

Furthermore, the sensitivity of *KPC-NDM-PCR* was also analyzed (Figure 9). The result showed that the PCR method in detection in detection of *KPC* and *NDM* genes has able to detect the genes until limit of detection 520 fg or equal to 10 copies of DNA in one reaction.




Figure 9 The PCR sensitivity test

- a. Lane M: 100 bp DNA ladder bio-helix, Lane 2-10: 10-fold serial dilution of KPC positive control  $1 \times 10^5$ - $1 \times 10^{-3}$ , respectively. Lane 11: negative control,
- b. Lane M: 100 bp DNA ladder bio-helix, Lane 2-8: 10-fold serial dilution of NDM positive control  $1 \times 10^5$ - $1 \times 10^{-1}$ , respectively. Lane 9: Negative control.

#### 4.5 The detection and optimization of *KPC* and *NDM* genes using Single LAMP (sLAMP)

To find the optimal condition of sLAMP of *KPC* and *NDM* genes, 2% of gel electrophoresis was analyzed. The intensity measurement using ImageJ and analyzed by two-way ANOVA confirmed that the temperature 65, 65, and 67 showed a significant higher intensity among other temperature ( $p < 0.0001$ ) (Figure 10). The results suggested that the optimum temperature of sLAMP in detection of both genes are between 65-67°C (Figure 11 (a)). The optimization of incubation time of sLAMP in both genes showed that the sLAMP were able to amplify started from 45 minutes (Figure 11 (b)). These compromised temperatures and incubation time are then used as compromised temperatures that will be used early condition of dLAMP in the detection of both genes.




Figure 10 The two-way ANOVA graph on analysis of sLAMP intensity for temperature optimization




Figure 11 The temperature and incubation time optimization in dLAMP


- Ladder M: 100 bp DNA ladder bio-helix; Lane 2-7: KPC sLAMP temperature 62, 63, 64, 65, 66, and 67°C, respectively.
- Ladder M: 100 bp DNA ladder bio-helix; Lane 2-7: NDM sLAMP temperature 62, 63, 64, 65, 66, and 67, respectively.
- Ladder M: 100 bp DNA ladder bio-helix; Lane 2-7: KPC sLAMP incubation time 30, 35, 40, 45, 50, and 55 minutes, respectively. Lane 8: Negative control
- Ladder M: 100 bp DNA ladder bio-helix; Lane 2-7: NDM sLAMP temperature 65°C with incubation time 30, 35, 40, 45, 50, and 55 minutes, respectively. Lane 8: Negative control



#### 4.6 The detection and optimization of *KPC* and *NDM* using dLAMP

After we obtained the optimum condition of sLAMP of both *KPC* and *NDM*, we performed a dLAMP assay that contained both gene DNA as the template. 2% gel electrophoresis of dLAMP were analyzed. As a result, we found two temperatures that give a clear band and three incubation times. The temperature of 63°C with incubation times 55 and 60 minutes, and the temperature of 65 with incubation times 50 and 55 minutes give the clear product band as well (Figure 12).

To obtain this conclusion, we analyze the yield concentration (Table 3) and intensity (Table 4) that we present in the table of summary as the average value plus-minus ( $\pm$ ) of the standard error with the comparison graph to see a significant difference (Figure 13).



*Figure 12* The possible optimum temperatures and incubation time of dLAMP

Lane M: 100 bp DNA ladder bio-helix; Lane 2 and 7 : Negative controls; Lane 3 and 4: dLAMP 63°C 55 minutes Lane 5 and 6: dLAMP 63°C 60 minutes; Lane 8 and 9: dLAMP 65°C 50 minutes; Lane 10 and 11: : dLAMP 65°C 55 minutes

*Table 3* The product yield of dLAMP optimization

Incubation time (°C)	DNA concentration (ng/μl)					
	Incubation times (minutes)					
	45	50	55	60	65	70
63	34±0.58	34±0.00	20±1.15	30±4.04	0	0
65	16±2.65	27±2.08	26±3.06	21±2.89	26±0.58	19±2.65
67	21±4.36	21±2.65	21±2.31	17±3.79	21±5.13	20±1.53
69	0	0	0	13±2.52	16±0.58	17±3.06
71	16±4.58	13±1.73	13±1.15	13±1.73	14±4.04	14±2.00

*Table 4* The intensity in dLAMP optimization

Incubation time (°C)	Intensity comparison to ladder (%) ± SD					
	Incubation times (minutes)					
	45	50	55	60	65	70
63	15±1.	12±1.	14±0.	15±1.	8±3.7	3±2.6
	85	31	72	89	9	7
<b>65</b>	<b>21±1.</b>	<b>22±3.</b>	<b>23±3.</b>	<b>17±6.</b>	<b>22±4.</b>	<b>9±5.0</b>
	<b>49</b>	<b>12</b>	<b>68</b>	<b>70</b>	<b>09</b>	<b>1</b>
67	10±4.	9±0.5	8±1.1	10±1.	9±2.8	9±6.6
	00	6	8	15	2	9
69	1±0.2	1±0.7	2±0.2	7±2.9	9±4.3	15±2.
	4	0	7	3	2	11
71	2±0.9	2±1.8	2±1.3	2±1.9	4±0.2	6±3.5
	9	3	1	3	0	1

#### 4.6.1 The intensity value of dLAMP

The intensity of dLAMP product on 2% gel electrophoresis was measured and analyzed. In Figure 13 showing the overall comparison of the intensity compared to the ladder of each temperature and incubation time.




Figure 13 The graph summary of temperature and incubation time optimization in dLAMP

We performed ANOVA two-way to get the significant difference between temperature and incubation time. The ANOVA test showed that the intensity based on each temperature shows a significant difference ( $P < 0.0001$ ), but for the incubation time, there is no significant difference ( $P > 0.6339$ ) (table 5).

Table 5 Two-way ANOVA for the intensity value based on varied temperatures and incubation time

Two-way ANOVA		Ordinary			
Alpha		0.05			
Source of Variation	% of total variation	P value	P value summary	Significant?	
Interaction	25.75	<0.0001	****	Yes	
Row Factor	61.45	<0.0001	****	Yes	
Column Factor	0.6952	0.6339	ns	No	
ANOVA table	SS	DF	MS	F (DFn, DFd)	P value
Interaction	1179	20	58.94	F (20, 60) = 6.376	P<0.0001
Row Factor	2814	4	703.4	F (4, 60) = 76.09	P<0.0001
Column Factor	31.83	5	6.367	F (5, 60) = 0.6887	P=0.6339
Residual	554.7	60	9.244		

Furthermore, based on the result we concluded that the temperature of 65°C with 55 minutes of incubation time showed the highest value of band intensity compared to 67,69, and 71°C in the same incubation time ( $p < 0.0001$ ) (Figure 14).




Figure 14 The two-way ANOVA graph for dLAMP intensity

#### 4.6.2 dLAMP product yield

We performed ANOVA two-way to get the significant difference between temperature and incubation time. The ANOVA test showed that the dLAMP yield on both each temperature and incubation time ( $P < 0.0001$ ) (table 6).

Table 6 Two-way ANOVA for dLAMP product yield based on varied temperatures and incubation

Two-way ANOVA		Ordinary			
<b>Alpha</b>		0.05			
<b>Source of Variation</b>	% of total variation		P value	P value summary	Significant ?
<b>Interaction</b>	47.50		<0.000	****	Yes
<b>Row Factor</b>	46.15		<0.000	****	Yes
<b>Column Factor</b>	2.783		<0.000	****	Yes
<b>ANOVA table</b>	SS	D	MS	F (DFn, DFd)	P value
<b>Interaction</b>	5159	20	257.9	F (20, 60) = 40.02	P<0.000 1
<b>Row Factor</b>	5012	4	1253	F (4, 60) = 194.4	P<0.000 1
<b>Column Factor</b>	302.2	5	60.44	F (5, 60) = 9.378	P<0.000 1
<b>Residual</b>	386.7	60	6.444		

Furthermore, based on the result we concluded that the temperature 65°C with 55 minutes incubation time showed as the highest value of band intensity compared to 63, 67, 69, and 71°C in the same incubation time ( $p < 0.0001$ ) (Figure 15).




Figure 15 The two-way ANOVA graph for dLAMP product yield

Based on the results of intensity and dLAMP product of each temperature in varied incubation time, we concluded that temperature 65°C with incubation time 55 minutes give a clear intensity and comparable dLAMP product concentration. Next, we used this optimum temperature and incubation time dLAMP condition in optimization of  $MgSO_4$  along with HNB volume to obtain the best condition of our developed dLAMP as well to be able to distinguish the positive and negative results by naked eyes.

#### 4.6.3 MgSO<sub>4</sub> and HNB optimization

The optimum of MgSO<sub>4</sub> correlation with the addition of HNB gives a significant result in this study. Based on the two-way ANOVA analysis (Table 7) on wavelength 650 nm, we concluded that as high the MgSO<sub>4</sub> and HNB concentration we added to the reaction, as high the absorbance on wavelength 650 nm ( $p \leq 0.0001$ ) (Figure 16).

Table 7 The two-way ANOVA table result of MgSO<sub>4</sub> and HNB concentration optimization

Two-way ANOVA	Ordinary			
Alpha	0.05			
Source of Variation	% of total variation	P value	P value summary	Significant ?
Interaction	10.19	<0.0001	****	Yes
Row Factor	81.74	<0.0001	****	Yes
Column Factor	6.576	<0.0001	****	Yes




Figure 16 The absorbance value for MgSO<sub>4</sub> and HNB optimization

As for the conclusion, the optimum MgSO<sub>4</sub> in its correlation on HNB concentration optimization on dLAMP assay based on the analysis of the absorbance on wavelength 650 nm using UV-Vis spectrophotometry instrument is at 6.5 mM

MgSO<sub>4</sub> with the addition of 160 μM HNB in 25 μL total volume of dLAMP reaction which show a significant higher than other condition of MgSO<sub>4</sub> and HNB volume ( $p \leq 0.0001$ ) that also shown in Figure 17 of the optimum MgSO<sub>4</sub> and HNB concentration for visualization.




Figure 17 The reaction tube for MgSO<sub>4</sub> and HNB optimization

Additionally, the optimization of MgSO<sub>4</sub> and HNB concentration shows no significant differences on intensity (Table 8) and dLAMP product yield (Table 9), that also able to be analyzed by graphic summary (Figure 18). The dLAMP product also analyzed using 2% gel electrophoresis (Figure 19).

Table 8 The one-way ANOVA of MgSO<sub>4</sub> on intensity

<b>ANOVA summary</b>	
F	0.6956
P value	0.6021
P value summary	ns
Significant diff. among means ( $P < 0.05$ )?	No
R squared	0.1001

Table 9 The one-way ANOVA of MgSO<sub>4</sub> on product yield

<b>ANOVA summary</b>	
F	1.375
P value	0.2780
P value summary	ns
Significant diff. among means ( $P < 0.05$ )?	No
R squared	0.2157




Figure 18 The graph summary of MgSO<sub>4</sub> and HNB concentration optimization




Figure 19 The varied MgSO<sub>4</sub> and HNB concentration on dLAMP gel electrophoresis result


Lane M: 100 bp DNA ladder bio-helix; Lane 2-6: MgSO<sub>4</sub> varied on dLAMP 3.5, 4.5, 5.5, 6.5, and 7.5 mM, respectively; Lane 7: Negative control.

Furthermore, the sensitivity of dLAMP was analyzed using ten-fold serial dilution of positive controls of *KPC* (Figure 20 (a)) and *NDM* (Figure 21 (a)). The result showed that the dLAMP can detect the *KPC* and *NDM* genes until the limit of detection 52 fg or equal to a copy of DNA each gene, respectively in one reaction.



The positive result also can be seen on the blue-sky color on the reaction of dLAMP with single template *KPC* (Figure 20 (b)) and *NDM* (Figure 21 (b)).

The specificity of dLAMP reaction was confirmed by cross react the template used in dLAMP with different genes, *OXA-48*. As the result, the specificity of dLAMP shown by Figure 22 (a) was specific and did not show any band product on gel electrophoresis and color changing in the reaction with addition of HNB (22 (b)).



*Figure 20* The sensitivity of dLAMP *KPC*

- Lane M: 100 bp DNA ladder bio-helix; Lane 2-13: ten-fold serial dilution for dLAMP sensitivity test,  $1.0 \times 10^7$ ,  $10^6$ ,  $10^5$ ,  $10^4$ ,  $10^3$ ,  $10^2$ ,  $10^1$ ,  $10^0$ ,  $10^{-1}$ ,  $10^{-2}$ ,  $10^{-3}$ , and  $10^{-4}$ , respectively.
- dLAMP tube reaction, a-l,  $1.0 \times 10^7$ ,  $10^6$ ,  $10^5$ ,  $10^4$ ,  $10^3$ ,  $10^2$ ,  $10^1$ ,  $10^0$ ,  $10^{-1}$ ,  $10^{-2}$ ,  $10^{-3}$ , and  $10^{-4}$ , respectively; NC: negative control.





Figure 21 The sensitivity of dLAMP NDM

- 1 Lane M: 100 bp DNA ladder bio-helix; Lane 2-13: ten-fold serial dilution for dLAMP sensitivity test,  $1.0 \times 10^7$ ,  $10^6$ ,  $10^5$ ,  $10^4$ ,  $10^3$ ,  $10^2$ ,  $10^1$ ,  $10^0$ ,  $10^{-1}$ ,  $10^{-2}$ ,  $10^{-3}$ , and  $10^{-4}$ , respectively.
- 2 dLAMP tube reaction, a-l:  $1.0 \times 10^7$ ,  $10^6$ ,  $10^5$ ,  $10^4$ ,  $10^3$ ,  $10^2$ ,  $10^1$ ,  $10^0$ ,  $10^{-1}$ ,  $10^{-2}$ ,  $10^{-3}$ , and  $10^{-4}$ , respectively; NC: negative control

The specificity of dLAMP reaction was confirmed by cross react the template used in dLAMP with different genes, *OXA-48*. As the result, the specificity of dLAMP shown by Figure 4.18 (a) was specific and did not show any band product on gel electrophoresis and color changing in the reaction with addition of HNB (4.18 (b)).



*Figure 22* The specificity of dLAMP

- a. Lane M: 100 bp DNA ladder bio-helix; Lane 2-5: dLAMP reaction with *OXA-48* DNA template, dLAMP reaction with *KPC* template, dLAMP reaction with *KPC* and *NDM* template, dLAMP reaction with *NDM* template.
- b. dLAMP tube reaction, a-e: Negative control, dLAMP reaction with *OXA-48* DNA template, dLAMP reaction with *KPC* template, dLAMP reaction with *KPC* and *NDM* template, dLAMP reaction with *NDM* template.



## CHAPTER V DISCUSSION

### 5.1 Targeted DNA sequences of *KPCs* and *NDMs* carbapenem-resistant (CR) genes

One hundred and twenty-three subtypes of *KPC* (*K. pneumoniae* carbapenemase) and forty-three subtypes of *NDM* (new-delhi- $\beta$ -Lactamase) were aligned with one hundred percent conserved region were used to ensure that the LAMP primers designed are specific to the desired DNA sequences of *KPCs* and *NDMs* CR genes.

### 5.2 Specificity of *KPCs* and *NDMs* DNA sequences

After the confirmation of the CR DNA sequences, the specificity of the sequences was checked using NCBI BLASTN software. The results showed that the *KPC* sequence is mostly found in plasmid (87.32%), and chromosome (5.17%), and clearly stated that it is the *KPC* sequence (7.51%). The *NDM* showed that the gene is mostly found in a plasmid (74.20%), chromosome (9.84%), and clearly states that it is the *NDM* sequence (15.96%). We checked their sequences in the chromosome and aligned them to make sure that they are both the same DNA sequences and confirmed that all the DNA sequences harbored in the chromosome are correctly the *KPC* and *NDM* CR DNA sequences. Then we ensure that these DNA sequences are specific enough to be used as the template for designing the primers of LAMP.

### 5.3 The universal LAMP primers of *KPC* and *NDM* genes

The LAMP primers were designed using the Primer Explorer version 5 software. The template for designing the primers used the DNA sequences of both

genes that previously aligned with a hundred percent of the conserved region from 123 subtypes of *KPC* and 43 subtypes of *NDM*. This makes the DNA sequences universal, meaning that the sequences are present in almost all these subtypes of *KPC* and *NDM* CR genes. By using these universal DNA sequences of both genes, we designed LAMP primers for both which are expected to be able to bind in all types of *KPC* and *NDM* CR genes making them the universal primers in the detection of both CR genes. The specificity of both sets of primers of *KPC* and *NDM* was then checked using BLASTN of the NCBI database to confirm their specificity. As a result, both *KPC* and *NDM* primer sets confirm that most will bind with the targeted sequence that is harbored in a plasmid with *K. pneumoniae* and *E. coli* are the species that mostly will be detected or bind with these primer sets. In the previous study, the LAMP primers were designed only based on 5 and 4 subtypes of *KPC* and *NDM* genes, respectively (Feng et al., 2021). This study represents a larger range of subtypes of both types of genes, which are later expected to be more reliable in the detection of *KPC* and *NDM* CR genes.

#### 5.4 Detection of *KPC* and *NDM* genes using Polymerase-chained reaction (PCR)

The positive controls obtained from the previous study (Kerdsin et al., 2019; Takeuchi et al., 2022) which were previously confirmed as *KPC* and *NDM* CR genes by whole genome sequencing (WGS). The extracted DNA of *E. asburiae* as the positive control of the *KPC* gene and *E. coli* as the *NDM* positive controls were confirmed using polymerase-chained reaction (PCR) using F3 and B3 that were designed for *KPC* and *NDM*. The result showed that both genes can be detected by the PCR band on 2% gel electrophoresis around 200 base pair products. In this research,

the PCR products obtained were shown in 200 bp. products (Figure 4.4), through the template of *KPC* and *NDM* we used to be around 800 bp. This is due to the designed LAMP F3 and B3 primers of both genes are designed to amplify the template and will stop amplifying if the product already produces 200 bp. product, to avoid hairpin formation in LAMP reaction (Notomi et al., 2000).

Our designed universal primers of *KPC* and *NDM* were used in PCR to check their specificity. We first check their specificity in our positive and negative controls. The band showed only in the specific DNA template that we mixed in the reaction tube. But didn't show any band when we mixed with crossed template to each other genes and our negative control, *OXA-48* CR genes. Furthermore, we check their specificity in different types of *NDM* by using extracted DNA of twenty-one clinical bacterial strains that were previously confirmed with *NDM* in a previous study (Takeuchi et al., 2022). The PCR result showed in 2% gel electrophoresis with F3 and B3 primers that the different subtypes of *NDM* can be detected using our developed universal primers.

Additionally, we perform the sensitivity test using our design primers in PCR using our positive controls *KPC* and *NDM*. The 10-fold serial dilution was performed to dilute the extracted bacterial DNA as the template to decrease the concentration as low as we could. The result showed that the PCR can detect the *KPC* and *NDM* gene in the limit around 520 fg or equal to approximately 10 copies/reaction, for both *KPC* and *NDM*.

### 5.5 The detection and optimization of *KPC* and *NDM* genes using Single LAMP (sLAMP)

The loop-mediated isothermal amplification (LAMP) performed in this study is aimed to determine the compromised temperatures of both CR genes, *KPC* and *NDM*. Both LAMP reactions contained with each of the *KPC* and *NDM* templates showed the same temperature in working well, which are around 65, 66, and 67 Celsius degree (Figure 4.8). This reaction was incubated around 30-70 minutes. We confirmed that the reaction was working well and started to show a band on 2% gel electrophoresis when we incubated them for 45 minutes. We use this result as a compromised temperature for both genes in duplex loop-mediated isothermal amplification (dLAMP) assay, as we expect that both genes can be detected using this method using the compromised temperature of both in the LAMP reaction. This finding also compromises with the previous study in the detection of CR genes as the incubation temperature was 65°C (Feng et al., 2021) which may also be an optimum temperature in the detection of *KPC* and *NDM* in all subtypes using LAMP.

### 5.6 The detection and optimization of *KPC* and *NDM* using dLAMP

The dLAMP method in this study was performed first using the compromised temperature of both genes around 65, 67, and 68°C with 45 minutes of incubation time. The result showed that the reaction can detect both genes, which is confirmed by a single template in the dLAMP mixture. Additionally, the band also showed when we added both templates in one single dLAMP reaction tube. After we confirmed the dLAMP reaction was working, the optimization of dLAMP in temperature, incubation time, and MgSO<sub>4</sub> along with HNB concentration was conducted. As the result of the

optimization, the optimum condition of the dLAMP in the detection of CR genes, *KPC*, and *NDM* are as follows; temperature 65°C with 55 minutes incubation time and 6.5 mM of MgSO<sub>4</sub> along with the addition of 160 μM of HNB in total volume of 25 μL dLAMP reaction.

The sensitivity of dLAMP primers in the detection of *KPC* and *NDM* CR genes was conducted to confirm the limit of detection of our developed dLAMP method. In this part, the template used was the bacterial DNA extraction from positive controls of both genes. The concentration of the extracted DNA is then measured using nanodrop and then diluted with a 10-fold serial dilution method. As a result, the limit of detection showed the dLAMP can detect the CR genes at the limit of detection of around 52 fg, which showed ten times more sensitivity than the PCR method.

Previous research in the detection of *KPC* and *NDM* CR genes using LAMP showed that the LAMP assay was found to be more sensitive than conventional PCR which confirmed that the PCR was not able to detect some isolates of that LAMP assay can detect it. Furthermore, the turnaround time of the LAMP assay is only 2-3 hours, which might be an alternative method for rapid detection of both genes (Solanki et al., 2013). The detection of CR genes using the dLAMP technique is a new technique yet gives a very limited comparison result in this study. Therefore, in this study, the comparison study is mostly compared to the LAMP method.

Finally, the specificity of the dLAMP method in the detection of other CR genes; *OXA-48* showed a very specific result, as no band presence on the gel electrophoresis and no color changing in the reaction by the addition of the HNB into sky-blue color. This finding is also consistent with a previous study about the detection of the *mcr-1* to *mcr-5* gene using multi-LAMP in comparison to the



conventional PCR method. The PCR method is known to possess high specificity, therefore the multi-LAMP also showed good consistency with PCR in the detection of the *mcr-1* to *mcr-5* gene (Zhong et al., 2019).



## CHAPTER VI

### CONCLUSION

This study has developed a duplex method of loop-mediated isothermal amplification (dLAMP) for enhancing the universality, rapid, sensitivity, and specificity of detecting CR genes; *KPC*, and *NDM* compared to the conventional PCR method. The dLAMP, utilizing a specially designed primers set, which can identify various subtypes of *KPC* and *NDM*, allows for visible results within an hour, even without the need for specialized equipment. In contrast, the standard PCR method requires 3.5 hours, including 30 minutes of gel electrophoresis, to achieve the same level of gene detection. Furthermore, when applied to clinical bacterial samples, the universal primers developed in this study demonstrated their ability to detect multiple types of *NDM* genes, affirming their suitability for identifying not only one subtype but multiple subtypes of CR genes, making them valuable for future application.

## REFERENCES

- Al-Tawfiq, J. A., & Tambyah, P. A. (2014). Healthcare associated infections (HAI) perspectives. *J Infect Public Health*, 7(4), 339-344. <https://doi.org/10.1016/j.jiph.2014.04.003>
- Armstrong, T., Fenn, S. J., & Hardie, K. R. (2021). JMM Profile: Carbapenems: a broad-spectrum antibiotic. *J Med Microbiol*, 70(12). <https://doi.org/10.1099/jmm.0.001462>
- Bartolini, A., Frasson, I., Cavallaro, A., Richter, S. N., & Palù, G. (2014). Comparison of phenotypic methods for the detection of carbapenem non-susceptible *Enterobacteriaceae*. *Gut Pathogens*, 6(13), 1-7. <https://doi.org/10.1186/1757-4749-6-13>
- Bartsch, S. M., McKinnell, J. A., Mueller, L. E., Miller, L. G., Gohil, S. K., Huang, S. S., & Lee, B. Y. (2017). Potential economic burden of carbapenem-resistant *Enterobacteriaceae* (CRE) in the United States. *Clin Microbiol Infect*, 23(1), 48.e49-48.e16. <https://doi.org/10.1016/j.cmi.2016.09.003>
- Bassetti, M., Giacobbe, D. R., Giamarellou, H., Viscoli, C., Daikos, G. L., Dimopoulos, G., De Rosa, F. G., Giamarellos-Bourboulis, E. J., Rossolini, G. M., Righi, E., Karaiskos, I., Tumbarello, M., Nicolau, D. P., Viale, P. L., Poulakou, G., Critically Ill Patients Study Group of the European Society of Clinical, M., Infectious, D., Hellenic Society of, C., & Societa Italiana di Terapia, A. (2018). Management of KPC-producing *Klebsiella pneumoniae* infections. *Clin Microbiol Infect*, 24(2), 133-144. <https://doi.org/10.1016/j.cmi.2017.08.030>
- Bassetti, M., Merelli, M., Temperoni, C., & Astilean, A. (2013). New antibiotics for bad bugs: where are we? *Annals of Clinical Microbiology and Antimicrobials*, 12(1), 22. <https://doi.org/10.1186/1476-0711-12-22>
- Bassetti, M., Peghin, M., Vena, A., & Giacobbe, D. R. (2019). Treatment of Infections Due to MDR Gram-Negative Bacteria. *Front Med (Lausanne)*, 6, 74. <https://doi.org/10.3389/fmed.2019.00074>
- Blair, J. M., Webber, M. A., Baylay, A. J., Ogbolu, D. O., & Piddock, L. J. (2015). Molecular mechanisms of antibiotic resistance. *Nat Rev Microbiol*, 13(1), 42-51. <https://doi.org/10.1038/nrmicro3380>
- Bojer, M. S., Hammerum, A. M., Jorgensen, S. L., Hansen, F., Olsen, S. S., Krogfelt, K. A., & Struve, C. (2012). Concurrent emergence of multidrug resistance and heat resistance by CTX-M-15-encoding conjugative plasmids in *Klebsiella pneumoniae*. *APMIS*, 120(9), 699-705. <https://doi.org/10.1111/j.1600-0463.2012.02885.x>
- Bonomo, R. A., Burd, E. M., Conly, J., Limbago, B. M., Poirel, L., Segre, J. A., & Westblade, L. F. (2018). Carbapenemase-Producing Organisms: A Global Scourge. *Clin Infect Dis*, 66(8), 1290-1297. <https://doi.org/10.1093/cid/cix893>
- Boucher, H. W., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009). Bad bugs, no drugs: no ESCAPE! An update from the Infectious Diseases Society of America. *Clin Infect Dis*.(1537-6591). <https://doi.org/10.1086/595011>
- Brejijeh, Z., Jubeh, B., & Karaman, R. (2020). Resistance of Gram-negative bacteria to current antibacterial agents and approaches to resolve it. *Molecules*, 25(6), 1340. <https://doi.org/10.3390/molecules25061340>

- Brink, A. J. (2019). Epidemiology of carbapenem-resistant Gram-negative infections globally. *Curr Opin Infect Dis*, 32(6), 609-616. <https://doi.org/10.1097/QCO.0000000000000608>
- Brogan, D. M., & Mossialos, E. (2016). A critical analysis of the review on antimicrobial resistance report and the infectious disease financing facility. *Global Health*, 12, 8. <https://doi.org/10.1186/s12992-016-0147-y>
- Brown, E. D., & Wright, G. D. (2016). Antibacterial drug discovery in the resistance era. *Nature*, 529(7586), 336-343. <https://doi.org/10.1038/nature17042>
- Browne, A. J., Chipeta, M. G., Haines-Woodhouse, G., Kumaran, E. P. A., Hamadani, B. H. K., Zarea, S., Henry, N. J., Deshpande, A., Reiner, R. C., Day, N. P. J., Lopez, A. D., Dunachie, S., Moore, C. E., Stergachis, A., Hay, S. I., & Dolecek, C. (2021). Global antibiotic consumption and usage in humans, 2000–18: a spatial modelling study. *The Lancet Planetary Health*, 5(12), e893-e904. [https://doi.org/10.1016/s2542-5196\(21\)00280-1](https://doi.org/10.1016/s2542-5196(21)00280-1)
- Bush, K., Courvalin, P., Dantas, G., Davies, J., Eisenstein, B., Huovinen, P., Jacoby, G. A., Kishony, R., Kreiswirth, B. N., Kutter, E., Lerner, S. A., Levy, S., Lewis, K., Lomovskaya, O., Miller, J. H., Mobashery, S., Piddock, L. J., Projan, S., Thomas, C. M., . . . Zgurskaya, H. I. (2011). Tackling antibiotic resistance. *Nat Rev Microbiol*, 9(12), 894-896. <https://doi.org/10.1038/nrmicro2693>
- Carmeli, Y., Akova, M., Cornaglia, G., Daikos, G. L., Garau, J., Harbarth, S., Rossolini, G. M., Souli, M., & Giamarellou, H. (2010). Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control. *Clin Microbiol Infect*, 16(2), 102-111. <https://doi.org/10.1111/j.1469-0691.2009.03115.x>
- Cassini, A., Högberg, L. D., Plachouras, D., Quattrocchi, A., Hoxha, A., Simonsen, G. S., Colomb-Cotinat, M., Kretzschmar, M. E., Devleeschauwer, B., Cecchini, M., Ouakrim, D. A., Oliveira, T. C., Struelens, M. J., Suetens, C., Monnet, D. L., Strauss, R., Mertens, K., Struyf, T., Catry, B., . . . Hopkins, S. (2019). Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. *The Lancet Infectious Diseases*, 19(1), 56-66. [https://doi.org/10.1016/s1473-3099\(18\)30605-4](https://doi.org/10.1016/s1473-3099(18)30605-4)
- CDC. (2019a). *Antibiotic Resistance Threats in the United States*. <https://www.cdc.gov/drugresistance/biggest-threats.html>
- CDC. (2019b). Antibiotic resistance threats in the United States, 2019 [Report]. <https://stacks.cdc.gov/view/cdc/82532>
- CDC. (2021). *Where Resistance Spreads*. Retrieved 31 July 2023 from <https://www.cdc.gov/drugresistance/where-resistance-spreads.html>
- Cheng, C., Fau, Z. F., & Rui, Y. (2014). Rapid detection of *bla*NDM, *bla*KPC, *bla*IMP, and *bla*VIM carbapenemase genes in bacteria by loop-mediated isothermal amplification. *Microb Drug Resist.*(1931-8448). <https://doi.org/10.1089/mdr.2014.0040>
- Choopara, I., Suea-Ngam, A., Teethaisong, Y., Howes, P. D., Schmelcher, M., Leelahavanichkul, A., Thunyaharn, S., Wongsawaeng, D., deMello, A. J., Dean, D., & Somboonna, N. (2021). Fluorometric Paper-Based, Loop-Mediated Isothermal Amplification Devices for Quantitative Point-of-Care Detection of Methicillin-Resistant Staphylococcus aureus (MRSA). *ACS Sens*, 6(3), 742-751.

- <https://doi.org/10.1021/acssensors.0c01405>
- Choopara, I., Teethaisong, Y., Arunrut, N., Thunyaharn, S., Kiatpathomchai, W., & Somboonna, N. (2021). Specific and sensitive, ready-to-use universal fungi detection by visual color using ITS1 loop-mediated isothermal amplification combined hydroxynaphthol blue. *PeerJ*, 9, e11082. <https://doi.org/10.7717/peerj.11082>
- Coque, T. M., Canton, R., Perez-Cobas, A. E., Fernandez-de-Bobadilla, M. D., & Baquero, F. (2023). Antimicrobial Resistance in the Global Health Network: Known Unknowns and Challenges for Efficient Responses in the 21st Century. *Microorganisms*, 11(4). <https://doi.org/10.3390/microorganisms11041050>
- Cuzon, G., Naas, T., Truong, H., Villegas, M. V., Wisell, K. T., Carmeli, Y., Gales, A. C., Venezia, S. N., Quinn, J. P., & Nordmann, P. (2010). Worldwide diversity of *Klebsiella pneumoniae* that produce beta-lactamase blaKPC-2 gene. *Emerg Infect Dis*, 16(9), 1349-1356. <https://doi.org/10.3201/eid1609.091389>
- Dadas, R., Chaudhary, D., Bhadouriya, S., Dhanavelu, M., K. R., Sudhakar, S. B., Venkatesan, G., & Pandey, A. B. (2013). *Development of N-gene based single step reverse transcription loop mediated isothermal amplification (RT-LAMP) for rapid detection of peste des petits ruminant virus (PPRV) in clinical samples.*
- Davey, P., Marwick, C. A., Scott, C. L., Charani, E., McNeil, K., Brown, E., Gould, I. M., Ramsay, C. R., & Michie, S. Interventions to improve antibiotic prescribing practices for hospital inpatients. (1469-493X (Electronic)).
- Davey, P., Marwick, C. A., Scott, C. L., Charani, E., McNeil, K., Brown, E., Gould, I. M., Ramsay, C. R., & Michie, S. (2017). Interventions to improve antibiotic prescribing practices for hospital inpatients. *Cochrane Database Syst Rev*, 2(2), CD003543. <https://doi.org/10.1002/14651858.CD003543.pub4>
- Davies, J., & Davies, D. (2010). Origins and evolution of antibiotic resistance. *Microbiol Mol Biol Rev*, 74(3), 417-433. <https://doi.org/10.1128/MMBR.00016-10>
- De Oliveira, D. M. P., Forde, B. A.-O., Kidd, T. J., Harris, P. N. A., Schembri, M. A.-O., Beatson, S. A.-O., Paterson, D. L., & Walker, M. J. (2020). Antimicrobial Resistance in ESKAPE Pathogens. *Clin Microbiol Rev*. (1098-6618). <https://doi.org/10.1128/CMR.00181-19>
- Drawz, S. M., & Bonomo, R. A. (2010). Three decades of beta-lactamase inhibitors. *Clin Microbiol Rev*.(1098-6618 ). <https://doi.org/10.1128/CMR.00037-09>
- El-Kholy, A. A., Abdelrahman, K., & Soliman, H. (2014). Rapid detection of BoHV-1 genomic DNA by loop-mediated isothermal amplification assay. *Journal of Virological Methods*, 204, 81-85. <https://doi.org/10.1016/j.jviromet.2014.04.011>
- Falagas, M. E., Tansarli, G. S., Karageorgopoulos, D. E., & Vardakas, K. Z. (2014). Deaths attributable to carbapenem-resistant *Enterobacteriaceae* infections. *Emerg Infect Dis*, 20(7), 1170-1175. <https://doi.org/10.3201/eid2007.121004>
- Fan, Z., Feng, Y., Xu, W., Feng, J., Yan, C., Fu, T., Zhao, H., Cui, J., Gan, L., Liu, S., Du, S., Zhang, R., Xu, Z., Li, N., Xue, G., & Yuan, J. (2022). Rapid Detection of Multi-Resistance Strains Carrying mcr-1 Gene Using Recombinase-Aided Amplification Directly on Clinical Samples. *Front Microbiol*, 13, 852488. <https://doi.org/10.3389/fmicb.2022.852488>
- Feng, W., Niu, S., Chang, Y., Jia, X., Huang, S., & Yang, P. (2021). Design of Rapid Detection System for Five Major Carbapenemase Families (bla KPC, bla NDM,



- bla VIM, bla IMP and bla OXA-48-Like) by Colorimetric Loop-Mediated Isothermal Amplification. *Infect Drug Resist*, 14, 1865-1874. <https://doi.org/10.2147/IDR.S301757>
- Fernandez, L., & Hancock, R. E. (2012). Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance. *Clin Microbiol Rev*, 25(4), 661-681. <https://doi.org/10.1128/CMR.00043-12>
- Fisher, J. F., Meroueh So Fau - Mobashery, S., & Mobashery, S. (2005). Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity. *Chem Rev*(0009-2665). <https://doi.org/10.1021/cr030102i>
- Fr, C. (2010). Performance standards for antimicrobial susceptibility testing. *Approved Standard M100-S20*.
- Garoy, E. Y., Gebreab, Y. B., Achila, O. O., Tekeste, D. G., Kesete, R., Ghirmay, R., Kiflay, R., & Tesfu, T. (2019). Methicillin-resistant *Staphylococcus aureus* (MRSA): Prevalence and antimicrobial sensitivity pattern among patients- A multicenter study in Asmara, Eritrea. *Can J Infect Dis Med Microbiol*, 2019, 8321834. <https://doi.org/10.1155/2019/8321834>
- Ghebremedhin, B., Halstenbach, A., Smiljanic, M., Kaase, M., & Ahmad-Nejad, P. (2016). MALDI-TOF MS based carbapenemase detection from culture isolates and from positive blood culture vials. *Ann Clin Microbiol Antimicrob*, 15, 5. <https://doi.org/10.1186/s12941-016-0120-x>
- Gong, J., Zhuang, L., Zhang, D., Zhang, P., Dou, X., & Wang, C. (2018). Establishment of a Multiplex Loop-Mediated Isothermal Amplification Method for Rapid Detection of Sulfonamide Resistance Genes (sul1, sul2, sul3) in Clinical Enterobacteriaceae Isolates from Poultry. *Foodborne Pathog Dis*, 15(7), 413-419. <https://doi.org/10.1089/fpd.2017.2410>
- Goto, M., Honda, E., Ogura, A., Nomoto, A., & Hanaki, K. (2009). Colorimetric detection of loop-mediated isothermal amplification reaction by using hydroxy naphthol blue. *Biotechniques*, 46(3), 167-172. <https://doi.org/10.2144/000113072>
- Goto, T., Kishita, M., Sun, Y., Sako, T., & Okajima, I. (2020). Degradation of Polylactic Acid Using Sub-Critical Water for Compost. *Polymers (Basel)*, 12(11). <https://doi.org/10.3390/polym12112434>
- Hernández-García, M., Castillo-Polo, J. A., Cordero, D. G., Pérez-Viso, B., García-Castillo, M., de la Fuente, J. S., Morosini, M. I., Cantón, R., & Ruiz-Garbajosaa, P. (2022). Impact of ceftazidime-avibactam treatment in the emergence of novel KPC Variants in the ST307-*Klebsiella pneumoniae* high-risk clone and consequences for their routine detection. *J Clin Microbiol*, 60(3), 1-9. <https://doi.org/10.1128/jcm.02245-21>
- Hindson, B. J., Ness, K. D., Masquelier, D. A., Belgrader, P., Heredia, N. J., Makarewicz, A. J., Bright, I. J., Lucero, M. Y., Hiddessen, A. L., Legler, T. C., Kitano, T. K., Hodel, M. R., Petersen, J. F., Wyatt, P. W., Steenblock, E. R., Shah, P. H., Bousse, L. J., Troup, C. B., Mellen, J. C., . . . Colston, B. W. (2011). High-Throughput Droplet Digital PCR System for Absolute Quantitation of DNA Copy Number. *Analytical Chemistry*, 83(22), 8604-8610. <https://doi.org/10.1021/ac202028g>
- Hong, Y., Ma, B., Li, J., Shuai, J., Zhang, X., Xu, H., & Zhang, M. (2023). Triplex-Loop-Mediated Isothermal Amplification Combined with a Lateral Flow

- Immunoassay for the Simultaneous Detection of Three Pathogens of Porcine Viral Diarrhea Syndrome in Swine. *Animals*, 13(12).
- Iwamoto, T., Sonobe, T., & Hayashi, K. (2003). Loop-mediated isothermal amplification for direct detection of Mycobacterium tuberculosis complex, M. avium, and M. intracellulare in sputum samples. *J Clin Microbiol*, 41(6), 2616-2622. <https://doi.org/10.1128/JCM.41.6.2616-2622.2003>
- Jang, W. S., Da Hye Lim, Jung yoon, Ahran Kim, Minsup Lim, Jeonghun Nam, Richard Yanagihara, Sook-Won Ryu, Bo Kyeung Jung, Nam-Hee Ryoo, Chae Seung Lim. (2021). Development of a multiplex Loop-Mediated Isothermal Amplification (LAMP) assay for on-site diagnosis of SARS Ccv-2. *PLOS ONE*, 16(3), 14. <https://doi.org/10.1371/journal.pone.0248042>
- Jang, W. S., Lim, D. H., Choe, Y., Jee, H., Moon, K. C., Kim, C., Choi, M., Park, I. S., & Lim, C. S. (2021). Development of a Multiplex Loop-Mediated Isothermal Amplification Assay for Diagnosis of Plasmodium spp., Plasmodium falciparum and Plasmodium vivax. *Diagnostics (Basel)*, 11(11). <https://doi.org/10.3390/diagnostics11111950>
- Jang, W. S., Lim, D. H., Choe, Y. L., Nam, J., Moon, K. C., Kim, C., Choi, M., Park, I., Park, D. W., & Lim, C. S. (2022). Developing a multiplex loop-mediated isothermal amplification assay (LAMP) to determine severe fever with thrombocytopenia syndrome (SFTS) and scrub typhus. *PLOS ONE*, 17(2), e0262302. <https://doi.org/10.1371/journal.pone.0262302>
- Jang, W. S., Lim, D. H., Nam, J., Mihn, D. C., Sung, H. W., Lim, C. S., & Kim, J. (2020). Development of a multiplex isothermal amplification molecular diagnosis method for on-site diagnosis of influenza. *PLOS ONE*, 15(9), e0238615. <https://doi.org/10.1371/journal.pone.0238615>
- Kahan, F. M., Kropp, H., Sundelof, J. G., & Birnbaum, J. (1983). Thienamycin: development of imipenem-cilastatin. *Journal of Antimicrobial Chemotherapy*, 12, 1-35. [https://doi.org/10.1093/jac/12.suppl\\_D.1](https://doi.org/10.1093/jac/12.suppl_D.1)
- Kaneko, H., Fukushima, E., & Suzutani, T. (2007). Tolerance of loop-mediated isothermal amplification to a culture medium and biological substances. *J Biochem Biophys Methods*.(0165-022X). <https://doi.org/10.1016/j.jbbm.2006.08.008>
- Kerdsin, A., Deekae, S., Chayangsu, S., Hatrongjit, R., Chopjitt, P., Takeuchi, D., Akeda, Y., Tomono, K., & Hamada, S. (2019). Genomic characterization of an emerging blaKPC-2 carrying Enterobacteriaceae clinical isolates in Thailand. *Sci Rep*, 9(1), 18521. <https://doi.org/10.1038/s41598-019-55008-x>
- Khan, M., Wang, R., Li, B., Liu, P., Weng, Q., & Chen, Q. (2018). Comparative Evaluation of the LAMP Assay and PCR-Based Assays for the Rapid Detection of Alternaria solani. *Front Microbiol*, 9, 2089. <https://doi.org/10.3389/fmicb.2018.02089>
- Kim, H. J., Kim, Y. J., Yong, D. E., Lee, K., Park, J. H., Lee, J. M., & Yoon, S. S. (2014). Loop-mediated isothermal amplification of vanA gene enables a rapid and naked-eye detection of vancomycin-resistant enterococci infection. *J Microbiol Methods*.(1872-8359). <https://doi.org/10.1016/j.mimet.2014.05.021>
- Kim, J., Park, B. G., Lim, D. H., Jang, W. S., Nam, J., Mihn, D. C., & Lim, C. S. (2021). Development and evaluation of a multiplex loop-mediated isothermal amplification (LAMP) assay for differentiation of Mycobacterium tuberculosis

- and non-tuberculosis mycobacterium in clinical samples. *PLOS ONE*, 16(1), e0244753. <https://doi.org/10.1371/journal.pone.0244753>
- Kim, J. H., Kang, M., Park, E., Chung, D. R., Kim, J., & Hwang, E. S. (2019). A Simple and Multiplex Loop-Mediated Isothermal Amplification (LAMP) Assay for Rapid Detection of SARS-CoV. *Biochip J*, 13(4), 341-351. <https://doi.org/10.1007/s13206-019-3404-3>
- Kitchel, B., Rasheed, J. K., Patel, J. B., Srinivasan, A., Navon-Venezia, S., Carmeli, Y., Brolund, A., & Giske, C. G. (2009). Molecular epidemiology of KPC-producing *Klebsiella pneumoniae* isolates in the United States: clonal expansion of multilocus sequence type 258. *Antimicrob Agents Chemother*, 53(8), 3365-3370. <https://doi.org/10.1128/AAC.00126-09>
- Kuchibiro, T., Komatsu, M., Yamasaki, K., Nakamura, T., Nishio, H., Nishi, I., Kimura, K., Niki, M., Ono, T., Sueyoshi, N., Kita, M., Kida, K., Ohama, M., Satoh, K., Toda, H., Mizutani, T., Fukuda, N., Sawa, K., Nakai, I., . . . Wada, Y. (2018). Evaluation of the modified carbapenem inactivation method for the detection of carbapenemase-producing Enterobacteriaceae. *J Infect Chemother*, 24(4), 262-266. <https://doi.org/10.1016/j.jiac.2017.11.010>
- Kulengowski, B., Ribes, J. A., & Burgess, D. S. (2019). Polymyxin B Etest((R)) compared with gold-standard broth microdilution in carbapenem-resistant Enterobacteriaceae exhibiting a wide range of polymyxin B MICs. *Clin Microbiol Infect*, 25(1), 92-95. <https://doi.org/10.1016/j.cmi.2018.04.008>
- Laxminarayan, R., Duse, A., Wattal, C., Zaidi, A. K., Wertheim, H. F., Sumpradit, N., Vlieghe, E., Hara, G. L., Gould, I. M., Goossens, H., Greko, C., So, A. D., Bigdeli, M., Tomson, G., Woodhouse, W., Ombaka, E., Peralta, A. Q., Qamar, F. N., Mir, F., . . . Cars, O. (2013). Antibiotic resistance-the need for global solutions. *Lancet Infect Dis*, 13(12), 1057-1098. [https://doi.org/10.1016/S1473-3099\(13\)70318-9](https://doi.org/10.1016/S1473-3099(13)70318-9)
- Li, J., & Macdonald, J. (2015). Advances in isothermal amplification: novel strategies inspired by biological processes. *Biosens Bioelectron.*(1873-4235). <https://doi.org/10.1016/j.bios.2014.08.069>
- Liang, C., Chu, Y., Cheng, S., Wu, H., Kajiyama, T., Kambara, H., & Zhou, G. (2012). Multiplex loop-mediated isothermal amplification detection by sequence-based barcodes coupled with nicking endonuclease-mediated pyrosequencing. *Anal Chem*, 84(8), 3758-3763. <https://doi.org/10.1021/ac3003825>
- Liu, N., Zou, D., Dong, D., Yang, Z., Ao, D., Liu, W., & Huang, L. (2017). Development of a multiplex loop-mediated isothermal amplification method for the simultaneous detection of *Salmonella* spp. and *Vibrio parahaemolyticus*. *Sci Rep*, 7, 45601. <https://doi.org/10.1038/srep45601>
- Livermore, D. M. (1995). Bacterial Resistance to Carbapenems. In (pp. 25-47). Springer US. [https://doi.org/10.1007/978-1-4757-9203-4\\_3](https://doi.org/10.1007/978-1-4757-9203-4_3)
- Mahony, J., Chong, S., Bulir, D., Ruyter, A., Mwawasi, K., & Waltho, D. (2013). Multiplex loop-mediated isothermal amplification (M-LAMP) assay for the detection of influenza A/H1, A/H3 and influenza B can provide a specimen-to-result diagnosis in 40 min with single genome copy sensitivity. *J Clin Virol*, 58(1), 127-131. <https://doi.org/10.1016/j.jcv.2013.06.006>
- Mangold, K. A., Santiano, K., Broekman, R., Krafft, C. A., Voss, B., Wang, V., Hacek, D. M., Usacheva, E. A., Thomson, R. B., Jr., Kaul, K. L., & Peterson, L. R.



- (2011). Real-time detection of blaKPC in clinical samples and surveillance specimens. *J Clin Microbiol*, 49(9), 3338-3339. <https://doi.org/10.1128/JCM.00268-11>
- Mardis, E. R. (2008). Next-generation DNA sequencing methods. *Annu Rev Genomics Hum Genet.*(1527-8204), 16. <https://doi.org/10.1146/annurev.genom.9.081307.164359>
- McKernan, C., Benson, T., Farrell, S., & Dean, M. (2021). Antimicrobial use in agriculture: critical review of the factors influencing behaviour. *JAC Antimicrob Resist*, 3(4), dlab178. <https://doi.org/10.1093/jacamr/dlab178>
- Meletis, G. (2016). Carbapenem resistance: overview of the problem and future perspectives. *Ther Adv Infect Dis*, 3(1), 15-21. <https://doi.org/10.1177/2049936115621709>
- Micek, S. T., Wunderink, R. G., Kollef, M. H., Chen, C., Rello, J., Chastre, J., Antonelli, M., Welte, T., Clair, B., Ostermann, H., Calbo, E., Torres, A., Menichetti, F., Schramm, G. E., & Menon, V. (2015). An international multicenter retrospective study of *Pseudomonas aeruginosa* nosocomial pneumonia: impact of multidrug resistance. *Crit Care*, 19, 219. <https://doi.org/10.1186/s13054-015-0926-5>
- Miller, S. I. (2016). Antibiotic Resistance and Regulation of the Gram-Negative Bacterial Outer Membrane Barrier by Host Innate Immune Molecules. *mBio*, 7(5). <https://doi.org/10.1128/mBio.01541-16>
- Milobedzka, A., Ferreira, C., Vaz-Moreira, I., Calderón-Franco, D., Gorecki, A., Purkrtova, S., Jan, B., Dziewit, L., Singleton, C. M., Nielsen, P. H., Weissbrodt, D. G., & Manaia, C. M. (2022). Monitoring antibiotic resistance genes in wastewater environments: The challenges of filling a gap in the One-Health cycle. *Journal of Hazardous Materials*, 424, 127407. <https://doi.org/10.1016/j.jhazmat.2021.127407>
- Moellering, R. C., Jr., & Sentochnik, D. E. The carbapenems: new broad spectrum beta-lactam antibiotics. *J Antimicrob Chemother.*(0305-7453). [https://doi.org/10.1093/jac/24.suppl\\_a.1](https://doi.org/10.1093/jac/24.suppl_a.1)
- Moonga, L. C., Hayashida, K., Kawai, N., Nakao, R., Sugimoto, C., Namangala, B., & Yamagishi, J. (2020). Development of a Multiplex Loop-Mediated Isothermal Amplification (LAMP) Method for Simultaneous Detection of Spotted Fever Group Rickettsiae and Malaria Parasites by Dipstick DNA Chromatography. *Diagnostics (Basel)*, 10(11). <https://doi.org/10.3390/diagnostics10110897>
- Mori, Y., Nagamine K Fau - Tomita, N., Tomita N Fau - Notomi, T., & Notomi, T. (2001). Detection of loop-mediated isothermal amplification reaction by turbidity derived from magnesium pyrophosphate formation. *BBRC*. <https://doi.org/10.1006/bbrc.2001.5921>
- Mori, Y., & Notomi, T. (2009). Loop-mediated isothermal amplification (LAMP): a rapid, accurate, and cost-effective diagnostic method for infectious diseases. *J Infect Chemother*, 15(2), 62-69. <https://doi.org/10.1007/s10156-009-0669-9>
- Nagamine, K., Hase, T., & Notomi, T. (2002). Accelerated reaction by loop-mediated isothermal amplification using loop primers. *Mol Cell Probes*, 16(3), 223-229. <https://doi.org/10.1006/mcpr.2002.0415>
- Nakano, R., Nakano, A., Ishii, Y., Ubagai, T., Kikuchi-Ueda, T., Kikuchi, H., Tansho-Nagakawa, S., Kamoshida, G., Mu, X., & Ono, Y. (2015). Rapid detection of the *Klebsiella pneumoniae* carbapenemase (KPC) gene by loop-mediated isothermal

- amplification (LAMP). *J Infect Chemother*, 21(3), 202-206. <https://doi.org/10.1016/j.jiac.2014.11.010>
- Nikaido, H. (2009). Multidrug resistance in bacteria. *Annu Rev Biochem*, 78, 119-146. <https://doi.org/10.1146/annurev.biochem.78.082907.145923>
- Nikaido, H. (2009). Multidrug Resistance in Bacteria. *Annual Review of Biochemistry*, 78(1), 119-146. <https://doi.org/10.1146/annurev.biochem.78.082907.145923>
- Nordmann, P., Dortet, L., & Poirel, L. (2012). Carbapenem resistance in *Enterobacteriaceae*: here is the storm! *Trends in Molecular Medicine*, 18(5), 263-272. <https://doi.org/10.1016/j.molmed.2012.03.003>
- Nordmann, P., Picazo, J. J., Mutters, R., Korten, V., Quintana, A., Laeuffer, J. M., Seak, J. C., Flamm, R. K., Morrissey, I., & group, C. s. (2011). Comparative activity of carbapenem testing: the COMPACT study. *J Antimicrob Chemother*, 66(5), 1070-1078. <https://doi.org/10.1093/jac/dkr056>
- Nordmann, P., & Poirel, L. (2019). Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria. *Clin Infect Dis*, 69, S521-S528. <https://doi.org/10.1093/cid/ciz824>
- Nordmann, P., Poirel, L., & Dortet, L. (2012). Rapid detection of carbapenemase-producing *Enterobacteriaceae*. *Emerg Infect Dis*, 18(9), 1503-1507. <https://doi.org/10.3201/eid1809.120355>
- Notomi, T., Okayama, H., Masubuchi, H., Yonekawa, T., Watanabe, K., Amino, N., & Hase, T. (2000). Loop-mediated isothermal amplification of DNA. *Nucleic Acids Res*, 28(12), 1-7. <https://doi.org/10.1093/nar/28.12.e63>
- Nyan, D. C., & Swinson, K. L. (2015). A novel multiplex isothermal amplification method for rapid detection and identification of viruses. *Sci Rep*, 5, 17925. <https://doi.org/10.1038/srep17925>
- O'Neill, J. (2014). *Antimicrobial Resistance: Tackling Crisis for the Health and Wealth of Nations*. <https://www.who.int/news/item/29-04-2019-new-report-calls-for-urgent-action-to-avert-antimicrobial-resistance-crisis>
- O'Neill, J. (2016). *Tackling Drug-Resistant Infections Globally: Final Report and Recommendations*. [https://amr-review.org/sites/default/files/160518\\_Final%20paper\\_with%20cover.pdf](https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf)
- OECD. (2018). *Stemming the Superbug Tide*. <https://doi.org/10.1787/9789264307599-en>
- Osterdahl, M. F., Lee, K. A., Lochlainn, M. N., Wilson, S., Douthwaite, S., Horsfall, R., Sheedy, A., Goldenberg, S. D., Stanley, C. J., Spector, T. D., & Steves, C. J. (2020). Detecting SARS-CoV-2 at point of care: preliminary data comparing loop-mediated isothermal amplification (LAMP) to polymerase chain reaction (PCR). *BMC Infect Dis*, 20(1), 783. <https://doi.org/10.1186/s12879-020-05484-8>
- Papp-wallace, K. M., A., E., M. A. T., & B., R. A. (2011). Carbapenem: Past, Present and Future. *Antimicrob Agents Chemother*, 55(11), 18. <https://doi.org/10.1128/AAC.00296-11>
- Papp-Wallace, K. M., Endimiani, A., Taracila, M. A., & Bonomo, R. A. (2011). Carbapenems: past, present, and future. *Antimicrob Agents Chemother*, 55(11), 4943-4960. <https://doi.org/10.1128/AAC.00296-11>
- Parida, M., Ishida, H., Dash, P. K., Saxena, P., Jana, A. M., Islam, M. A., Inoue, S., Hosaka, N., & Morita, K. (2005). Rapid detection and differentiation of dengue virus serotypes by a real-time reverse transcription-loop-mediated isothermal

- amplification assay. *J Clin Microbiol.*(0095-1137).  
<https://doi.org/10.1128/JCM.43.6.2895-2903.2005>
- Parida, M., Sannarangaiah, S., Dash, P. K., Rao, P. V., & Morita, K. (2008). Loop mediated isothermal amplification (LAMP): a new generation of innovative gene amplification technique; perspectives in clinical diagnosis of infectious diseases. *Rev Med Virol*, 18(6), 407-421. <https://doi.org/10.1002/rmv.593>
- Patel, G., & Bonomo, R. A. (2011). Status report on carbapenemases: challenges and prospects. *Expert Review of Anti-infective Therapy*, 9(5), 555-570. <https://doi.org/10.1586/eri.11.28>
- Phaneuf, C. R., Mangadu, B., Tran, H. M., Light, Y. K., Sinha, A., Charbonier, F. W., Eckles, T. P., Singh, A. K., & Koh, C. Y. (2018). Integrated LAMP and immunoassay platform for diarrheal disease detection. *Biosens Bioelectron*(1873-4235).
- Pitout, J. D., Nordmann, P., & Poirel, L. (2015). Carbapenemase-Producing *Klebsiella pneumoniae*, a Key Pathogen Set for Global Nosocomial Dominance. *Antimicrob Agents Chemother*, 59(10), 5873-5884. <https://doi.org/10.1128/AAC.01019-15>
- Poirier, A. C., Kuang, D., Siedler, B. S., Borah, K., Mehat, J. W., Liu, J., Tai, C., Wang, X., van Vliet, A. H. M., Ma, W., Jenkins, D. R., Clark, J., La Ragione, R. M., Qu, J., & McFadden, J. (2021). Development of Loop-Mediated Isothermal Amplification Rapid Diagnostic Assays for the Detection of *Klebsiella pneumoniae* and Carbapenemase Genes in Clinical Samples. *Front Mol Biosci*, 8, 794961. <https://doi.org/10.3389/fmolb.2021.794961>
- Poon, L. L., Tashiro, M., Chan, K. H., Wong, B. W. Y., Yuen, K. Y., Guan, Y., & Peiris, J. S. M. (2004). Rapid detection of the severe acute respiratory syndrome (SARS) coronavirus by a loop-mediated isothermal amplification assay. *Clin Chem*. (0009-9147). <https://doi.org/10.1373/clinchem.2004.032011>
- Qin, Y., Duan, X., Peng, Y., & Rui, Y. (2021). Rapid detection of a novel B1-beta-lactamase gene, blaAFM-1 using a loop-mediated isothermal amplification (LAMP) assay. *Ann Clin Microbiol Antimicrob*, 20(1), 80. <https://doi.org/10.1186/s12941-021-00486-z>
- Ramirez, M. S., Bonomo, R. A., & Tolmasky, M. E. (2020). Carbapenemases: Transforming *Acinetobacter baumannii* into a Yet More Dangerous Menace. *Biomolecules*, 10(5). <https://doi.org/10.3390/biom10050720>
- Rohatensky, M. G., Livingstone, D. M., Mintchev, P., Barnes, H. K., Nakoneshny, S. C., Demetrick, D. J., Dort, J. C., & van Marle, G. (2018). Assessing the performance of a Loop Mediated Isothermal Amplification (LAMP) assay for the detection and subtyping of high-risk suptypes of Human Papilloma Virus (HPV) for Oropharyngeal Squamous Cell Carcinoma (OPSCC) without DNA purification. *BMC Cancer*, 18(1), 166. <https://doi.org/10.1186/s12885-018-4087-1>
- Sader, H. S., Rhomberg, P. R., Fuhrmeister, A. S., Mendes, R. E., Flamm, R. K., & Jones, R. N. (2019). Antimicrobial Resistance Surveillance and New Drug Development. *Open Forum Infect Dis*, 6(Suppl 1), S5-S13. <https://doi.org/10.1093/ofid/ofy345>
- Sattabongkot, J., Han, E.-T., Bantuchai, S., & Buates, S. (2014). Loop-mediated isothermal amplification assay for rapid diagnosis of malaria infections in an area of endemicity in Thailand. *J Clin Microbiol.* (1098-660X).

- <https://doi.org/10.1128/JCM.03313-13>
- Sauer, S., & Kliem, M. (2010). Mass spectrometry tools for the classification and identification of bacteria. *Nat Rev Microbiol.*(1740-1534). <https://doi.org/https://doi.org/10.1038/nrmicro2243>
- Selvarajah, D., Naing, C., Htet, N. H., & Mak, J. W. (2020). Loop-mediated isothermal amplification (LAMP) test for diagnosis of uncomplicated malaria in endemic areas: a meta-analysis of diagnostic test accuracy. *Malaria Journal*, 19(1), 211. <https://doi.org/10.1186/s12936-020-03283-9>
- Shao, Y., Zhu, S., Jin, C., & Chen, F. (2011). Development of multiplex loop-mediated isothermal amplification-RFLP (mLAMP-RFLP) to detect *Salmonella* spp. and *Shigella* spp. in milk. *Int J Food Microbiol*, 148(2), 75-79. <https://doi.org/10.1016/j.ijfoodmicro.2011.05.004>
- Sharma, S., Kumar, S., Ahmed, M. Z., Bhardwaj, N., Singh, J., Kumari, S., Savargaonkar, D., Anvikar, A. R., & Das, J. (2021). Advanced Multiplex Loop Mediated Isothermal Amplification (mLAMP) Combined with Lateral Flow Detection (LFD) for Rapid Detection of Two Prevalent Malaria Species in India and Melting Curve Analysis. *Diagnostics (Basel)*, 12(1). <https://doi.org/10.3390/diagnostics12010032>
- Solanki, R., Vanjari, L., Ede, N., Gungi, A., Soory, A., & Vemu, L. (2013). Evaluation of LAMP assay using phenotypic tests and conventional PCR for detection of blaNDM-1 and blaKPC genes among carbapenem-resistant clinical Gram-negative isolates. *J Med Microbiol*, 62(Pt 10), 1540-1544. <https://doi.org/10.1099/jmm.0.059907-0>
- Sonaty, G. T. (2015). Multiplexed Loop-mediated Isothermal Amplification of the 16S rRNA Gene for the Diagnosis of Neonatal Sepsis in Resource-limited Environments. *The University of Arkansas Undergraduate Research Journal*, 19(8), 43-52. <http://scholarworks.uark.edu/inquiry/vol19/iss1/8>
- Sood, S. (2014). Identification and differentiation of carbapenemases in *Klebsiella pneumoniae*: a phenotypic test evaluation study from Jaipur, India. *J Clin Diagn Res*, 8(7), DC01-03. <https://doi.org/10.7860/JCDR/2014/7027.4614>
- Takeuchi, D., Kerdsin, A., Akeda, Y., Sugawara, Y., Sakamoto, N., Matsumoto, Y., Motooka, D., Ishihara, T., Nishi, I., Laolerd, W., Santanirand, P., Yamamoto, N., Tomono, K., & Hamada, S. (2022). Nationwide surveillance in Thailand revealed genotype-dependent dissemination of carbapenem-resistant Enterobacterales. *Microb Genom*, 8(4). <https://doi.org/10.1099/mgen.0.000797>
- Tamma, P. D., Goodman, K. E., Harris, A. D., Tekle, T., Roberts, A., Taiwo, A., & Simner, P. J. (2017). Comparing the outcomes of patients with carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant *Enterobacteriaceae* bacteremia. *Clin Infect Dis*, 64(3), 257-264. <https://doi.org/10.1093/cid/ciw741>
- Tamura, K., Stecher, G., & Kumar, S. (2021). MEGA11: Molecular Evolutionary Genetics Analysis Version 11. *Mol Biol Evol*, 38(7), 3022-3027. <https://doi.org/10.1093/molbev/msab120>
- Tanner, N. A., Zhang, Y., & Evans, T. C., Jr. (2012). Simultaneous multiple target detection in real-time loop-mediated isothermal amplification. *Biotechniques*, 53(2), 81-89. <https://doi.org/10.2144/0000113902>
- Tomita, N., Mori, Y., Kanda, H., & Notomi, T. (2008). Loop-mediated isothermal



- amplification (LAMP) of gene sequences and simple visual detection of products. *Nature Protocols*, 3(5), 877-882. <https://doi.org/10.1038/nprot.2008.57>
- Tzouvelekis, L. S., Markogiannakis A Fau - Psychogiou, M., Psychogiou M Fau - Tassios, P. T., Tassios Pt Fau - Daikos, G. L., & Daikos, G. L. (2012). Carbapenemases in *Klebsiella pneumoniae* and other Enterobacteriaceae: an evolving crisis of global dimensions. *Clin Microbiol Rev.* (1098-6618). <https://doi.org/10.1128/CMR.05035-11>
- Tzouvelekis, L. S., Markogiannakis, A., Piperaki, E., Souli, M., & Daikos, G. L. (2014). Treating infections caused by carbapenemase-producing Enterobacteriaceae. *Clin Microbiol Infect*, 20(9), 862-872. <https://doi.org/10.1111/1469-0691.12697>
- van Duin, D., & Doi, Y. (2018). The global epidemiology of carbapenemase-producing Enterobacteriaceae. *Virulence*(2150-5608). <https://doi.org/10.1080/21505594.2016.1222343>
- Walsh, T. R., & Toleman, M. A. (2012). The emergence of pan-resistant Gram-negative pathogens merits a rapid global political response. *Journal of Antimicrobial Chemotherapy*, 67(1), 1-3. <https://doi.org/10.1093/jac/dkr378>
- Walsh, T. R., Weeks, J., Livermore, D. M., & Toleman, M. A. (2011). Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. *The Lancet Infectious Diseases*, 11(5), 355-362. [https://doi.org/10.1016/s1473-3099\(11\)70059-7](https://doi.org/10.1016/s1473-3099(11)70059-7)
- WHO. (2019). *WHO Report on Surveillance of Antibiotic Consumption*. World Health Organization.
- WHO. (2021). *Antimicrobial Resistance*. World Health Organization. Retrieved 31 July 2023 from <https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance>
- Wong, Y. P., Othman, S., Lau, Y. L., Radu, S., & Chee, H. Y. (2018). Loop-mediated isothermal amplification (LAMP): a versatile technique for detection of microorganisms. *J Appl Microbiol*, 124(3), 626-643. <https://doi.org/10.1111/jam.13647>
- Wright, G. D. (2011). Molecular mechanisms of antibiotic resistance. *Chem Commun (Camb)*, 47(14), 4055-4061. <https://doi.org/10.1039/c0cc05111j>
- Wright, G. D. (2016). Antibiotic Adjuvants: Rescuing Antibiotics from Resistance. *Trends Microbiol.*(1878-4380). <https://doi.org/10.1016/j.tim.2016.06.009>
- Wu, Q., Han, L., Sun, J., & Ni, Y. (2009). Plasmid-mediated 16S rRNA methylases in aminoglycoside-resistant Enterobacteriaceae isolates in Shanghai, China. *Antimicrob Agents Chemother.* (1098-6596). <https://doi.org/10.1128/AAC.00748-08>
- Yamamoto, N., Hamaguchi, S., Akeda, Y., Santanirand, P., Kerdsin, A., Seki, M., Ishii, Y., Paveenkittiporn, W., Bonomo, R. A., Oishi, K., Malathum, K., & Tomono, K. (2015). Clinical specimen-direct LAMP: A useful tool for the surveillance of *blaOXA-23*-positive carbapenem-resistant *Acinetobacter baumannii*. *PLOS ONE*, 10(7), e0133204. <https://doi.org/10.1371/journal.pone.0133204>
- Yang, R., Zhang, H., Li, X., Ye, L., Gong, M., Yang, J., Yu, J., & Bai, J. (2018). A multiplex loop-mediated isothermal amplification assay for rapid screening of *Acinetobacter baumannii* and D carbapenemase *OXA-23* gene. *Biosci Rep*, 38(5). <https://doi.org/10.1042/BSR20180425>
- Yigit, H., Queenan Am Fau - Anderson, G. J., Anderson GJ Fau - Domenech-Sanchez, A., Domenech-Sanchez A Fau - Biddle, J. W., Biddle JW Fau - Steward, C. D.,

- Steward Cd Fau - Alberti, S., Alberti S Fau - Bush, K., Bush K Fau - Tenover, F. C., & Tenover, F. C. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of *Klebsiella pneumoniae*. (0066-4804 (Print)).
- Yong, D., Toleman, M. A., Giske, C. G., Cho, H. S., Sundman, K., Lee, K., & Walsh, T. R. (2009). Characterization of a new metallo-beta-lactamase gene, *bla(NDM-1)*, and a novel erythromycin esterase gene carried on a unique genetic structure in *Klebsiella pneumoniae* sequence type 14 from India. *Antimicrob Agents Chemother*, 53(12), 5046-5054. <https://doi.org/10.1128/AAC.00774-09>
- Zhong, L. L., Zhou, Q., Tan, C. Y., Roberts, A. P., El-Sayed Ahmed, M. A. E., Chen, G., Dai, M., Yang, F., Xia, Y., Liao, K., Liang, Y., Yang, Y., Feng, S., Zheng, X., & Tian, G. B. (2019). Multiplex loop-mediated isothermal amplification (multi-LAMP) assay for rapid detection of *mcr-1* to *mcr-5* in colistin-resistant bacteria. *Infect Drug Resist*, 12, 1877-1887. <https://doi.org/10.2147/IDR.S210226>



## APPENDIX

## A. Subtypes of KPC and NDM

## 123 Subtypes of KPC

<b>Allele</b>	<b>Product name</b>	<b>RefSeq nucleotide</b>	<b>GenBank nucleotide</b>
<b>blaKP C-100</b>	inhibitor-resistant carbapenem-hydrolyzing class A beta-lactamase KPC-100	NG_0810 70.1	ON521726. 1
<b>blaKP C-101</b>	inhibitor-resistant carbapenem-hydrolyzing class A beta-lactamase KPC-101	NG_0883 94.1	OK086805. 1
<b>blaKP C-102</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-102	NG_0780 63.1	OK652013. 1
<b>blaKP C-103</b>	class A beta-lactamase KPC-103	NG_0780 51.1	OL445423. 1
<b>blaKP C-104</b>	class A beta-lactamase KPC-104	NG_0780 52.1	OL445424. 1
<b>blaKP C-105</b>	class A beta-lactamase KPC-105	NG_0780 54.1	OL445426. 1
<b>blaKP C-106</b>	class A beta-lactamase KPC-106	NG_0780 56.1	OL445428. 1
<b>blaKP C-107</b>	class A beta-lactamase KPC-107	NG_0780 53.1	OL445425. 1
<b>blaKP C-108</b>	class A beta-lactamase KPC-108	NG_0780 55.1	OL445427. 1
<b>blaKP C-109</b>	inhibitor-resistant carbapenem-hydrolyzing class A beta-lactamase KPC-109	NG_1496 59.1	OL744263. 1
<b>blaKP C-110</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-10	NG_0492 43.1	GQ140348. 1
<b>blaKP C-111</b>	inhibitor-resistant class A beta-lactamase KPC- 110	NG_0883 95.1	CP100313. 1
<b>blaKP C-112</b>	inhibitor-resistant class A beta-lactamase KPC- 111	NG_0817 91.1	OL744330. 1
<b>blaKP C-113</b>	inhibitor-resistant carbapenem-hydrolyzing class A beta-lactamase KPC-112	NG_0792 30.1	OM177660 .1
<b>blaKP C-114</b>	inhibitor-resistant carbapenem-hydrolyzing class A beta-lactamase KPC-113	NG_0798 88.1	OM728506 .1
<b>blaKP C-115</b>	inhibitor-resistant carbapenem-hydrolyzing class A beta-lactamase KPC-114	NG_0798 89.1	OM728507 .1
<b>blaKP C-116</b>	inhibitor-resistant class A beta-lactamase KPC- 115	NG_0798 90.1	OM714909 .1
<b>blaKP C-116</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-116	NG_0798 91.1	OM729575 .1

<b>blaKP C-117</b>	inhibitor-resistant carbapenem-hydrolyzing class A beta-lactamase KPC-117	NG_0798 92.1	OM933711 .1
<b>blaKP C-118</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-118	NG_0798 93.1	OM933712 .1
<b>blaKP C-119</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-119	NG_0798 94.1	OM933713 .1
<b>blaKP C-11</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-11	NG_0492 44.1	HM066995 .1
<b>blaKP C-120</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-120	NG_0798 95.1	OM933715 .1
<b>blaKP C-121</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-121	NG_0798 96.1	OM933717 .1
<b>blaKP C-122</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-122	NG_0798 97.1	OM933720 .1
<b>blaKP C-123</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-123	NG_0798 98.1	ON012820. 1
<b>blaKP C-124</b>	inhibitor-resistant carbapenem-hydrolyzing class A beta-lactamase KPC-124	NG_2033 93.1	ON221403. 1
<b>blaKP C-125</b>	inhibitor-resistant carbapenem-hydrolyzing class A beta-lactamase KPC-125	NG_0807 78.1	CP095778. 1
<b>blaKP C-126</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-126	NG_0807 79.1	OM830488 .1
<b>blaKP C-127</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-127	NG_0810 71.1	ON521725. 1
<b>blaKP C-128</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-128	NG_0810 72.1	ON521727. 1
<b>blaKP C-129</b>	class A beta-lactamase KPC-129	NG_2033 94.1	ON751738. 1
<b>blaKP C-12</b>	extended-spectrum class A beta-lactamase KPC-12	NG_0492 45.1	HQ641421. 1
<b>blaKP C-130</b>	class A beta-lactamase KPC-130	NG_0816 99.1	ON794466. 1
<b>blaKP C-131</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-131	NG_0817 00.1	ON823194. 1
<b>blaKP C-132</b>	inhibitor-resistant class A beta-lactamase KPC-132	NG_0817 83.1	OP081092. 1
<b>blaKP C-133</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-133	NG_0817 84.1	OP081531. 1
<b>blaKP C-134</b>	inhibitor-resistant class A beta-lactamase KPC-134	NG_0883 96.1	OP293349. 1
<b>blaKP C-135</b>	inhibitor-resistant class A beta-lactamase KPC-135	NG_0883 97.1	OP205646. 1
<b>blaKP C-136</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-136	NG_1570 07.1	OQ579152. 1
<b>blaKP C-138</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-138	NG_0883 98.1	OP432320. 1
<b>blaKP</b>	inhibitor-resistant carbapenem-hydrolyzing class	NG_0883	OP503887.



<b>C-139</b>	A beta-lactamase KPC-139	99.1	1
<b>blaKP C-13</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-13	NG_0492 46.1	HQ342889. 1
<b>blaKP C-140</b>	inhibitor-resistant carbapenem-hydrolyzing class A beta-lactamase KPC-140	NG_0884 00.1	OP503888. 1
<b>blaKP C-141</b>	inhibitor-resistant carbapenem-hydrolyzing class A beta-lactamase KPC-141	NG_0884 01.1	OP503889. 1
<b>blaKP C-142</b>	inhibitor-resistant carbapenem-hydrolyzing class A beta-lactamase KPC-142	NG_0884 02.1	OP503890. 1
<b>blaKP C-143</b>	inhibitor-resistant carbapenem-hydrolyzing class A beta-lactamase KPC-143	NG_0884 03.1	OP503891. 1
<b>blaKP C-144</b>	inhibitor-resistant carbapenem-hydrolyzing class A beta-lactamase KPC-144	NG_0884 04.1	OP559533. 1
<b>blaKP C-145</b>	class A beta-lactamase KPC-145	NG_1486 22.1	OP626310. 1
<b>blaKP C-146</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-146	NG_1486 23.1	OP696903. 1
<b>blaKP C-147</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-147	NG_1486 24.1	OP696904. 1
<b>blaKP C-148</b>	class A beta-lactamase KPC-148	NG_1486 25.1	JAOZYA0 10000028.1
<b>blaKP C-14</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-14	NG_0492 47.1	JX524191. 1
<b>blaKP C-151</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-151	NG_1486 26.1	OP823148. 1
<b>blaKP C-153</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-153	NG_1486 27.1	OP884096. 1
<b>blaKP C-154</b>	class A beta-lactamase KPC-154	NG_2315 45.1	OQ096263. 1
<b>blaKP C-155</b>	inhibitor-resistant class A beta-lactamase KPC-155	NG_1496 60.1	OQ139542. 1
<b>blaKP C-156</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-156	NG_1496 61.1	OQ390084. 1
<b>blaKP C-157</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-157	NG_1496 62.1	JAPQEX02 0000004.1
<b>blaKP C-158</b>	inhibitor-resistant carbapenem-hydrolyzing class A beta-lactamase KPC-158	NG_2286 70.1	OQ305823. 1
<b>blaKP C-159</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-159	NG_1570 08.1	OQ450354. 1
<b>blaKP C-15</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-15	NG_0492 48.1	KC433553. 1
<b>blaKP C-160</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-160	NG_1570 09.1	OQ579136. 1
<b>blaKP C-161</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-161	NG_1570 10.1	OQ579137. 1
<b>blaKP C-162</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-162	NG_1570 11.1	OQ579138. 1

<b>blaKP C-163</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-163	NG_1570 12.1	OQ579139. 1
<b>blaKP C-164</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-164	NG_1570 13.1	OQ579140. 1
<b>blaKP C-165</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-165	NG_1570 14.1	OQ579141. 1
<b>blaKP C-166</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-166	NG_1570 15.1	OQ592369. 1
<b>blaKP C-167</b>	class A beta-lactamase KPC-167	NG_1570 16.1	OQ592370. 1
<b>blaKP C-16</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-16	NG_0492 49.1	KC465199. 1
<b>blaKP C-170</b>	inhibitor-resistant carbapenem-hydrolyzing class A beta-lactamase KPC-170	NG_2315 46.1	OR449906. 1
<b>blaKP C-178</b>	inhibitor-resistant class A beta-lactamase KPC-178	NG_2033 95.1	OQ926587. 1
<b>blaKP C-179</b>	class A beta-lactamase KPC-179	NG_2033 96.1	OR115556. 1
<b>blaKP C-17</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-17	NG_0492 50.1	KC465200. 1
<b>blaKP C-180</b>	inhibitor-resistant carbapenem-hydrolyzing class A beta-lactamase KPC-180	NG_2033 97.1	OR206047. 1
<b>blaKP C-181</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-181	NG_2286 71.1	OR282795. 1
<b>blaKP C-182</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-182	NG_2286 72.1	OR282796. 1
<b>blaKP C-183</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-183	NG_2286 73.1	OR282800. 1
<b>blaKP C-184</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-184	NG_2286 74.1	OR282801. 1
<b>blaKP C-185</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-185	NG_2315 47.1	OR359279. 1
<b>blaKP C-186</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-186	NG_2315 48.1	OR466746. 1
<b>blaKP C-187</b>	inhibitor-resistant class A beta-lactamase KPC-187	NG_2315 49.1	OR466751. 1
<b>blaKP C-189</b>	extended-spectrum class A beta-lactamase KPC-189	NG_2315 50.1	OR501577. 1
<b>blaKP C-18</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-18	NG_0492 51.1	KP681699. 1
<b>blaKP C-190</b>	inhibitor-resistant class A beta-lactamase KPC-190	NG_2315 51.1	OR499110. 1
<b>blaKP C-191</b>	inhibitor-resistant class A beta-lactamase KPC-191	NG_2315 52.1	OR499111. 1
<b>blaKP C-192</b>	inhibitor-resistant carbapenem-hydrolyzing class A beta-lactamase KPC-192	NG_2315 53.1	OR529436. 1
<b>blaKP</b>	carbapenem-hydrolyzing class A beta-lactamase	NG_0492	KJ775801.

<b>C-19</b>	KPC-19	52.1	1
<b>blaKP C-21</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-21	NG_0492 54.1	LN609376. 1
<b>blaKP C-22</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-22	NG_0492 55.1	KM379100 .1
<b>blaKP C-23</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-23	NG_0605 69.1	MH450213 .1
<b>blaKP C-24</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-24	NG_0492 56.1	KR052099. 1
<b>blaKP C-25</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-25	NG_0511 67.1	KU216748. 1
<b>blaKP C-26</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-26	NG_0514 69.1	KX619622. 1
<b>blaKP C-27</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-27	NG_0528 62.1	KX828722. 1
<b>blaKP C-28</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-28	NG_0525 81.1	KY282958. 1
<b>blaKP C-29</b>	inhibitor-resistant carbapenem-hydrolyzing class A beta-lactamase KPC-29	NG_0555 80.1	KY563764. 1
<b>blaKP C-2</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-2	NG_0492 53.1	AY034847. 1
<b>blaKP C-30</b>	inhibitor-resistant carbapenem-hydrolyzing class A beta-lactamase KPC-30	NG_0546 85.1	KY646302. 1
<b>blaKP C-31</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-31	NG_0554 94.1	MAPH010 00113.1
<b>blaKP C-32</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-32	NG_0554 95.1	MAPO010 00050.1
<b>blaKP C-33</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-33	NG_0561 70.1	CP025144. 1
<b>blaKP C-34</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-34	NG_0574 47.1	KU985429. 1
<b>blaKP C-35</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-35	NG_0605 24.1	MH404098 .1
<b>blaKP C-36</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-36	NG_0613 89.1	MH593787 .1
<b>blaKP C-37</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-37	NG_0616 12.1	MH718730 .1
<b>blaKP C-38</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-38	NG_0623 57.1	MK098861 .1
<b>blaKP C-39</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-39	NG_0638 41.1	MK118771 .1
<b>blaKP C-3</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-3	NG_0492 57.1	AF395881. 1
<b>blaKP C-40</b>	inhibitor-resistant carbapenem-hydrolyzing class A beta-lactamase KPC-40	NG_0647 26.1	QRBR0100 0058.1
<b>blaKP C-41</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-41	NG_0658 76.1	MK497255 .1

<b>blaKP C-42</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-42	NG_0647 27.1	MK467612 .1
<b>blaKP C-43</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-43	NG_0647 28.1	MK628511 .1
<b>blaKP C-44</b>	inhibitor-resistant carbapenem-hydrolyzing class A beta-lactamase KPC-44	NG_0654 27.1	MK823188 .1
<b>blaKP C-45</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-45	NG_0658 77.1	MN104596 .1
<b>blaKP C-46</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-46	NG_0658 78.1	MN267701 .1
<b>blaKP C-47</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-47	NG_0747 14.1	MN422012 .1
<b>blaKP C-48</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-48	NG_0747 15.1	MN422013 .1
<b>blaKP C-49</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-49	NG_0712 03.1	MN619655 .1
<b>blaKP C-4</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-4	NG_0492 58.1	EU447304. 1
<b>blaKP C-50</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-50	NG_0685 07.1	MN654342 .1
<b>blaKP C-51</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-51	NG_0672 24.1	MN725731 .1
<b>blaKP C-52</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-52	NG_0672 25.1	MN725732 .1
<b>blaKP C-53</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-53	NG_0681 76.1	CP058327. 1
<b>blaKP C-54</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-54	NG_0672 26.1	MN854706 .1
<b>blaKP C-55</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-55	NG_0681 77.1	MT028409. 1
<b>blaKP C-56</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-56	NG_0680 16.1	MT040751. 1
<b>blaKP C-57</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-57	NG_0685 08.1	MT358626. 1
<b>blaKP C-58</b>	inhibitor-resistant class A beta-lactamase KPC-58	NG_0701 77.1	MT463289. 1
<b>blaKP C-59</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-59	NG_0701 78.1	MT463290. 1
<b>blaKP C-5</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-5	NG_0492 59.1	EU400222. 2
<b>blaKP C-60</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-60	NG_0701 79.1	MT482411. 1
<b>blaKP C-61</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-61	NG_0701 80.1	MK559426 .1
<b>blaKP C-62</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-62	NG_0734 65.1	MT604163. 1
<b>blaKP</b>	inhibitor-resistant extended-spectrum class A	NG_0734	MT604164.

<b>C-63</b>	beta-lactamase KPC-63	66.1	1
<b>blaKP C-64</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-64	NG_0734 67.1	MT604165. 1
<b>blaKP C-65</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-65	NG_0734 68.1	MT604166. 1
<b>blaKP C-66</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-66	NG_0707 39.1	MT833884. 1
<b>blaKP C-67</b>	inhibitor-resistant carbapenem-hydrolyzing class A beta-lactamase KPC-67	NG_0747 16.1	MT809697. 1
<b>blaKP C-68</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-68	NG_0747 17.1	MT809698. 1
<b>blaKP C-69</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-69	NG_0747 18.1	MT809700. 1
<b>blaKP C-6</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-6	NG_0492 60.1	EU555534. 1
<b>blaKP C-70</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-70	NG_0747 19.1	MT809701. 1
<b>blaKP C-71</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-71	NG_0708 95.1	MW015092 .1
<b>blaKP C-72</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-72	NG_0707 40.1	MT833885. 1
<b>blaKP C-73</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-73	NG_0707 41.1	MT833886. 1
<b>blaKP C-74</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-74	NG_0707 42.1	MT856045. 1
<b>blaKP C-75</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-75	NG_0707 43.1	MT920645. 1
<b>blaKP C-76</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-76	NG_0708 96.1	MT550690. 1
<b>blaKP C-77</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-77	NG_0708 97.1	MW030519 .1
<b>blaKP C-78</b>	inhibitor-resistant carbapenem-hydrolyzing class A beta-lactamase KPC-78	NG_0712 04.1	MW319056 .1
<b>blaKP C-79</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-79	NG_0712 05.1	MT875328. 1
<b>blaKP C-7</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-7	NG_0492 61.1	EU729727. 1
<b>blaKP C-80</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-80	NG_0734 69.1	MW444845 .1
<b>blaKP C-81</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-81	NG_0734 70.1	MW444846 .1
<b>blaKP C-82</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-82	NG_0734 71.1	MW485086 .1
<b>blaKP C-83</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-83	NG_0792 31.1	MW581775 .1
<b>blaKP C-84</b>	inhibitor-resistant extended-spectrum carbapenem-hydrolyzing class A beta-lactamase	NG_0747 20.1	MW657985 .1

KPC-84			
<b>blaKP C-85</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-85	NG_0747 21.1	MW896839 .1
<b>blaKP C-86</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-86	NG_0747 22.1	MZ067229. 1
<b>blaKP C-87</b>	inhibitor-resistant carbapenem-hydrolyzing class A beta-lactamase KPC-87	NG_0747 23.1	MZ067230. 1
<b>blaKP C-88</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-88	NG_0747 24.1	MZ067231. 1
<b>blaKP C-89</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-89	NG_0792 32.1	MZ401141. 1
<b>blaKP C-8</b>	inhibitor-resistant carbapenem-hydrolyzing class A beta-lactamase KPC-8	NG_0492 62.1	FJ234412.1
<b>blaKP C-90</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-90	NG_0766 66.1	MZ404504. 1
<b>blaKP C-91</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-91	NG_0766 67.1	MZ404505. 1
<b>blaKP C-92</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-92	NG_0792 33.1	MZ461464. 1
<b>blaKP C-93</b>	inhibitor-resistant carbapenem-hydrolyzing class A beta-lactamase KPC-93	NG_0807 80.1	MZ569034. 1
<b>blaKP C-94</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-94	NG_0766 80.1	MZ646140. 1
<b>blaKP C-95</b>	inhibitor-resistant extended-spectrum class A beta-lactamase KPC-95	NG_0766 81.1	MZ646141. 1
<b>blaKP C-96</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-96	NG_0780 37.1	OK086970. 1
<b>blaKP C-97</b>	class A beta-lactamase KPC-97	NG_0780 38.1	OK086971. 1
<b>blaKP C-98</b>	carbapenem-hydrolyzing class A beta-lactamase KPC-98	NG_0780 32.1	MZ893466. 1
<b>blaKP C-99</b>	inhibitor-resistant carbapenem-hydrolyzing class A beta-lactamase KPC-99	NG_0884 05.1	OK086803. 1

## 43 subtypes of NDM


<b>Allele</b>	<b>Product name</b>	<b>RefSeq nucleotide</b>	<b>GenBank nucleotide</b>
<b>blaND M-10</b>	subclass B1 metallo-beta-lactamase NDM- 10	NG_04932 7.1	KF361506.1
<b>blaND M-11</b>	subclass B1 metallo-beta-lactamase NDM- 11	NG_04932 8.1	KP265939.1
<b>blaND M-12</b>	subclass B1 metallo-beta-lactamase NDM- 12	NG_04932 9.1	AB926431.1
<b>blaND M-13</b>	subclass B1 metallo-beta-lactamase NDM- 13	NG_04933 0.1	LC012596.1

<b>blaND M-14</b>	subclass B1 metallo-beta-lactamase NDM-14	NG_04933 1.1	KM210086.1
<b>blaND M-15</b>	subclass B1 metallo-beta-lactamase NDM-15	NG_04933 2.1	KP735848.1
<b>blaND M-16a</b>	subclass B1 metallo-beta-lactamase NDM-16a	NG_04933 3.1	KP862821.1
<b>blaND M-16b</b>	subclass B1 metallo-beta-lactamase NDM-16b	NG_07472 6.1	AP024206.1
<b>blaND M-17</b>	subclass B1 metallo-beta-lactamase NDM-17	NG_05266 2.1	KX812714.1
<b>blaND M-18</b>	subclass B1 metallo-beta-lactamase NDM-18	NG_05286 6.1	KY503030.1
<b>blaND M-19</b>	subclass B1 metallo-beta-lactamase NDM-19	NG_05549 8.1	MF370080.1
<b>blaND M-1</b>	subclass B1 metallo-beta-lactamase NDM-1	NG_04932 6.1	FN396876.1
<b>blaND M-20</b>	subclass B1 metallo-beta-lactamase NDM-20	NG_05745 5.1	KY654092.1
<b>blaND M-21</b>	subclass B1 metallo-beta-lactamase NDM-21	NG_05566 4.1	MG183694.1
<b>blaND M-22</b>	subclass B1 metallo-beta-lactamase NDM-22	NG_05761 2.1	MH243357.1
<b>blaND M-23</b>	subclass B1 metallo-beta-lactamase NDM-23	NG_06057 0.1	MH450214.1
<b>blaND M-24</b>	subclass B1 metallo-beta-lactamase NDM-24	NG_06057 1.1	MH450215.1
<b>blaND M-25</b>	subclass B1 metallo-beta-lactamase NDM-25	NG_06671 1.1	MH986670.1
<b>blaND M-26</b>	subclass B1 metallo-beta-lactamase NDM-26	NG_06714 4.1	MK079575.1
<b>blaND M-27</b>	subclass B1 metallo-beta-lactamase NDM-27	NG_06235 8.1	MK105832.1
<b>blaND M-28</b>	subclass B1 metallo-beta-lactamase NDM-28	NG_06472 9.1	MK425035.1
<b>blaND M-29</b>	subclass B1 metallo-beta-lactamase NDM-29	NG_06714 5.1	MN624980.1
<b>blaND M-2</b>	subclass B1 metallo-beta-lactamase NDM-2	NG_04933 4.1	JF703135.1
<b>blaND M-30</b>	subclass B1 metallo-beta-lactamase NDM-30	NG_07120 6.1	MW306748.1
<b>blaND M-31</b>	subclass B1 metallo-beta-lactamase NDM-31	NG_07120 7.1	MW306749.1
<b>blaND M-33</b>	subclass B1 metallo-beta-lactamase NDM-33	NG_08078 2.1	MZ004933.1
<b>blaND M-34</b>	subclass B1 metallo-beta-lactamase NDM-34	NG_07666 1.1	MZ254705.1
<b>blaND</b>	subclass B1 metallo-beta-lactamase NDM-	NG_07666	MZ265788.1

<b>M-35</b>	35	2.1	
<b>blaND M-36</b>	subclass B1 metallo-beta-lactamase NDM-36	NG_07664 1.1	JAHAWL0100 00074.1
<b>blaND M-37</b>	subclass B1 metallo-beta-lactamase NDM-37	NG_07664 2.1	CP091926.1
<b>blaND M-38</b>	subclass B1 metallo-beta-lactamase NDM-38	NG_07666 4.1	MZ359766.1
<b>blaND M-39</b>	subclass B1 metallo-beta-lactamase NDM-39	NG_07684 2.1	MZ748325.1
<b>blaND M-3</b>	subclass B1 metallo-beta-lactamase NDM-3	NG_04933 5.1	JQ734687.1
<b>blaND M-40</b>	subclass B1 metallo-beta-lactamase NDM-40	NG_07684 3.1	MZ748326.1
<b>blaND M-41</b>	subclass B1 metallo-beta-lactamase NDM-41	NG_07803 4.1	MZ913436.1
<b>blaND M-42</b>	subclass B1 metallo-beta-lactamase NDM-42	NG_08078 3.1	ON205946.1
<b>blaND M-43</b>	subclass B1 metallo-beta-lactamase NDM-43	NG_08170 1.1	ON954084.1
<b>blaND M-44</b>	subclass B1 metallo-beta-lactamase NDM-44	NG_08840 9.1	OP288001.1
<b>blaND M-45</b>	subclass B1 metallo-beta-lactamase NDM-45	NG_14863 6.1	OP696898.1
<b>blaND M-46</b>	subclass B1 metallo-beta-lactamase NDM-46	NG_14863 7.1	OP696899.1
<b>blaND M-47</b>	subclass B1 metallo-beta-lactamase NDM-47	NG_14863 8.1	OP696900.1
<b>blaND M-48</b>	subclass B1 metallo-beta-lactamase NDM-48	NG_14863 9.1	OP696902.1
<b>blaND M-49</b>	subclass B1 metallo-beta-lactamase NDM-49	NG_14966 3.1	OP966824.1
<b>blaND M-4</b>	subclass B1 metallo-beta-lactamase NDM-4	NG_04933 6.1	JQ348841.1
<b>blaND M-50</b>	subclass B1 metallo-beta-lactamase NDM-50	NG_14966 4.1	ABJWWM020 000052.1
<b>blaND M-51</b>	subclass B1 metallo-beta-lactamase NDM-51	NG_15701 7.1	OQ442836.1
<b>blaND M-52</b>	subclass B1 metallo-beta-lactamase NDM-52	NG_15701 8.1	OQ564973.1
<b>blaND M-53</b>	subclass B1 metallo-beta-lactamase NDM-53	NG_15701 9.1	OQ595422.1
<b>blaND M-54</b>	subclass B1 metallo-beta-lactamase NDM-54	NG_15702 0.1	OQ595423.1
<b>blaND M-55</b>	subclass B1 metallo-beta-lactamase NDM-55	NG_15702 1.1	OQ708894.1
<b>blaND M-56</b>	subclass B1 metallo-beta-lactamase NDM-56	NG_20339 9.1	OQ870699.1



<b>blaND M-57</b>	subclass B1 metallo-beta-lactamase NDM- 57	NG_20340 0.1	OQ870700.1
<b>blaND M-58</b>	subclass B1 metallo-beta-lactamase NDM- 58	NG_20340 1.1	OR081828.1
<b>blaND M-5</b>	subclass B1 metallo-beta-lactamase NDM- 5	NG_04933 7.1	JN104597.1
<b>blaND M-60</b>	subclass B1 metallo-beta-lactamase NDM- 60	NG_20340 2.1	OR139852.1
<b>blaND M-61</b>	subclass B1 metallo-beta-lactamase NDM- 61	NG_23155 4.1	DAPGEA0100 00082.1
<b>blaND M-6</b>	subclass B1 metallo-beta-lactamase NDM- 6	NG_04933 8.1	JN967644.1
<b>blaND M-7</b>	subclass B1 metallo-beta-lactamase NDM- 7	NG_04933 9.1	JX262694.1
<b>blaND M-8</b>	subclass B1 metallo-beta-lactamase NDM- 8	NG_04934 0.1	AB744718.1
<b>blaND M-9</b>	taniborbactam-resistant subclass B1 metallo-beta-lactamase NDM-9	NG_04934 1.1	KC999080.2



## B. Two-way ANOVA and Multiple comparisons of dLAMP optimization

### a. Temperature 63°C

Two-way ANOVA of temperature 63 with different incubation times in band intensity and dLAMP product

Table Analyzed	Temperature 63°C band intensity and dLAMP product yield				
Two-way ANOVA	Ordinary				
Alpha	0.05				
Source of Variation	% of total variation	P valu e	P value summary	Significa nt?	
Interaction	23.80	<0.0 001	****	Yes	
Row Factor	55.23	<0.0 001	****	Yes	
Column Factor	13.80	<0.0 001	****	Yes	
ANOVA table	SS	DF	MS	F (DFn, DFd)	P value
Interaction	1729	5	345.8	F (5, 24) = 15.94	P<0. 0001
Row Factor	4012	5	802.4	F (5, 24) = 36.99	P<0. 0001
Column Factor	1003	1	1003	F (1, 24) = 46.22	P<0. 0001
Residual	520.7	24	21.69		
Difference between columns means					
Mean of Band intensity (%)	11.17				
Mean of dLAMP product yield (ng/μL)	21.72				
Difference between means	-10.56				
SE of difference	1.553				
95% CI of difference	-13.76 to -7.351				
Data summary					
Number of columns (Column Factor)	2				
Number of rows (Row Factor)	6				
Number of values	36				

Tukey multiple comparisons of temperature 63 in different incubation times in band intensity and dLAMP product  
**WITHIN EACH COLUMN, COMPARE ROWS (SIMPLE EFFECTS WITHIN COLUMNS)**

<b>NUMBER OF FAMILIES</b>	2				
<b>NUMBER OF COMPARISONS PER FAMILY</b>	15				
<b>ALPHA</b>	0.05				
<b>TUKEY'S MULTIPLE COMPARISONS TEST</b>	Mean Diff.	95.00% CI of diff.	Below threshold?	Summary	Adjusted P Value
<b>BAND INTENSITY (%)</b>					
<b>45 MINUTES VS. 50 MINUTES</b>	2.333	-9.425 to 14.09	No	ns	0.9890
<b>45 MINUTES VS. 55 MINUTES</b>	0.333	-11.43 to 12.09	No	ns	>0.9999
<b>45 MINUTES VS. 60 MINUTES</b>	-0.333	-12.09 to 11.43	No	ns	>0.9999
<b>45 MINUTES VS. 65 MINUTES</b>	7.000	-4.759 to 18.76	No	ns	0.4603
<b>45 MINUTES VS. 70 MINUTES</b>	11.667	-0.09201 to 23.43	No	ns	0.0527
<b>50 MINUTES VS. 55 MINUTES</b>	-2.000	-13.76 to 9.759	No	ns	0.9946
<b>50 MINUTES VS. 60 MINUTES</b>	-2.667	-14.43 to 9.092	No	ns	0.9800
<b>50 MINUTES VS. 65 MINUTES</b>	4.667	-7.092 to 16.43	No	ns	0.8195
<b>50 MINUTES VS. 70 MINUTES</b>	9.333	-2.425 to 21.09	No	ns	0.1779
<b>55 MINUTES VS. 60 MINUTES</b>	-0.667	-12.43 to 11.09	No	ns	>0.9999
<b>55 MINUTES VS. 65 MINUTES</b>	6.667	-5.092 to 18.43	No	ns	0.5125
<b>55 MINUTES VS. 70 MINUTES</b>	11.333	-0.4253 to 23.09	No	ns	0.0634
<b>60 MINUTES VS. 65 MINUTES</b>	7.333	-4.425 to 19.09	No	ns	0.4102
<b>60 MINUTES VS. 70 MINUTES</b>	12.000	0.2413 to 23.76	Yes	*	0.0436
<b>65 MINUTES VS. 70 MINUTES</b>	4.667	-7.092 to 16.43	No	ns	0.8195
<b>DLAMP PRODUCT YIELD (NG/ML)</b>					
<b>45 MINUTES VS. 50 MINUTES</b>	12.667	0.9080 to 24.43	Yes	*	0.0296
<b>45 MINUTES VS. 55 MINUTES</b>	27.333	15.57 to 39.09	Yes	****	<0.0001
<b>45 MINUTES VS. 60 MINUTES</b>	16.333	4.575 to 28.09	Yes	**	0.0030
<b>45 MINUTES VS. 65 MINUTES</b>	46.667	34.91 to 58.43	Yes	****	<0.0001
<b>45 MINUTES VS. 70 MINUTES</b>	46.667	34.91 to 58.43	Yes	****	<0.0001
<b>50 MINUTES VS. 55 MINUTES</b>	14.667	2.908 to 26.43	Yes	**	0.0087
<b>50 MINUTES VS. 60 MINUTES</b>	3.667	-8.092 to 15.43	No	ns	0.9248



<b>65 MINUTES VS. 70 MINUTES</b>	7.66 7	3.000	4.667	3.80 3	3	3	1.7 35	24 .0 0
<b>DLAMP PRODUCT YIELD (NG/ML)</b>								
<b>45 MINUTES VS. 50 MINUTES</b>	46.6 7	34.00	12.67	3.80 3	3	3	4.7 10	24 .0 0
<b>45 MINUTES VS. 55 MINUTES</b>	46.6 7	19.33	27.33	3.80 3	3	3	10. 16	24 .0 0
<b>45 MINUTES VS. 60 MINUTES</b>	46.6 7	30.33	16.33	3.80 3	3	3	6.0 74	24 .0 0
<b>45 MINUTES VS. 65 MINUTES</b>	46.6 7	0.000	46.67	3.80 3	3	3	17. 35	24 .0 0
<b>45 MINUTES VS. 70 MINUTES</b>	46.6 7	0.000	46.67	3.80 3	3	3	17. 35	24 .0 0
<b>50 MINUTES VS. 55 MINUTES</b>	34.0 0	19.33	14.67	3.80 3	3	3	5.4 54	24 .0 0
<b>50 MINUTES VS. 60 MINUTES</b>	34.0 0	30.33	3.667	3.80 3	3	3	1.3 64	24 .0 0
<b>50 MINUTES VS. 65 MINUTES</b>	34.0 0	0.000	34.00	3.80 3	3	3	12. 64	24 .0 0
<b>50 MINUTES VS. 70 MINUTES</b>	34.0 0	0.000	34.00	3.80 3	3	3	12. 64	24 .0 0
<b>55 MINUTES VS. 60 MINUTES</b>	19.3 3	30.33	-11.00	3.80 3	3	3	4.0 91	24 .0 0
<b>55 MINUTES VS. 65 MINUTES</b>	19.3 3	0.000	19.33	3.80 3	3	3	7.1 89	24 .0 0
<b>55 MINUTES VS. 70 MINUTES</b>	19.3 3	0.000	19.33	3.80 3	3	3	7.1 89	24 .0 0
<b>60 MINUTES VS. 65 MINUTES</b>	30.3 3	0.000	30.33	3.80 3	3	3	11. 28	24 .0 0
<b>60 MINUTES VS. 70 MINUTES</b>	30.3 3	0.000	30.33	3.80 3	3	3	11. 28	24 .0 0

b. Temperature 65°C

Two-way ANOVA of temperature 65 with different incubation times in band intensity and dLAMP product

Table Analyzed	Temperature 65°C band intensity and dLAMP product yield				
Two-way ANOVA	Ordinary				
Alpha	0.05				
Source of Variation	% of total variation	P valu	P value summary	Significa nt?	

		e			
Interaction	9.807	0.0154	*	Yes	
Row Factor	28.51	<0.001	****	Yes	
Column Factor	48.39	<0.001	****	Yes	
ANOVA table	SS	DF	MS	F (DFn, DFd)	P value
Interaction	218.5	5	43.69	F (5, 24) = 3.543	P=0.0154
Row Factor	635.1	5	127.0	F (5, 24) = 10.30	P<0.0001
Column Factor	1078	1	1078	F (1, 24) = 87.41	P<0.0001
Residual	296.0	24	12.33		
Difference between column means					
Mean of Band intensity (%)	19.22				
Mean of dLAMP product yield (ng/ $\mu$ L)	30.17				
Difference between means	-10.94				
SE of difference	1.171				
95% CI of difference	-13.36 to -8.528				
Data summary					
Number of columns (Column Factor)	2				
Number of rows (Row Factor)	6				
Number of values	36				

Tukey multiple comparisons of temperature 65 in different incubation times in band intensity and dLAMP product

Within each column, compare rows  
(simple effects within columns)

	Number of families	Number of comparisons per family	Alpha	Šidák's multiple comparisons test	Mean Diff.	95.00% CI of diff.	Below threshold ?	Summary	Adjusted P Value
	2	15	0.05						
Band intensity (%)									
45 minutes vs. 50 minutes					-0.333	-9.648 to 8.982	No	ns	>0.9999
45 minutes vs. 55 minutes					-1.667	-10.98 to 7.648	No	ns	>0.9999
45 minutes vs. 60 minutes					-4.000	-5.315 to	No	ns	0.9450

		13.32						
<i>45 minutes vs. 65 minutes</i>	-	-10.32 to	No	ns	>0.9999			
	1.000	8.315						
<i>45 minutes vs. 70 minutes</i>	11.67	2.352 to	Yes	**	0.0066			
		20.98						
<i>50 minutes vs. 55 minutes</i>	-	-10.65 to	No	ns	>0.9999			
	1.333	7.982						
<i>50 minutes vs. 60 minutes</i>	4.333	-4.982 to	No	ns	0.9026			
		13.65						
<i>50 minutes vs. 65 minutes</i>	-	-9.982 to	No	ns	>0.9999			
	0.666	8.648						
	7							
<i>50 minutes vs. 70 minutes</i>	12.00	2.685 to	Yes	**	0.0049			
		21.32						
<i>55 minutes vs. 60 minutes</i>	5.667	-3.648 to	No	ns	0.6030			
		14.98						
<i>55 minutes vs. 65 minutes</i>	0.666	-8.648 to	No	ns	>0.9999			
	7	9.982						
<i>55 minutes vs. 70 minutes</i>	13.33	4.018 to	Yes	**	0.0015			
		22.65						
<i>60 minutes vs. 65 minutes</i>	-	-14.32 to	No	ns	0.7726			
	5.000	4.315						
<i>60 minutes vs. 70 minutes</i>	7.667	-1.648 to	No	ns	0.1817			
		16.98						
<i>65 minutes vs. 70 minutes</i>	12.67	3.352 to	Yes	**	0.0027			
		21.98						
<i>dLAMP product yield (ng/μL)</i>								
<i>45 minutes vs. 50 minutes</i>	-	-22.98 to -	Yes	**	0.0011			
	13.67	4.352						
<i>45 minutes vs. 55 minutes</i>	-	-21.98 to -	Yes	**	0.0027			
	12.67	3.352						
<i>45 minutes vs. 60 minutes</i>	-	-15.65 to	No	ns	0.4319			
	6.333	2.982						
<i>45 minutes vs. 65 minutes</i>	-	-21.65 to -	Yes	**	0.0037			
	12.33	3.018						
<i>45 minutes vs. 70 minutes</i>	-	-13.32 to	No	ns	0.9450			
	4.000	5.315						
<i>50 minutes vs. 55 minutes</i>	1.000	-8.315 to	No	ns	>0.9999			
		10.32						
<i>50 minutes vs. 60 minutes</i>	7.333	-1.982 to	No	ns	0.2301			
		16.65						
<i>50 minutes vs. 65 minutes</i>	1.333	-7.982 to	No	ns	>0.9999			
		10.65						
<i>50 minutes vs. 70 minutes</i>	9.667	0.3515 to	Yes	*	0.0373			
		18.98						
<i>55 minutes vs. 60 minutes</i>	6.333	-2.982 to	No	ns	0.4319			
		15.65						
<i>55 minutes vs. 65 minutes</i>	0.333	-8.982 to	No	ns	>0.9999			
	3	9.648						
<i>55 minutes vs. 70 minutes</i>	8.667	-0.6485 to	No	ns	0.0847			
		17.98						
<i>60 minutes vs. 65 minutes</i>	-	-15.32 to	No	ns	0.5154			
	6.000	3.315						
<i>60 minutes vs. 70 minutes</i>	2.333	-6.982 to	No	ns	0.9997			
		11.65						
<i>65 minutes vs. 70 minutes</i>	8.333	-0.9818 to	No	ns	0.1101			
		17.65						
<i>Test details</i>	Mean	Mean 2	Mean	SE of	N1	N	t	DF
	1		Diff.	diff.		2		
<i>Band intensity (%)</i>								
<i>45 minutes vs. 50 minutes</i>	21.33	21.67	-0.3333	2.867	3	3	0.1	24.
							162	00
<i>45 minutes vs. 55 minutes</i>	21.33	23.00	-1.667	2.867	3	3	0.5	24.

<i>45 minutes vs. 60 minutes</i>	21.33	17.33	4.000	2.867	3	3	812	00
							1.3	24.
							95	00
<i>45 minutes vs. 65 minutes</i>	21.33	22.33	-1.000	2.867	3	3	0.3	24.
							487	00
<i>45 minutes vs. 70 minutes</i>	21.33	9.667	11.67	2.867	3	3	4.0	24.
							69	00
<i>50 minutes vs. 55 minutes</i>	21.67	23.00	-1.333	2.867	3	3	0.4	24.
							650	00
<i>50 minutes vs. 60 minutes</i>	21.67	17.33	4.333	2.867	3	3	1.5	24.
							11	00
<i>50 minutes vs. 65 minutes</i>	21.67	22.33	-0.6667	2.867	3	3	0.2	24.
							325	00
<i>50 minutes vs. 70 minutes</i>	21.67	9.667	12.00	2.867	3	3	4.1	24.
							85	00
<i>55 minutes vs. 60 minutes</i>	23.00	17.33	5.667	2.867	3	3	1.9	24.
							76	00
<i>55 minutes vs. 65 minutes</i>	23.00	22.33	0.6667	2.867	3	3	0.2	24.
							325	00
<i>55 minutes vs. 70 minutes</i>	23.00	9.667	13.33	2.867	3	3	4.6	24.
							50	00
<i>60 minutes vs. 65 minutes</i>	17.33	22.33	-5.000	2.867	3	3	1.7	24.
							44	00
<i>60 minutes vs. 70 minutes</i>	17.33	9.667	7.667	2.867	3	3	2.6	24.
							74	00
<i>65 minutes vs. 70 minutes</i>	22.33	9.667	12.67	2.867	3	3	4.4	24.
							17	00
<i>dLAMP product yield (ng/μL)</i>								
<i>45 minutes vs. 50 minutes</i>	22.00	35.67	-13.67	2.867	3	3	4.7	24.
							66	00
<i>45 minutes vs. 55 minutes</i>	22.00	34.67	-12.67	2.867	3	3	4.4	24.
							17	00
<i>45 minutes vs. 60 minutes</i>	22.00	28.33	-6.333	2.867	3	3	2.2	24.
							09	00
<i>45 minutes vs. 65 minutes</i>	22.00	34.33	-12.33	2.867	3	3	4.3	24.
							01	00
<i>45 minutes vs. 70 minutes</i>	22.00	26.00	-4.000	2.867	3	3	1.3	24.
							95	00
<i>50 minutes vs. 55 minutes</i>	35.67	34.67	1.000	2.867	3	3	0.3	24.
							487	00
<i>50 minutes vs. 60 minutes</i>	35.67	28.33	7.333	2.867	3	3	2.5	24.
							57	00
<i>50 minutes vs. 65 minutes</i>	35.67	34.33	1.333	2.867	3	3	0.4	24.
							650	00
<i>50 minutes vs. 70 minutes</i>	35.67	26.00	9.667	2.867	3	3	3.3	24.
							71	00
<i>55 minutes vs. 60 minutes</i>	34.67	28.33	6.333	2.867	3	3	2.2	24.
							09	00
<i>55 minutes vs. 65 minutes</i>	34.67	34.33	0.3333	2.867	3	3	0.1	24.
							162	00
<i>55 minutes vs. 70 minutes</i>	34.67	26.00	8.667	2.867	3	3	3.0	24.
							22	00
<i>60 minutes vs. 65 minutes</i>	28.33	34.33	-6.000	2.867	3	3	2.0	24.
							92	00
<i>60 minutes vs. 70 minutes</i>	28.33	26.00	2.333	2.867	3	3	0.8	24.
							137	00
<i>65 minutes vs. 70 minutes</i>	34.33	26.00	8.333	2.867	3	3	2.9	24.
							06	00

## c. Temperature 67°C



Two-way ANOVA of temperature 67 with different incubation times in band intensity and dLAMP product

Table Analyzed	Temperature 67°C band intensity and dLAMP product yield				
Two-way ANOVA	Ordinary				
Alpha	0.05				
Source of Variation	% of total variation	P val ue	P value summar y	Significa nt?	
Interaction	3.030	0.5 133	ns	No	
Row Factor	2.426	0.6 288	ns	No	
Column Factor	75.30	<0. 000 1	****	Yes	
ANOVA table	SS (Type III)	DF	MS	F (DFn, DFd)	P valu e
Interaction	39.55	5	7.910	F (5, 23) = 0.8747	P=0. 513 3
Row Factor	31.67	5	6.333	F (5, 23) = 0.7003	P=0. 628 8
Column Factor	983.0	1	983.0	F (1, 23) = 108.7	P<0. 000 1
Residual	208.0	23	9.043		
Difference between column means					
Predicted (LS) mean of Band intensity (%)	9.722				
Predicted (LS) mean of dLAMP product yield (ng/μL)	20.39				
Difference between predicted means	-10.67				
SE of difference	1.023				
95% CI of difference	-12.78 to -8.550				
Data summary					
Number of columns (Column Factor)	2				
Number of rows (Row	6				

Factor)					
Number of values	35				

Tukey multiple comparisons of temperature 67 in different incubation times in band intensity and dLAMP product  
**WITHIN EACH COLUMN,  
 COMPARE ROWS (SIMPLE  
 EFFECTS WITHIN COLUMNS)**

<b>NUMBER OF FAMILIES</b>	2				
<b>NUMBER OF COMPARISONS PER FAMILY</b>	15				
<b>ALPHA</b>	0.05				
<b>ŠÍDÁK'S MULTIPLE COMPARISONS TEST</b>	Predicted (LS) mean diff.	95.00% CI of diff.	Below threshold?	Summary	Adjusted P Value
<b>BAND INTENSITY (%)</b>					
<b>45 MINUTES VS. 50 MINUTES</b>	1.000	-7.014 to 9.014	No	ns	>0.9999
<b>45 MINUTES VS. 55 MINUTES</b>	1.333	-6.681 to 9.348	No	ns	>0.9999
<b>45 MINUTES VS. 60 MINUTES</b>	0.3333	-7.681 to 8.348	No	ns	>0.9999
<b>45 MINUTES VS. 65 MINUTES</b>	0.3333	-7.681 to 8.348	No	ns	>0.9999
<b>45 MINUTES VS. 70 MINUTES</b>	-3.333	-12.29 to 5.627	No	ns	0.9827
<b>50 MINUTES VS. 55 MINUTES</b>	0.3333	-7.681 to 8.348	No	ns	>0.9999
<b>50 MINUTES VS. 60 MINUTES</b>	-0.6667	-8.681 to 7.348	No	ns	>0.9999
<b>50 MINUTES VS. 65 MINUTES</b>	-0.6667	-8.681 to 7.348	No	ns	>0.9999
<b>50 MINUTES VS. 70 MINUTES</b>	-4.333	-13.29 to 4.627	No	ns	0.8721
<b>55 MINUTES VS. 60 MINUTES</b>	-1.000	-9.014 to 7.014	No	ns	>0.9999
<b>55 MINUTES VS. 65 MINUTES</b>	-1.000	-9.014 to 7.014	No	ns	>0.9999
<b>55 MINUTES VS. 70 MINUTES</b>	-4.667	-13.63 to 4.294	No	ns	0.8030
<b>60 MINUTES VS. 65 MINUTES</b>	0.000	-8.014 to 8.014	No	ns	>0.9999
<b>60 MINUTES VS. 70 MINUTES</b>	-3.667	-12.63 to 5.294	No	ns	0.9612
<b>65 MINUTES VS. 70 MINUTES</b>	-3.667	-12.63 to 5.294	No	ns	0.9612
<b>DLAMP PRODUCT YIELD (NG/ML)</b>					
<b>45 MINUTES VS. 50 MINUTES</b>	0.000	-8.014 to 8.014	No	ns	>0.9999
<b>45 MINUTES VS. 55 MINUTES</b>	-0.3333	-8.348 to 7.681	No	ns	>0.9999
<b>45 MINUTES VS. 60 MINUTES</b>	3.667	-4.348 to 11.68	No	ns	0.9110
<b>45 MINUTES VS. 65 MINUTES</b>	-0.3333	-8.348 to 7.681	No	ns	>0.9999
<b>45 MINUTES VS. 70 MINUTES</b>	0.6667	-7.348 to 8.681	No	ns	>0.9999
<b>50 MINUTES VS. 55 MINUTES</b>	-0.3333	-8.348 to 7.681	No	ns	>0.9999
<b>50 MINUTES VS. 60 MINUTES</b>	3.667	-4.348 to 11.68	No	ns	0.9110

<b>50 MINUTES VS. 65 MINUTES</b>	-0.3333	-8.348 to 7.681	No	ns	>0.999 9			
<b>50 MINUTES VS. 70 MINUTES</b>	0.6667	-7.348 to 8.681	No	ns	>0.999 9			
<b>55 MINUTES VS. 60 MINUTES</b>	4.000	-4.014 to 12.01	No	ns	0.8451			
<b>55 MINUTES VS. 65 MINUTES</b>	0.000	-8.014 to 8.014	No	ns	>0.999 9			
<b>55 MINUTES VS. 70 MINUTES</b>	1.000	-7.014 to 9.014	No	ns	>0.999 9			
<b>60 MINUTES VS. 65 MINUTES</b>	-4.000	-12.01 to 4.014	No	ns	0.8451			
<b>60 MINUTES VS. 70 MINUTES</b>	-3.000	-11.01 to 5.014	No	ns	0.9817			
<b>65 MINUTES VS. 70 MINUTES</b>	1.000	-7.014 to 9.014	No	ns	>0.999 9			
<b>TEST DETAILS</b>	Predicted (LS) mean 1	Predicted (LS) mean 2	Predicted (LS) mean diff.	SE of diff.	N1	N 2	t	D F
<b>BAND INTENSITY (%)</b>								
<b>45 MINUTES VS. 50 MINUTES</b>	9.667	8.667	1.000	2.45 5	3	3	0. 40 73	2 3. 0 0
<b>45 MINUTES VS. 55 MINUTES</b>	9.667	8.333	1.333	2.45 5	3	3	0. 54 30	2 3. 0 0
<b>45 MINUTES VS. 60 MINUTES</b>	9.667	9.333	0.3333	2.45 5	3	3	0. 13 58	2 3. 0 0
<b>45 MINUTES VS. 65 MINUTES</b>	9.667	9.333	0.3333	2.45 5	3	3	0. 13 58	2 3. 0 0
<b>45 MINUTES VS. 70 MINUTES</b>	9.667	13.00	-3.333	2.74 5	3	2	1. 21 4	2 3. 0 0
<b>50 MINUTES VS. 55 MINUTES</b>	8.667	8.333	0.3333	2.45 5	3	3	0. 13 58	2 3. 0 0
<b>50 MINUTES VS. 60 MINUTES</b>	8.667	9.333	-0.6667	2.45 5	3	3	0. 27 15	2 3. 0 0
<b>50 MINUTES VS. 65 MINUTES</b>	8.667	9.333	-0.6667	2.45 5	3	3	0. 27 15	2 3. 0 0
<b>50 MINUTES VS. 70 MINUTES</b>	8.667	13.00	-4.333	2.74 5	3	2	1. 57 9	2 3. 0 0
<b>55 MINUTES VS. 60 MINUTES</b>	8.333	9.333	-1.000	2.45 5	3	3	0. 40 73	2 3. 0 0
<b>55 MINUTES VS. 65 MINUTES</b>	8.333	9.333	-1.000	2.45 5	3	3	0. 40 73	2 3. 0 0

<b>55 MINUTES VS. 70 MINUTES</b>	8.333	13.00	-4.667	2.74 5	3	2	1. 70 0	2 3. 0
<b>60 MINUTES VS. 65 MINUTES</b>	9.333	9.333	0.000	2.45 5	3	3	0. 00 0	2 3. 0
<b>60 MINUTES VS. 70 MINUTES</b>	9.333	13.00	-3.667	2.74 5	3	2	1. 33 6	2 3. 0
<b>65 MINUTES VS. 70 MINUTES</b>	9.333	13.00	-3.667	2.74 5	3	2	1. 33 6	2 3. 0
<b>DLAMP PRODUCT YIELD (NG/ML) 45 MINUTES VS. 50 MINUTES</b>	21.00	21.00	0.000	2.45 5	3	3	0. 00 0	2 3. 0
<b>45 MINUTES VS. 55 MINUTES</b>	21.00	21.33	-0.3333	2.45 5	3	3	0. 13 58	2 3. 0
<b>45 MINUTES VS. 60 MINUTES</b>	21.00	17.33	3.667	2.45 5	3	3	1. 49 3	2 3. 0
<b>45 MINUTES VS. 65 MINUTES</b>	21.00	21.33	-0.3333	2.45 5	3	3	0. 13 58	2 3. 0
<b>45 MINUTES VS. 70 MINUTES</b>	21.00	20.33	0.6667	2.45 5	3	3	0. 27 15	2 3. 0
<b>50 MINUTES VS. 55 MINUTES</b>	21.00	21.33	-0.3333	2.45 5	3	3	0. 13 58	2 3. 0
<b>50 MINUTES VS. 60 MINUTES</b>	21.00	17.33	3.667	2.45 5	3	3	1. 49 3	2 3. 0
<b>50 MINUTES VS. 65 MINUTES</b>	21.00	21.33	-0.3333	2.45 5	3	3	0. 13 58	2 3. 0
<b>50 MINUTES VS. 70 MINUTES</b>	21.00	20.33	0.6667	2.45 5	3	3	0. 27 15	2 3. 0
<b>55 MINUTES VS. 60 MINUTES</b>	21.33	17.33	4.000	2.45 5	3	3	1. 62 9	2 3. 0
<b>55 MINUTES VS. 65 MINUTES</b>	21.33	21.33	0.000	2.45 5	3	3	0. 00 0	2 3. 0
<b>55 MINUTES VS. 70 MINUTES</b>	21.33	20.33	1.000	2.45	3	3	0.	2

				5			40	3.
							73	0
								0
<b>60 MINUTES VS. 65 MINUTES</b>	17.33	21.33	-4.000	2.45	3	3	1.	2
				5			62	3.
							9	0
								0
<b>60 MINUTES VS. 70 MINUTES</b>	17.33	20.33	-3.000	2.45	3	3	1.	2
				5			22	3.
							2	0
								0
<b>65 MINUTES VS. 70 MINUTES</b>	21.33	20.33	1.000	2.45	3	3	0.	2
				5			40	3.
							73	0
								0

d. Temperature 69°C

Two-way ANOVA of temperature 69 with different incubation times in band intensity and dLAMP product

Table Analyzed	Temperature 69°C band intensity and dLAMP product yield				
Two-way ANOVA	Ordinary				
Alpha	0.05				
Source of Variation	% of total variation	P valu e	P value summary	Significa nt?	
Interaction	7.147	0.00 08	***	Yes	
Row Factor	85.69	<0.0 001	****	Yes	
Column Factor	1.620	0.01 41	*	Yes	
ANOVA table	SS	DF	MS	F (DFn, DFd)	P value
Interaction	117.8	5	23.56	F (5, 24) = 6.191	P=0. 0008
Row Factor	1412	5	282.5	F (5, 24) = 74.23	P<0. 0001
Column Factor	26.69	1	26.69	F (1, 24) = 7.015	P=0. 0141
Residual	91.33	24	3.806		
Difference between column means					
Mean of Band intensity (%)	6.000				
Mean of dLAMP	7.722				

product yield (ng/ $\mu$ L)					
Difference between means	-1.722				
SE of difference	0.6503				
95% CI of difference	-3.064 to -0.3801				
Data summary					
Number of columns (Column Factor)	2				
Number of rows (Row Factor)	6				
Number of values	36				

Tukey multiple comparisons of temperature 69 in different incubation times in band intensity and dLAMP product

WITHIN EACH COLUMN, COMPARE ROWS (SIMPLE EFFECTS WITHIN COLUMNS)

NUMBER OF FAMILIES	2				
NUMBER OF COMPARISONS PER FAMILY	15				
ALPHA	0.05				
TUKEY'S MULTIPLE COMPARISONS TEST	Mean	95.00% CI of diff.	Below threshold?	Summary	Adjusted P Value
<b>BAND INTENSITY (%)</b>					
<b>45 MINUTES VS. 50 MINUTES</b>	0.00	-4.925 to 4.925	No	ns	>0.9999
<b>45 MINUTES VS. 55 MINUTES</b>	0.00	-5.925 to 3.925	No	ns	0.9878
<b>45 MINUTES VS. 60 MINUTES</b>	5.667	-10.59 to -0.7418	Yes	*	0.0176
<b>45 MINUTES VS. 65 MINUTES</b>	8.000	-12.92 to -3.075	Yes	***	0.0005
<b>45 MINUTES VS. 70 MINUTES</b>	13.333	-18.26 to -8.408	Yes	****	<0.0001
<b>50 MINUTES VS. 55 MINUTES</b>	0.00	-5.925 to 3.925	No	ns	0.9878
<b>50 MINUTES VS. 60 MINUTES</b>	5.667	-10.59 to -0.7418	Yes	*	0.0176
<b>50 MINUTES VS. 65 MINUTES</b>	8.000	-12.92 to -3.075	Yes	***	0.0005
<b>50 MINUTES VS. 70 MINUTES</b>	13.333	-18.26 to -8.408	Yes	****	<0.0001
<b>55 MINUTES VS. 60 MINUTES</b>	4.667	-9.592 to 0.2582	No	ns	0.0705
<b>55 MINUTES VS. 65 MINUTES</b>	7.000	-11.92 to -	Yes	**	0.0024



<b>45 MINUTES VS. 55 MINUTES</b>	1.33 3	2.333	-1.000	1.59 3	3	3	0.8 87 9 0	24 .0
<b>45 MINUTES VS. 60 MINUTES</b>	1.33 3	7.000	-5.667	1.59 3	3	3	5.0 31 0	24 .0
<b>45 MINUTES VS. 65 MINUTES</b>	1.33 3	9.333	-8.000	1.59 3	3	3	7.1 03 0	24 .0
<b>45 MINUTES VS. 70 MINUTES</b>	1.33 3	14.67	-13.33	1.59 3	3	3	11. 84 0	24 .0
<b>50 MINUTES VS. 55 MINUTES</b>	1.33 3	2.333	-1.000	1.59 3	3	3	0.8 87 9 0	24 .0
<b>50 MINUTES VS. 60 MINUTES</b>	1.33 3	7.000	-5.667	1.59 3	3	3	5.0 31 0	24 .0
<b>50 MINUTES VS. 65 MINUTES</b>	1.33 3	9.333	-8.000	1.59 3	3	3	7.1 03 0	24 .0
<b>50 MINUTES VS. 70 MINUTES</b>	1.33 3	14.67	-13.33	1.59 3	3	3	11. 84 0	24 .0
<b>55 MINUTES VS. 60 MINUTES</b>	2.33 3	7.000	-4.667	1.59 3	3	3	4.1 43 0	24 .0
<b>55 MINUTES VS. 65 MINUTES</b>	2.33 3	9.333	-7.000	1.59 3	3	3	6.2 15 0	24 .0
<b>55 MINUTES VS. 70 MINUTES</b>	2.33 3	14.67	-12.33	1.59 3	3	3	10. 95 0	24 .0
<b>60 MINUTES VS. 65 MINUTES</b>	7.00 0	9.333	-2.333	1.59 3	3	3	2.0 72 0	24 .0
<b>60 MINUTES VS. 70 MINUTES</b>	7.00 0	14.67	-7.667	1.59 3	3	3	6.8 07 0	24 .0
<b>65 MINUTES VS. 70 MINUTES</b>	9.33 3	14.67	-5.333	1.59 3	3	3	4.7 35 0	24 .0
<b>DLAMP PRODUCT YIELD (NG/ML)</b>								
<b>45 MINUTES VS. 50 MINUTES</b>	0.00 0	0.000	0.000	1.59 3	3	3	0.0 00 0	24 .0
<b>45 MINUTES VS. 55 MINUTES</b>	0.00 0	0.000	0.000	1.59 3	3	3	0.0 00 0	24 .0
<b>45 MINUTES VS. 60 MINUTES</b>	0.00 0	13.33	-13.33	1.59 3	3	3	11. 84 0	24 .0
<b>45 MINUTES VS. 65 MINUTES</b>	0.00 0	15.67	-15.67	1.59 3	3	3	13. 91 0	24 .0
<b>45 MINUTES VS. 70 MINUTES</b>	0.00 0	17.33	-17.33	1.59 3	3	3	15. 39 0	24 .0
<b>50 MINUTES VS. 55 MINUTES</b>	0.00 0	0.000	0.000	1.59 3	3	3	0.0 00 0	24 .0
<b>50 MINUTES VS. 60 MINUTES</b>	0.00 0	13.33	-13.33	1.59 3	3	3	11. 84 0	24 .0



<b>50 MINUTES VS. 65 MINUTES</b>	0.00 0	15.67	-15.67	1.59 3	3	3	13.91	24.00
<b>50 MINUTES VS. 70 MINUTES</b>	0.00 0	17.33	-17.33	1.59 3	3	3	15.39	24.00
<b>55 MINUTES VS. 60 MINUTES</b>	0.00 0	13.33	-13.33	1.59 3	3	3	11.84	24.00
<b>55 MINUTES VS. 65 MINUTES</b>	0.00 0	15.67	-15.67	1.59 3	3	3	13.91	24.00
<b>55 MINUTES VS. 70 MINUTES</b>	0.00 0	17.33	-17.33	1.59 3	3	3	15.39	24.00
<b>60 MINUTES VS. 65 MINUTES</b>	13.3 3	15.67	-2.333	1.59 3	3	3	2.72	24.00
<b>60 MINUTES VS. 70 MINUTES</b>	13.3 3	17.33	-4.000	1.59 3	3	3	3.51	24.00
<b>65 MINUTES VS. 70 MINUTES</b>	15.6 7	17.33	-1.667	1.59 3	3	3	1.80	24.00

e. Temperature 71°C

Two-way ANOVA of temperature 71 with different incubation times in band intensity and dLAMP product

Table Analyzed	Temperature 71°C band intensity and dLAMP product yield				
Two-way ANOVA	Ordinary				
Alpha	0.05				
Source of Variation	% of total variation	P val ue	P value summar y	Significa nt?	
Interaction	0.2837	0.9 678	ns	No	
Row Factor	1.531	0.4 766	ns	No	
Column Factor	92.76	<0. 000 1	****	Yes	
ANOVA table	SS (Type III)	DF	MS	F (DFn, DFd)	P valu e
Interaction	3.014	5	0.6027	F (5, 16) = 0.1759	P=0. 967 8
Row Factor	16.27	5	3.253	F (5, 16)	P=0.

				= 0.9493	476 6
Column Factor	985.5	1	985.5	F (1, 16) = 287.6	P<0. 000 1
Residual	54.83	16	3.427		
Difference between column means					
Predicted (LS) mean of Band intensity (%)	1.500				
Predicted (LS) mean of dLAMP product yield (ng/μL)	13.58				
Difference between predicted means	-12.08				
SE of difference	0.7125				
95% CI of difference	-13.59 to -10.57				
Data summary					
Number of columns (Column Factor)	2				
Number of rows (Row Factor)	6				
Number of values	28				

Tukey multiple comparisons of temperature 71 in different incubation times in band intensity and dLAMP product

**WITHIN EACH COLUMN,  
COMPARE ROWS (SIMPLE  
EFFECTS WITHIN COLUMNS)**

<b>NUMBER OF FAMILIES</b>	2				
<b>NUMBER OF COMPARISONS PER FAMILY</b>	15				
<b>ALPHA</b>	0.05				
<b>TUKEY'S MULTIPLE COMPARISONS TEST</b>	Predicted (LS) mean diff.	95.00% CI of diff.	Below threshold?	Summary	Adjusted P Value
<b>BAND INTENSITY (%)</b>					
<b>45 MINUTES VS. 50 MINUTES</b>	-0.5000	-6.465 to 5.465	No	ns	0.9998
<b>45 MINUTES VS. 55 MINUTES</b>	0.000	-5.965 to 5.965	No	ns	>0.9999
<b>45 MINUTES VS. 60 MINUTES</b>	0.000	-5.965 to 5.965	No	ns	>0.9999
<b>45 MINUTES VS. 65 MINUTES</b>	0.000	-5.965 to 5.965	No	ns	>0.9999
<b>45 MINUTES VS. 70 MINUTES</b>	-2.500	-8.465 to 3.465	No	ns	0.7540
<b>50 MINUTES VS. 55 MINUTES</b>	0.5000	-5.465 to 6.465	No	ns	0.9998
<b>50 MINUTES VS. 60 MINUTES</b>	0.5000	-5.465 to 6.465	No	ns	0.9998
<b>50 MINUTES VS. 65 MINUTES</b>	0.5000	-5.465 to 6.465	No	ns	0.9998

<b>50 MINUTES VS. 70 MINUTES</b>	-2.000	-7.965 to 3.965	No	ns	0.8821			
<b>55 MINUTES VS. 60 MINUTES</b>	0.000	-5.965 to 5.965	No	ns	>0.999 9			
<b>55 MINUTES VS. 65 MINUTES</b>	0.000	-5.965 to 5.965	No	ns	>0.999 9			
<b>55 MINUTES VS. 70 MINUTES</b>	-2.500	-8.465 to 3.465	No	ns	0.7540			
<b>60 MINUTES VS. 65 MINUTES</b>	0.000	-5.965 to 5.965	No	ns	>0.999 9			
<b>60 MINUTES VS. 70 MINUTES</b>	-2.500	-8.465 to 3.465	No	ns	0.7540			
<b>65 MINUTES VS. 70 MINUTES</b>	-2.500	-8.465 to 3.465	No	ns	0.7540			
<b>DLAMP PRODUCT YIELD (NG/ML)</b>								
<b>45 MINUTES VS. 50 MINUTES</b>	0.5000	-4.945 to 5.945	No	ns	0.9996			
<b>45 MINUTES VS. 55 MINUTES</b>	0.8333	-4.612 to 6.279	No	ns	0.9957			
<b>45 MINUTES VS. 60 MINUTES</b>	0.5000	-4.945 to 5.945	No	ns	0.9996			
<b>45 MINUTES VS. 65 MINUTES</b>	-0.8333	-6.279 to 4.612	No	ns	0.9957			
<b>45 MINUTES VS. 70 MINUTES</b>	-1.500	-7.465 to 4.465	No	ns	0.9614			
<b>50 MINUTES VS. 55 MINUTES</b>	0.3333	-4.537 to 5.204	No	ns	>0.999 9			
<b>50 MINUTES VS. 60 MINUTES</b>	0.000	-4.870 to 4.870	No	ns	>0.999 9			
<b>50 MINUTES VS. 65 MINUTES</b>	-1.333	-6.204 to 3.537	No	ns	0.9455			
<b>50 MINUTES VS. 70 MINUTES</b>	-2.000	-7.445 to 3.445	No	ns	0.8383			
<b>55 MINUTES VS. 60 MINUTES</b>	-0.3333	-5.204 to 4.537	No	ns	>0.999 9			
<b>55 MINUTES VS. 65 MINUTES</b>	-1.667	-6.537 to 3.204	No	ns	0.8733			
<b>55 MINUTES VS. 70 MINUTES</b>	-2.333	-7.779 to 3.112	No	ns	0.7374			
<b>60 MINUTES VS. 65 MINUTES</b>	-1.333	-6.204 to 3.537	No	ns	0.9455			
<b>60 MINUTES VS. 70 MINUTES</b>	-2.000	-7.445 to 3.445	No	ns	0.8383			
<b>65 MINUTES VS. 70 MINUTES</b>	-0.6667	-6.112 to 4.779	No	ns	0.9985			
<b>TEST DETAILS</b>								
	Predicted (LS) mean 1	Predicted (LS) mean 2	Predicted (LS) mean diff.	SE of diff.	N1	N 2	q	D F
<b>BAND INTENSITY (%)</b>								
<b>45 MINUTES VS. 50 MINUTES</b>	1.000	1.500	-0.5000	1.85 1	2	2	0. 38 20	1 6. 0 0
<b>45 MINUTES VS. 55 MINUTES</b>	1.000	1.000	0.000	1.85 1	2	2	0. 00 0	1 6. 0 0
<b>45 MINUTES VS. 60 MINUTES</b>	1.000	1.000	0.000	1.85 1	2	2	0. 00 0	1 6. 0 0
<b>45 MINUTES VS. 65 MINUTES</b>	1.000	1.000	0.000	1.85 1	2	2	0. 00 0	1 6. 0 0



<b>45 MINUTES VS. 70 MINUTES</b>	13.50	15.00	-1.500	1.85 1	2	2	1.	1
							14	6.
							6	0
							0	0
<b>50 MINUTES VS. 55 MINUTES</b>	13.00	12.67	0.3333	1.51 2	3	3	0.	1
							31	6.
							19	0
							0	0
<b>50 MINUTES VS. 60 MINUTES</b>	13.00	13.00	0.000	1.51 2	3	3	0.	1
							00	6.
							0	0
							0	0
<b>50 MINUTES VS. 65 MINUTES</b>	13.00	14.33	-1.333	1.51 2	3	3	1.	1
							24	6.
							7	0
							0	0
<b>50 MINUTES VS. 70 MINUTES</b>	13.00	15.00	-2.000	1.69 0	3	2	1.	1
							67	6.
							4	0
							0	0
<b>55 MINUTES VS. 60 MINUTES</b>	12.67	13.00	-0.3333	1.51 2	3	3	0.	1
							31	6.
							19	0
							0	0
<b>55 MINUTES VS. 65 MINUTES</b>	12.67	14.33	-1.667	1.51 2	3	3	1.	1
							55	6.
							9	0
							0	0
<b>55 MINUTES VS. 70 MINUTES</b>	12.67	15.00	-2.333	1.69 0	3	2	1.	1
							95	6.
							3	0
							0	0
<b>60 MINUTES VS. 65 MINUTES</b>	13.00	14.33	-1.333	1.51 2	3	3	1.	1
							24	6.
							7	0
							0	0
<b>60 MINUTES VS. 70 MINUTES</b>	13.00	15.00	-2.000	1.69 0	3	2	1.	1
							67	6.
							4	0
							0	0
<b>65 MINUTES VS. 70 MINUTES</b>	14.33	15.00	-0.6667	1.69 0	3	2	0.	1
							55	6.
							79	0
							0	0

## 2. Two-way ANOVA on MgSO<sub>4</sub> and HNB concentration di dLAMP

### Two-way ANAVA on MgSO<sub>4</sub> and HNB concentration in dLAMP

Table Analyzed	UVVIS				
Two-way ANOVA	Ordinary				
Alpha	0.05				
Source of Variation	% of total variation	P value	P value summary	Significant ?	
Interaction	10.19	<0.001	****	Yes	
Row Factor	81.74	<0.001	****	Yes	
Column Factor	6.576	<0.0	****	Yes	

		001			
ANOVA table	SS	DF	MS	F (DFn, DFd)	P value
Interaction	0.001731	8	0.0002164	F (8, 30) = 25.43	P<0.001
Row Factor	0.01389	2	0.006946	F (2, 30) = 816.1	P<0.001
Column Factor	0.001118	4	0.0002794	F (4, 30) = 32.83	P<0.001
Residual	0.0002553	30	8.511e-006		
Data summary					
Number of columns (Column Factor)	5				
Number of rows (Row Factor)	3				
Number of values	45				

Tukey test for multiple comparison in MgSO<sub>4</sub> and HNB concentration in dLAMP  
**COMPARE CELL MEANS  
REGARDLESS OF ROWS AND  
COLUMNS**

NUMBER OF FAMILIES	1				
NUMBER OF COMPARISONS PER FAMILY	105				
ALPHA	0.05				
TUKEY'S MULTIPLE COMPARISONS TEST	Mean Diff.	95.00% CI of diff.	Below threshold?	Summary	Adjusted P Value
HNB (80 MM):MGSO4 3.5 MMOL VS. HNB (80 MM):MGSO4 4.5 MMOL	-0.01000	-0.01878 to -0.001222	Yes	*	0.0144
HNB (80 MM):MGSO4 3.5 MMOL VS. HNB (80 MM):MGSO4 5.5 MMOL	0.007667	-0.001111 to 0.01644	No	ns	0.1378
HNB (80 MM):MGSO4 3.5 MMOL VS. HNB (80 MM):MGSO4 6.5 MMOL	-0.01900	-0.02778 to -0.01022	Yes	****	<0.0001
HNB (80 MM):MGSO4 3.5 MMOL VS. HNB (80 MM):MGSO4 7.5 MMOL	0.02367	-0.03244 to -0.01489	Yes	****	<0.0001
HNB (80 MM):MGSO4 3.5 MMOL VS. HNB (120 MM):MGSO4 3.5 MMOL	0.03067	-0.03944 to -0.02189	Yes	****	<0.0001
HNB (80 MM):MGSO4 3.5 MMOL VS. HNB (120 MM):MGSO4 4.5 MMOL	0.02300	-0.03178 to -0.01422	Yes	****	<0.0001
HNB (80 MM):MGSO4 3.5 MMOL VS. HNB (120 MM):MGSO4 5.5 MMOL	0.03533	-0.04411 to -0.02656	Yes	****	<0.0001
HNB (80 MM):MGSO4 3.5 MMOL VS. HNB (120 MM):MGSO4 6.5 MMOL	0.04200	-0.05078 to -0.03322	Yes	****	<0.0001
HNB (80 MM):MGSO4 3.5 MMOL VS. HNB (120 MM):MGSO4 7.5 MMOL	0.02933	-0.03811 to -0.02056	Yes	****	<0.0001
HNB (80 MM):MGSO4 3.5 MMOL VS. HNB (160 MM):MGSO4 3.5 MMOL	0.052	-0.06111 to -0.04356	Yes	****	<0.0001

	33				
HNB (80 MM):MGSO4 3.5 MMOL VS. HNB (160 MM):MGSO4 4.5 MMOL	- 0.055	-0.06411 to -0.04656	Yes	****	<0.0001
	33				
HNB (80 MM):MGSO4 3.5 MMOL VS. HNB (160 MM):MGSO4 5.5 MMOL	- 0.047	-0.05644 to -0.03889	Yes	****	<0.0001
	67				
HNB (80 MM):MGSO4 3.5 MMOL VS. HNB (160 MM):MGSO4 6.5 MMOL	- 0.057	-0.06578 to -0.04822	Yes	****	<0.0001
	00				
HNB (80 MM):MGSO4 3.5 MMOL VS. HNB (160 MM):MGSO4 7.5 MMOL	- 0.047	-0.05644 to -0.03889	Yes	****	<0.0001
	67				
HNB (80 MM):MGSO4 4.5 MMOL VS. HNB (80 MM):MGSO4 5.5 MMOL	0.017	0.008889 to 0.02644	Yes	****	<0.0001
HNB (80 MM):MGSO4 4.5 MMOL VS. HNB (80 MM):MGSO4 6.5 MMOL	- 0.009	-0.01778 to -0.0002222	Yes	*	0.0402
	000				
HNB (80 MM):MGSO4 4.5 MMOL VS. HNB (80 MM):MGSO4 7.5 MMOL	- 0.013	-0.02244 to -0.004889	Yes	***	0.0002
	67				
HNB (80 MM):MGSO4 4.5 MMOL VS. HNB (120 MM):MGSO4 3.5 MMOL	- 0.020	-0.02944 to -0.01189	Yes	****	<0.0001
	67				
HNB (80 MM):MGSO4 4.5 MMOL VS. HNB (120 MM):MGSO4 4.5 MMOL	- 0.013	-0.02178 to -0.004222	Yes	***	0.0005
	00				
HNB (80 MM):MGSO4 4.5 MMOL VS. HNB (120 MM):MGSO4 5.5 MMOL	- 0.025	-0.03411 to -0.01656	Yes	****	<0.0001
	33				
HNB (80 MM):MGSO4 4.5 MMOL VS. HNB (120 MM):MGSO4 6.5 MMOL	- 0.032	-0.04078 to -0.02322	Yes	****	<0.0001
	00				
HNB (80 MM):MGSO4 4.5 MMOL VS. HNB (120 MM):MGSO4 7.5 MMOL	- 0.019	-0.02811 to -0.01056	Yes	****	<0.0001
	33				
HNB (80 MM):MGSO4 4.5 MMOL VS. HNB (160 MM):MGSO4 3.5 MMOL	- 0.042	-0.05111 to -0.03356	Yes	****	<0.0001
	33				
HNB (80 MM):MGSO4 4.5 MMOL VS. HNB (160 MM):MGSO4 4.5 MMOL	- 0.045	-0.05411 to -0.03656	Yes	****	<0.0001
	33				
HNB (80 MM):MGSO4 4.5 MMOL VS. HNB (160 MM):MGSO4 5.5 MMOL	- 0.037	-0.04644 to -0.02889	Yes	****	<0.0001
	67				
HNB (80 MM):MGSO4 4.5 MMOL VS. HNB (160 MM):MGSO4 6.5 MMOL	- 0.047	-0.05578 to -0.03822	Yes	****	<0.0001
	00				
HNB (80 MM):MGSO4 4.5 MMOL VS. HNB (160 MM):MGSO4 7.5 MMOL	- 0.037	-0.04644 to -0.02889	Yes	****	<0.0001
	67				
HNB (80 MM):MGSO4 5.5 MMOL VS. HNB (80 MM):MGSO4 6.5 MMOL	- 0.026	-0.03544 to -0.01789	Yes	****	<0.0001
	67				
HNB (80 MM):MGSO4 5.5 MMOL VS. HNB (80 MM):MGSO4 7.5 MMOL	- 0.031	-0.04011 to -0.02256	Yes	****	<0.0001
	33				
HNB (80 MM):MGSO4 5.5 MMOL VS. HNB (120 MM):MGSO4 3.5 MMOL	- 0.038	-0.04711 to -0.02956	Yes	****	<0.0001
	33				
HNB (80 MM):MGSO4 5.5 MMOL VS. HNB (120 MM):MGSO4 4.5 MMOL	- 0.030	-0.03944 to -0.02189	Yes	****	<0.0001
	67				

HNB (80 MM):MGSO4 5.5 MMOL VS. HNB (120 MM):MGSO4 5.5 MMOL	- 0.043 00	-0.05178 to -0.03422	Yes	****	<0.0001
HNB (80 MM):MGSO4 5.5 MMOL VS. HNB (120 MM):MGSO4 6.5 MMOL	- 0.049 67	-0.05844 to -0.04089	Yes	****	<0.0001
HNB (80 MM):MGSO4 5.5 MMOL VS. HNB (120 MM):MGSO4 7.5 MMOL	- 0.037 00	-0.04578 to -0.02822	Yes	****	<0.0001
HNB (80 MM):MGSO4 5.5 MMOL VS. HNB (160 MM):MGSO4 3.5 MMOL	- 0.060 00	-0.06878 to -0.05122	Yes	****	<0.0001
HNB (80 MM):MGSO4 5.5 MMOL VS. HNB (160 MM):MGSO4 4.5 MMOL	- 0.063 00	-0.07178 to -0.05422	Yes	****	<0.0001
HNB (80 MM):MGSO4 5.5 MMOL VS. HNB (160 MM):MGSO4 5.5 MMOL	- 0.055 33	-0.06411 to -0.04656	Yes	****	<0.0001
HNB (80 MM):MGSO4 5.5 MMOL VS. HNB (160 MM):MGSO4 6.5 MMOL	- 0.064 67	-0.07344 to -0.05589	Yes	****	<0.0001
HNB (80 MM):MGSO4 5.5 MMOL VS. HNB (160 MM):MGSO4 7.5 MMOL	- 0.055 33	-0.06411 to -0.04656	Yes	****	<0.0001
HNB (80 MM):MGSO4 6.5 MMOL VS. HNB (80 MM):MGSO4 7.5 MMOL	- 0.004 667	-0.01344 to 0.004111	No	ns	0.8053
HNB (80 MM):MGSO4 6.5 MMOL VS. HNB (120 MM):MGSO4 3.5 MMOL	- 0.011 67	-0.02044 to -0.002889	Yes	**	0.0023
HNB (80 MM):MGSO4 6.5 MMOL VS. HNB (120 MM):MGSO4 4.5 MMOL	- 0.004 000	-0.01278 to 0.004778	No	ns	0.9236
HNB (80 MM):MGSO4 6.5 MMOL VS. HNB (120 MM):MGSO4 5.5 MMOL	- 0.016 33	-0.02511 to -0.007556	Yes	****	<0.0001
HNB (80 MM):MGSO4 6.5 MMOL VS. HNB (120 MM):MGSO4 6.5 MMOL	- 0.023 00	-0.03178 to -0.01422	Yes	****	<0.0001
HNB (80 MM):MGSO4 6.5 MMOL VS. HNB (120 MM):MGSO4 7.5 MMOL	- 0.010 33	-0.01911 to -0.001556	Yes	*	0.0101
HNB (80 MM):MGSO4 6.5 MMOL VS. HNB (160 MM):MGSO4 3.5 MMOL	- 0.033 33	-0.04211 to -0.02456	Yes	****	<0.0001
HNB (80 MM):MGSO4 6.5 MMOL VS. HNB (160 MM):MGSO4 4.5 MMOL	- 0.036 33	-0.04511 to -0.02756	Yes	****	<0.0001
HNB (80 MM):MGSO4 6.5 MMOL VS. HNB (160 MM):MGSO4 5.5 MMOL	- 0.028 67	-0.03744 to -0.01989	Yes	****	<0.0001
HNB (80 MM):MGSO4 6.5 MMOL VS. HNB (160 MM):MGSO4 6.5 MMOL	- 0.038 00	-0.04678 to -0.02922	Yes	****	<0.0001
HNB (80 MM):MGSO4 6.5 MMOL VS. HNB (160 MM):MGSO4 7.5 MMOL	- 0.028 67	-0.03744 to -0.01989	Yes	****	<0.0001
HNB (80 MM):MGSO4 7.5 MMOL VS. HNB (120 MM):MGSO4 3.5 MMOL	- 0.007 000	-0.01578 to 0.001778	No	ns	0.2352
HNB (80 MM):MGSO4 7.5 MMOL VS. HNB (120 MM):MGSO4 4.5 MMOL	0.000 6667	-0.008111 to 0.009444	No	ns	>0.9999
HNB (80 MM):MGSO4 7.5 MMOL VS. HNB (80 MM):MGSO4 7.5 MMOL VS.	-	-0.02044 to	Yes	**	0.0023



HNB (120 MM):MGSO4 5.5 MMOL	0.011	-0.002889			
	67				
HNB (80 MM):MGSO4 7.5 MMOL VS. HNB (120 MM):MGSO4 6.5 MMOL	-	-0.02711 to	Yes	****	<0.0001
	0.018	-0.009556			
	33				
HNB (80 MM):MGSO4 7.5 MMOL VS. HNB (120 MM):MGSO4 7.5 MMOL	-	-0.01444 to	No	ns	0.5465
	0.005	0.003111			
	667				
HNB (80 MM):MGSO4 7.5 MMOL VS. HNB (160 MM):MGSO4 3.5 MMOL	-	-0.03744 to	Yes	****	<0.0001
	0.028	-0.01989			
	67				
HNB (80 MM):MGSO4 7.5 MMOL VS. HNB (160 MM):MGSO4 4.5 MMOL	-	-0.04044 to	Yes	****	<0.0001
	0.031	-0.02289			
	67				
HNB (80 MM):MGSO4 7.5 MMOL VS. HNB (160 MM):MGSO4 5.5 MMOL	-	-0.03278 to	Yes	****	<0.0001
	0.024	-0.01522			
	00				
HNB (80 MM):MGSO4 7.5 MMOL VS. HNB (160 MM):MGSO4 6.5 MMOL	-	-0.04211 to	Yes	****	<0.0001
	0.033	-0.02456			
	33				
HNB (80 MM):MGSO4 7.5 MMOL VS. HNB (160 MM):MGSO4 7.5 MMOL	-	-0.03278 to	Yes	****	<0.0001
	0.024	-0.01522			
	00				
HNB (120 MM):MGSO4 3.5 MMOL VS. HNB (120 MM):MGSO4 4.5 MMOL	0.007	-0.001111	No	ns	0.1378
	667	to 0.01644			
HNB (120 MM):MGSO4 3.5 MMOL VS. HNB (120 MM):MGSO4 5.5 MMOL	-	-0.01344 to	No	ns	0.8053
	0.004	0.004111			
	667				
HNB (120 MM):MGSO4 3.5 MMOL VS. HNB (120 MM):MGSO4 6.5 MMOL	-	-0.02011 to	Yes	**	0.0034
	0.011	-0.002556			
	33				
HNB (120 MM):MGSO4 3.5 MMOL VS. HNB (120 MM):MGSO4 7.5 MMOL	0.001	-0.007444	No	ns	>0.9999
	333	to 0.01011			
HNB (120 MM):MGSO4 3.5 MMOL VS. HNB (160 MM):MGSO4 3.5 MMOL	-	-0.03044 to	Yes	****	<0.0001
	0.021	-0.01289			
	67				
HNB (120 MM):MGSO4 3.5 MMOL VS. HNB (160 MM):MGSO4 4.5 MMOL	-	-0.03344 to	Yes	****	<0.0001
	0.024	-0.01589			
	67				
HNB (120 MM):MGSO4 3.5 MMOL VS. HNB (160 MM):MGSO4 5.5 MMOL	-	-0.02578 to	Yes	****	<0.0001
	0.017	-0.008222			
	00				
HNB (120 MM):MGSO4 3.5 MMOL VS. HNB (160 MM):MGSO4 6.5 MMOL	-	-0.03511 to	Yes	****	<0.0001
	0.026	-0.01756			
	33				
HNB (120 MM):MGSO4 3.5 MMOL VS. HNB (160 MM):MGSO4 7.5 MMOL	-	-0.02578 to	Yes	****	<0.0001
	0.017	-0.008222			
	00				
HNB (120 MM):MGSO4 4.5 MMOL VS. HNB (120 MM):MGSO4 5.5 MMOL	-	-0.02111 to	Yes	**	0.0011
	0.012	-0.003556			
	33				
HNB (120 MM):MGSO4 4.5 MMOL VS. HNB (120 MM):MGSO4 6.5 MMOL	-	-0.02778 to	Yes	****	<0.0001
	0.019	-0.01022			
	00				
HNB (120 MM):MGSO4 4.5 MMOL VS. HNB (120 MM):MGSO4 7.5 MMOL	-	-0.01511 to	No	ns	0.3740
	0.006	0.002444			
	333				
HNB (120 MM):MGSO4 4.5 MMOL VS. HNB (160 MM):MGSO4 3.5 MMOL	-	-0.03811 to	Yes	****	<0.0001
	0.029	-0.02056			
	33				
HNB (120 MM):MGSO4 4.5 MMOL	-	-0.04111 to	Yes	****	<0.0001

VS. HNB (160 MM):MGSO4 4.5 MMOL	0.032	-0.02356			
HNB (120 MM):MGSO4 4.5 MMOL	33				
VS. HNB (160 MM):MGSO4 5.5 MMOL	-	-0.03344 to	Yes	****	<0.0001
HNB (120 MM):MGSO4 4.5 MMOL	0.024	-0.01589			
VS. HNB (160 MM):MGSO4 6.5 MMOL	67				
HNB (120 MM):MGSO4 4.5 MMOL	-	-0.04278 to	Yes	****	<0.0001
VS. HNB (160 MM):MGSO4 6.5 MMOL	0.034	-0.02522			
HNB (120 MM):MGSO4 4.5 MMOL	00				
VS. HNB (160 MM):MGSO4 7.5 MMOL	-	-0.03344 to	Yes	****	<0.0001
HNB (120 MM):MGSO4 4.5 MMOL	0.024	-0.01589			
VS. HNB (120 MM):MGSO4 6.5 MMOL	67				
HNB (120 MM):MGSO4 5.5 MMOL	-	-0.01544 to	No	ns	0.2995
VS. HNB (120 MM):MGSO4 6.5 MMOL	0.006	0.002111			
HNB (120 MM):MGSO4 5.5 MMOL	667				
VS. HNB (120 MM):MGSO4 7.5 MMOL	0.006	-0.002778 to	No	ns	0.4572
HNB (120 MM):MGSO4 5.5 MMOL	000	to 0.01478			
VS. HNB (160 MM):MGSO4 3.5 MMOL	-	-0.02578 to	Yes	****	<0.0001
HNB (120 MM):MGSO4 5.5 MMOL	0.017	-0.008222			
VS. HNB (160 MM):MGSO4 4.5 MMOL	00				
HNB (120 MM):MGSO4 5.5 MMOL	-	-0.02878 to	Yes	****	<0.0001
VS. HNB (160 MM):MGSO4 4.5 MMOL	0.020	-0.01122			
HNB (120 MM):MGSO4 5.5 MMOL	00				
VS. HNB (160 MM):MGSO4 5.5 MMOL	-	-0.02111 to	Yes	**	0.0011
HNB (120 MM):MGSO4 5.5 MMOL	0.012	-0.003556			
VS. HNB (160 MM):MGSO4 6.5 MMOL	33				
HNB (120 MM):MGSO4 5.5 MMOL	-	-0.03044 to	Yes	****	<0.0001
VS. HNB (160 MM):MGSO4 6.5 MMOL	0.021	-0.01289			
HNB (120 MM):MGSO4 5.5 MMOL	67				
VS. HNB (160 MM):MGSO4 7.5 MMOL	-	-0.02111 to	Yes	**	0.0011
HNB (120 MM):MGSO4 5.5 MMOL	0.012	-0.003556			
VS. HNB (160 MM):MGSO4 7.5 MMOL	33				
HNB (120 MM):MGSO4 6.5 MMOL	0.012	0.003889 to	Yes	***	0.0008
VS. HNB (120 MM):MGSO4 7.5 MMOL	67	0.02144			
HNB (120 MM):MGSO4 6.5 MMOL	-	-0.01911 to	Yes	*	0.0101
VS. HNB (160 MM):MGSO4 3.5 MMOL	0.010	-0.001556			
HNB (120 MM):MGSO4 6.5 MMOL	33				
VS. HNB (160 MM):MGSO4 4.5 MMOL	-	-0.02211 to	Yes	***	0.0004
HNB (120 MM):MGSO4 6.5 MMOL	0.013	-0.004556			
VS. HNB (160 MM):MGSO4 5.5 MMOL	33				
HNB (120 MM):MGSO4 6.5 MMOL	-	-0.01444 to	No	ns	0.5465
VS. HNB (160 MM):MGSO4 5.5 MMOL	0.005	0.003111			
HNB (120 MM):MGSO4 6.5 MMOL	667				
VS. HNB (160 MM):MGSO4 6.5 MMOL	-	-0.02378 to	Yes	****	<0.0001
HNB (120 MM):MGSO4 6.5 MMOL	0.015	-0.006222			
VS. HNB (160 MM):MGSO4 7.5 MMOL	00				
HNB (120 MM):MGSO4 6.5 MMOL	-	-0.01444 to	No	ns	0.5465
VS. HNB (160 MM):MGSO4 7.5 MMOL	0.005	0.003111			
HNB (120 MM):MGSO4 7.5 MMOL	667				
VS. HNB (160 MM):MGSO4 3.5 MMOL	-	-0.03178 to	Yes	****	<0.0001
HNB (120 MM):MGSO4 7.5 MMOL	0.023	-0.01422			
VS. HNB (160 MM):MGSO4 4.5 MMOL	00				
HNB (120 MM):MGSO4 7.5 MMOL	-	-0.03478 to	Yes	****	<0.0001
VS. HNB (160 MM):MGSO4 4.5 MMOL	0.026	-0.01722			
HNB (120 MM):MGSO4 7.5 MMOL	00				
VS. HNB (160 MM):MGSO4 5.5 MMOL	-	-0.02711 to	Yes	****	<0.0001
HNB (120 MM):MGSO4 7.5 MMOL	0.018	-0.009556			
VS. HNB (160 MM):MGSO4 6.5 MMOL	33				
HNB (120 MM):MGSO4 7.5 MMOL	-	-0.03644 to	Yes	****	<0.0001
VS. HNB (160 MM):MGSO4 6.5 MMOL	0.027	-0.01889			
HNB (120 MM):MGSO4 7.5 MMOL	67				
VS. HNB (160 MM):MGSO4 7.5 MMOL	-	-0.02711 to	Yes	****	<0.0001

VS. HNB (160 MM):MGSO4 7.5 MMOL	0.01833	-0.009556						
HNB (160 MM):MGSO4 3.5 MMOL VS. HNB (160 MM):MGSO4 4.5 MMOL	0.003000	-0.01178 to 0.005778	No	ns			0.9925	
HNB (160 MM):MGSO4 3.5 MMOL VS. HNB (160 MM):MGSO4 5.5 MMOL	0.004667	-0.004111 to 0.01344	No	ns			0.8053	
HNB (160 MM):MGSO4 3.5 MMOL VS. HNB (160 MM):MGSO4 6.5 MMOL	0.004667	-0.01344 to 0.004111	No	ns			0.8053	
HNB (160 MM):MGSO4 3.5 MMOL VS. HNB (160 MM):MGSO4 7.5 MMOL	0.004667	-0.004111 to 0.01344	No	ns			0.8053	
HNB (160 MM):MGSO4 4.5 MMOL VS. HNB (160 MM):MGSO4 5.5 MMOL	0.007667	-0.001111 to 0.01644	No	ns			0.1378	
HNB (160 MM):MGSO4 4.5 MMOL VS. HNB (160 MM):MGSO4 6.5 MMOL	0.001667	-0.01044 to 0.007111	No	ns			>0.9999	
HNB (160 MM):MGSO4 4.5 MMOL VS. HNB (160 MM):MGSO4 7.5 MMOL	0.007667	-0.001111 to 0.01644	No	ns			0.1378	
HNB (160 MM):MGSO4 5.5 MMOL VS. HNB (160 MM):MGSO4 6.5 MMOL	0.009333	-0.01811 to -0.0005555	Yes	*			0.0288	
HNB (160 MM):MGSO4 5.5 MMOL VS. HNB (160 MM):MGSO4 7.5 MMOL	0.000	-0.008778 to 0.008778	No	ns			>0.9999	
HNB (160 MM):MGSO4 6.5 MMOL VS. HNB (160 MM):MGSO4 7.5 MMOL	0.009333	0.0005555 to 0.01811	Yes	*			0.0288	
<b>TEST DETAILS</b>	Mea n 1	Mean 2	Mean Diff.	SE of diff.	N1	N 2	q	D F
HNB (80 MM):MGSO4 3.5 MMOL VS. HNB (80 MM):MGSO4 4.5 MMOL	0.06333	0.07333	-0.01000	0.002382	3	3	5.937	30.0
HNB (80 MM):MGSO4 3.5 MMOL VS. HNB (80 MM):MGSO4 5.5 MMOL	0.06333	0.05567	0.007667	0.002382	3	3	4.552	30.0
HNB (80 MM):MGSO4 3.5 MMOL VS. HNB (80 MM):MGSO4 6.5 MMOL	0.06333	0.08233	-0.01900	0.002382	3	3	11.28	30.0
HNB (80 MM):MGSO4 3.5 MMOL VS. HNB (80 MM):MGSO4 7.5 MMOL	0.06333	0.08700	-0.02367	0.002382	3	3	14.05	30.0
HNB (80 MM):MGSO4 3.5 MMOL VS. HNB (120 MM):MGSO4 3.5 MMOL	0.06333	0.09400	-0.03067	0.002382	3	3	18.21	30.0
HNB (80 MM):MGSO4 3.5 MMOL VS. HNB (120 MM):MGSO4 4.5 MMOL	0.06333	0.08633	-0.02300	0.002382	3	3	13.66	30.0
HNB (80 MM):MGSO4 3.5 MMOL VS. HNB (120 MM):MGSO4 5.5 MMOL	0.06333	0.09867	-0.03533	0.002382	3	3	20.98	30.0
HNB (80 MM):MGSO4 3.5 MMOL VS. HNB (120 MM):MGSO4 6.5 MMOL	0.06333	0.1053	-0.04200	0.002382	3	3	24.94	30.0
HNB (80 MM):MGSO4 3.5 MMOL VS. HNB (120 MM):MGSO4 7.5 MMOL	0.06333	0.09267	-0.02933	0.002382	3	3	17.42	30.0
HNB (80 MM):MGSO4 3.5 MMOL VS.	0.063	0.1157	-	0.00	3	3	31.	30

HNB (160 MM):MGSO4 3.5 MMOL	33	0.05233	2382			07	.0
							0
HNB (80 MM):MGSO4 3.5 MMOL VS. HNB (160 MM):MGSO4 4.5 MMOL	0.063 33	0.1187	- 0.00 0.05533 2382	3	3	32. 85	30 .0
							0
HNB (80 MM):MGSO4 3.5 MMOL VS. HNB (160 MM):MGSO4 5.5 MMOL	0.063 33	0.1110	- 0.00 0.04767 2382	3	3	28. 30	30 .0
							0
HNB (80 MM):MGSO4 3.5 MMOL VS. HNB (160 MM):MGSO4 6.5 MMOL	0.063 33	0.1203	- 0.00 0.05700 2382	3	3	33. 84	30 .0
							0
HNB (80 MM):MGSO4 3.5 MMOL VS. HNB (160 MM):MGSO4 7.5 MMOL	0.063 33	0.1110	- 0.00 0.04767 2382	3	3	28. 30	30 .0
							0
HNB (80 MM):MGSO4 4.5 MMOL VS. HNB (80 MM):MGSO4 5.5 MMOL	0.073 33	0.05567	0.01767 0.00 2382	3	3	10. 49	30 .0
							0
HNB (80 MM):MGSO4 4.5 MMOL VS. HNB (80 MM):MGSO4 6.5 MMOL	0.073 33	0.08233	- 0.00 0.00900 2382	3	3	5.3 43	30 .0
			0				0
HNB (80 MM):MGSO4 4.5 MMOL VS. HNB (80 MM):MGSO4 7.5 MMOL	0.073 33	0.08700	- 0.00 0.01367 2382	3	3	8.1 14	30 .0
							0
HNB (80 MM):MGSO4 4.5 MMOL VS. HNB (120 MM):MGSO4 3.5 MMOL	0.073 33	0.09400	- 0.00 0.02067 2382	3	3	12. 27	30 .0
							0
HNB (80 MM):MGSO4 4.5 MMOL VS. HNB (120 MM):MGSO4 4.5 MMOL	0.073 33	0.08633	- 0.00 0.01300 2382	3	3	7.7 18	30 .0
							0
HNB (80 MM):MGSO4 4.5 MMOL VS. HNB (120 MM):MGSO4 5.5 MMOL	0.073 33	0.09867	- 0.00 0.02533 2382	3	3	15. 04	30 .0
							0
HNB (80 MM):MGSO4 4.5 MMOL VS. HNB (120 MM):MGSO4 6.5 MMOL	0.073 33	0.1053	- 0.00 0.03200 2382	3	3	19. 00	30 .0
							0
HNB (80 MM):MGSO4 4.5 MMOL VS. HNB (120 MM):MGSO4 7.5 MMOL	0.073 33	0.09267	- 0.00 0.01933 2382	3	3	11. 48	30 .0
							0
HNB (80 MM):MGSO4 4.5 MMOL VS. HNB (160 MM):MGSO4 3.5 MMOL	0.073 33	0.1157	- 0.00 0.04233 2382	3	3	25. 13	30 .0
							0
HNB (80 MM):MGSO4 4.5 MMOL VS. HNB (160 MM):MGSO4 4.5 MMOL	0.073 33	0.1187	- 0.00 0.04533 2382	3	3	26. 91	30 .0
							0
HNB (80 MM):MGSO4 4.5 MMOL VS. HNB (160 MM):MGSO4 5.5 MMOL	0.073 33	0.1110	- 0.00 0.03767 2382	3	3	22. 36	30 .0
							0
HNB (80 MM):MGSO4 4.5 MMOL VS. HNB (160 MM):MGSO4 6.5 MMOL	0.073 33	0.1203	- 0.00 0.04700 2382	3	3	27. 90	30 .0
							0
HNB (80 MM):MGSO4 4.5 MMOL VS. HNB (160 MM):MGSO4 7.5 MMOL	0.073 33	0.1110	- 0.00 0.03767 2382	3	3	22. 36	30 .0
							0
HNB (80 MM):MGSO4 5.5 MMOL VS. HNB (80 MM):MGSO4 6.5 MMOL	0.055 67	0.08233	- 0.00 0.02667 2382	3	3	15. 83	30 .0
							0
HNB (80 MM):MGSO4 5.5 MMOL VS. HNB (80 MM):MGSO4 7.5 MMOL	0.055 67	0.08700	- 0.00 0.03133 2382	3	3	18. 60	30 .0
							0
HNB (80 MM):MGSO4 5.5 MMOL VS. HNB (120 MM):MGSO4 3.5 MMOL	0.055 67	0.09400	- 0.00 0.03833 2382	3	3	22. 76	30 .0
							0
HNB (80 MM):MGSO4 5.5 MMOL VS.	0.055	0.08633	- 0.00	3	3	18.	30

HNB (120 MM):MGSO4 4.5 MMOL	67		0.03067	2382			21	.0
								0
HNB (80 MM):MGSO4 5.5 MMOL VS. HNB (120 MM):MGSO4 5.5 MMOL	0.055 67	0.09867	- 0.04300	0.00 2382	3	3	25. 53	30 .0
								0
HNB (80 MM):MGSO4 5.5 MMOL VS. HNB (120 MM):MGSO4 6.5 MMOL	0.055 67	0.1053	- 0.04967	0.00 2382	3	3	29. 49	30 .0
								0
HNB (80 MM):MGSO4 5.5 MMOL VS. HNB (120 MM):MGSO4 7.5 MMOL	0.055 67	0.09267	- 0.03700	0.00 2382	3	3	21. 97	30 .0
								0
HNB (80 MM):MGSO4 5.5 MMOL VS. HNB (160 MM):MGSO4 3.5 MMOL	0.055 67	0.1157	- 0.06000	0.00 2382	3	3	35. 62	30 .0
								0
HNB (80 MM):MGSO4 5.5 MMOL VS. HNB (160 MM):MGSO4 4.5 MMOL	0.055 67	0.1187	- 0.06300	0.00 2382	3	3	37. 40	30 .0
								0
HNB (80 MM):MGSO4 5.5 MMOL VS. HNB (160 MM):MGSO4 5.5 MMOL	0.055 67	0.1110	- 0.05533	0.00 2382	3	3	32. 85	30 .0
								0
HNB (80 MM):MGSO4 5.5 MMOL VS. HNB (160 MM):MGSO4 6.5 MMOL	0.055 67	0.1203	- 0.06467	0.00 2382	3	3	38. 39	30 .0
								0
HNB (80 MM):MGSO4 5.5 MMOL VS. HNB (160 MM):MGSO4 7.5 MMOL	0.055 67	0.1110	- 0.05533	0.00 2382	3	3	32. 85	30 .0
								0
HNB (80 MM):MGSO4 6.5 MMOL VS. HNB (80 MM):MGSO4 7.5 MMOL	0.082 33	0.08700	- 0.00466	0.00 2382	3	3	2.7 71	30 .0
								0
HNB (80 MM):MGSO4 6.5 MMOL VS. HNB (120 MM):MGSO4 3.5 MMOL	0.082 33	0.09400	- 0.01167	0.00 2382	3	3	6.9 27	30 .0
								0
HNB (80 MM):MGSO4 6.5 MMOL VS. HNB (120 MM):MGSO4 4.5 MMOL	0.082 33	0.08633	- 0.00400	0.00 2382	3	3	2.3 75	30 .0
								0
HNB (80 MM):MGSO4 6.5 MMOL VS. HNB (120 MM):MGSO4 5.5 MMOL	0.082 33	0.09867	- 0.01633	0.00 2382	3	3	9.6 97	30 .0
								0
HNB (80 MM):MGSO4 6.5 MMOL VS. HNB (120 MM):MGSO4 6.5 MMOL	0.082 33	0.1053	- 0.02300	0.00 2382	3	3	13. 66	30 .0
								0
HNB (80 MM):MGSO4 6.5 MMOL VS. HNB (120 MM):MGSO4 7.5 MMOL	0.082 33	0.09267	- 0.01033	0.00 2382	3	3	6.1 35	30 .0
								0
HNB (80 MM):MGSO4 6.5 MMOL VS. HNB (160 MM):MGSO4 3.5 MMOL	0.082 33	0.1157	- 0.03333	0.00 2382	3	3	19. 79	30 .0
								0
HNB (80 MM):MGSO4 6.5 MMOL VS. HNB (160 MM):MGSO4 4.5 MMOL	0.082 33	0.1187	- 0.03633	0.00 2382	3	3	21. 57	30 .0
								0
HNB (80 MM):MGSO4 6.5 MMOL VS. HNB (160 MM):MGSO4 5.5 MMOL	0.082 33	0.1110	- 0.02867	0.00 2382	3	3	17. 02	30 .0
								0
HNB (80 MM):MGSO4 6.5 MMOL VS. HNB (160 MM):MGSO4 6.5 MMOL	0.082 33	0.1203	- 0.03800	0.00 2382	3	3	22. 56	30 .0
								0
HNB (80 MM):MGSO4 6.5 MMOL VS. HNB (160 MM):MGSO4 7.5 MMOL	0.082 33	0.1110	- 0.02867	0.00 2382	3	3	17. 02	30 .0
								0
HNB (80 MM):MGSO4 7.5 MMOL VS. HNB (120 MM):MGSO4 3.5 MMOL	0.087 00	0.09400	- 0.00700	0.00 2382	3	3	4.1 56	30 .0
								0
HNB (80 MM):MGSO4 7.5 MMOL VS.	0.087	0.08633	0.00066	0.00	3	3	0.3	30

HNB (120 MM):MGSO4 4.5 MMOL	00		67	2382			95	.0
							8	0
HNB (80 MM):MGSO4 7.5 MMOL VS. HNB (120 MM):MGSO4 5.5 MMOL	0.087 00	0.09867	- 0.01167	0.00 2382	3	3	6.9	30 .0
							27	0
HNB (80 MM):MGSO4 7.5 MMOL VS. HNB (120 MM):MGSO4 6.5 MMOL	0.087 00	0.1053	- 0.01833	0.00 2382	3	3	10.	30 .0
							88	0
HNB (80 MM):MGSO4 7.5 MMOL VS. HNB (120 MM):MGSO4 7.5 MMOL	0.087 00	0.09267	- 0.00566	0.00 2382	3	3	3.3	30 .0
			7				64	0
HNB (80 MM):MGSO4 7.5 MMOL VS. HNB (160 MM):MGSO4 3.5 MMOL	0.087 00	0.1157	- 0.02867	0.00 2382	3	3	17.	30 .0
							02	0
HNB (80 MM):MGSO4 7.5 MMOL VS. HNB (160 MM):MGSO4 4.5 MMOL	0.087 00	0.1187	- 0.03167	0.00 2382	3	3	18.	30 .0
							80	0
HNB (80 MM):MGSO4 7.5 MMOL VS. HNB (160 MM):MGSO4 5.5 MMOL	0.087 00	0.1110	- 0.02400	0.00 2382	3	3	14.	30 .0
							25	0
HNB (80 MM):MGSO4 7.5 MMOL VS. HNB (160 MM):MGSO4 6.5 MMOL	0.087 00	0.1203	- 0.03333	0.00 2382	3	3	19.	30 .0
							79	0
HNB (80 MM):MGSO4 7.5 MMOL VS. HNB (160 MM):MGSO4 7.5 MMOL	0.087 00	0.1110	- 0.02400	0.00 2382	3	3	14.	30 .0
							25	0
HNB (120 MM):MGSO4 3.5 MMOL VS. HNB (120 MM):MGSO4 4.5 MMOL	0.094 00	0.08633	0.00766 7	0.00 2382	3	3	4.5	30 .0
							52	0
HNB (120 MM):MGSO4 3.5 MMOL VS. HNB (120 MM):MGSO4 5.5 MMOL	0.094 00	0.09867	- 0.00466	0.00 2382	3	3	2.7	30 .0
			7				71	0
HNB (120 MM):MGSO4 3.5 MMOL VS. HNB (120 MM):MGSO4 6.5 MMOL	0.094 00	0.1053	- 0.01133	0.00 2382	3	3	6.7	30 .0
							29	0
HNB (120 MM):MGSO4 3.5 MMOL VS. HNB (120 MM):MGSO4 7.5 MMOL	0.094 00	0.09267	0.00133 3	0.00 2382	3	3	0.7	30 .0
							91	0
HNB (120 MM):MGSO4 3.5 MMOL VS. HNB (160 MM):MGSO4 3.5 MMOL	0.094 00	0.1157	- 0.02167	0.00 2382	3	3	12.	30 .0
							86	0
HNB (120 MM):MGSO4 3.5 MMOL VS. HNB (160 MM):MGSO4 4.5 MMOL	0.094 00	0.1187	- 0.02467	0.00 2382	3	3	14.	30 .0
							64	0
HNB (120 MM):MGSO4 3.5 MMOL VS. HNB (160 MM):MGSO4 5.5 MMOL	0.094 00	0.1110	- 0.01700	0.00 2382	3	3	10.	30 .0
							09	0
HNB (120 MM):MGSO4 3.5 MMOL VS. HNB (160 MM):MGSO4 6.5 MMOL	0.094 00	0.1203	- 0.02633	0.00 2382	3	3	15.	30 .0
							63	0
HNB (120 MM):MGSO4 3.5 MMOL VS. HNB (160 MM):MGSO4 7.5 MMOL	0.094 00	0.1110	- 0.01700	0.00 2382	3	3	10.	30 .0
							09	0
HNB (120 MM):MGSO4 4.5 MMOL VS. HNB (120 MM):MGSO4 5.5 MMOL	0.086 33	0.09867	- 0.01233	0.00 2382	3	3	7.3	30 .0
							22	0
HNB (120 MM):MGSO4 4.5 MMOL VS. HNB (120 MM):MGSO4 6.5 MMOL	0.086 33	0.1053	- 0.01900	0.00 2382	3	3	11.	30 .0
							28	0
HNB (120 MM):MGSO4 4.5 MMOL VS. HNB (120 MM):MGSO4 7.5 MMOL	0.086 33	0.09267	- 0.00633	0.00 2382	3	3	3.7	30 .0
			3				60	0
HNB (120 MM):MGSO4 4.5 MMOL	0.086	0.1157	-	0.00	3	3	17.	30

VS. HNB (160 MM):MGSO4 3.5 MMOL	33		0.02933	2382			42	.0
HNB (120 MM):MGSO4 4.5 MMOL	0.086	0.1187	-	0.00	3	3	19.	30
VS. HNB (160 MM):MGSO4 4.5 MMOL	33		0.03233	2382			20	.0
HNB (120 MM):MGSO4 4.5 MMOL	0.086	0.1110	-	0.00	3	3	14.	30
VS. HNB (160 MM):MGSO4 5.5 MMOL	33		0.02467	2382			64	.0
HNB (120 MM):MGSO4 4.5 MMOL	0.086	0.1203	-	0.00	3	3	20.	30
VS. HNB (160 MM):MGSO4 6.5 MMOL	33		0.03400	2382			19	.0
HNB (120 MM):MGSO4 4.5 MMOL	0.086	0.1110	-	0.00	3	3	14.	30
VS. HNB (160 MM):MGSO4 7.5 MMOL	33		0.02467	2382			64	.0
HNB (120 MM):MGSO4 5.5 MMOL	0.098	0.1053	-	0.00	3	3	3.9	30
VS. HNB (120 MM):MGSO4 6.5 MMOL	67		0.00666	2382			58	.0
HNB (120 MM):MGSO4 5.5 MMOL	0.098	0.09267	0.00600	0.00	3	3	3.5	30
VS. HNB (120 MM):MGSO4 7.5 MMOL	67		0	2382			62	.0
HNB (120 MM):MGSO4 5.5 MMOL	0.098	0.1157	-	0.00	3	3	10.	30
VS. HNB (160 MM):MGSO4 3.5 MMOL	67		0.01700	2382			09	.0
HNB (120 MM):MGSO4 5.5 MMOL	0.098	0.1187	-	0.00	3	3	11.	30
VS. HNB (160 MM):MGSO4 4.5 MMOL	67		0.02000	2382			87	.0
HNB (120 MM):MGSO4 5.5 MMOL	0.098	0.1110	-	0.00	3	3	7.3	30
VS. HNB (160 MM):MGSO4 5.5 MMOL	67		0.01233	2382			22	.0
HNB (120 MM):MGSO4 5.5 MMOL	0.098	0.1203	-	0.00	3	3	12.	30
VS. HNB (160 MM):MGSO4 6.5 MMOL	67		0.02167	2382			86	.0
HNB (120 MM):MGSO4 5.5 MMOL	0.098	0.1110	-	0.00	3	3	7.3	30
VS. HNB (160 MM):MGSO4 7.5 MMOL	67		0.01233	2382			22	.0
HNB (120 MM):MGSO4 6.5 MMOL	0.105	0.09267	0.01267	0.00	3	3	7.5	30
VS. HNB (120 MM):MGSO4 7.5 MMOL	3			2382			20	.0
HNB (120 MM):MGSO4 6.5 MMOL	0.105	0.1157	-	0.00	3	3	6.1	30
VS. HNB (160 MM):MGSO4 3.5 MMOL	3		0.01033	2382			35	.0
HNB (120 MM):MGSO4 6.5 MMOL	0.105	0.1187	-	0.00	3	3	7.9	30
VS. HNB (160 MM):MGSO4 4.5 MMOL	3		0.01333	2382			16	.0
HNB (120 MM):MGSO4 6.5 MMOL	0.105	0.1110	-	0.00	3	3	3.3	30
VS. HNB (160 MM):MGSO4 5.5 MMOL	3		0.00566	2382			64	.0
HNB (120 MM):MGSO4 6.5 MMOL	0.105	0.1203	-	0.00	3	3	8.9	30
VS. HNB (160 MM):MGSO4 6.5 MMOL	3		0.01500	2382			06	.0
HNB (120 MM):MGSO4 6.5 MMOL	0.105	0.1110	-	0.00	3	3	3.3	30
VS. HNB (160 MM):MGSO4 7.5 MMOL	3		0.00566	2382			64	.0
HNB (120 MM):MGSO4 7.5 MMOL	0.092	0.1157	-	0.00	3	3	13.	30
VS. HNB (160 MM):MGSO4 3.5 MMOL	67		0.02300	2382			66	.0
HNB (120 MM):MGSO4 7.5 MMOL	0.092	0.1187	-	0.00	3	3	15.	30
VS. HNB (160 MM):MGSO4 4.5 MMOL	67		0.02600	2382			44	.0
HNB (120 MM):MGSO4 7.5 MMOL	0.092	0.1110	-	0.00	3	3	10.	30
VS. HNB (160 MM):MGSO4 5.5 MMOL	67		0.01833	2382			88	.0
HNB (120 MM):MGSO4 7.5 MMOL	0.092	0.1203	-	0.00	3	3	16.	30

VS. HNB (160 MM):MGSO4 6.5 MMOL	67		0.02767	2382			43	.0
HNB (120 MM):MGSO4 7.5 MMOL	0.092	0.1110	-	0.00	3	3	10.	30
VS. HNB (160 MM):MGSO4 7.5 MMOL	67		0.01833	2382			88	.0
HNB (160 MM):MGSO4 3.5 MMOL	0.115	0.1187	-	0.00	3	3	1.7	30
VS. HNB (160 MM):MGSO4 4.5 MMOL	7		0.00300	2382			81	.0
HNB (160 MM):MGSO4 3.5 MMOL	0.115	0.1110	0.00466	0.00	3	3	2.7	30
VS. HNB (160 MM):MGSO4 5.5 MMOL	7		7	2382			71	.0
HNB (160 MM):MGSO4 3.5 MMOL	0.115	0.1203	-	0.00	3	3	2.7	30
VS. HNB (160 MM):MGSO4 6.5 MMOL	7		0.00466	2382			71	.0
HNB (160 MM):MGSO4 3.5 MMOL	0.115	0.1110	0.00466	0.00	3	3	2.7	30
VS. HNB (160 MM):MGSO4 7.5 MMOL	7		7	2382			71	.0
HNB (160 MM):MGSO4 4.5 MMOL	0.118	0.1110	0.00766	0.00	3	3	4.5	30
VS. HNB (160 MM):MGSO4 5.5 MMOL	7		7	2382			52	.0
HNB (160 MM):MGSO4 4.5 MMOL	0.118	0.1203	-	0.00	3	3	0.9	30
VS. HNB (160 MM):MGSO4 6.5 MMOL	7		0.00166	2382			89	.0
HNB (160 MM):MGSO4 4.5 MMOL	0.118	0.1110	0.00766	0.00	3	3	4.5	30
VS. HNB (160 MM):MGSO4 7.5 MMOL	7		7	2382			52	.0
HNB (160 MM):MGSO4 5.5 MMOL	0.111	0.1203	-	0.00	3	3	5.5	30
VS. HNB (160 MM):MGSO4 6.5 MMOL	0		0.00933	2382			41	.0
HNB (160 MM):MGSO4 5.5 MMOL	0.111	0.1110	0.000	0.00	3	3	0.0	30
VS. HNB (160 MM):MGSO4 7.5 MMOL	0			2382			00	.0
HNB (160 MM):MGSO4 6.5 MMOL	0.120	0.1110						0
VS. HNB (160 MM):MGSO4 7.5 MMOL	3							0



C. List of clinical bacterial

List of *Escherichia coli* clinical bacteria harboring NDM gene

<b>Iso No.</b>	<b>Hospital</b>	<b>Organism</b>	<b>MLST</b>	<b>NGS Carbapenemase</b>	<b>NGS blaOXA</b>
<b>V417</b>	Phetchabul	Escherichia coli	410	NDM-1	blaOXA-1
<b>C015</b>	Sakon Nakhon	Escherichia coli	410	NDM-5	blaOXA-1
<b>C032</b>	Sakon Nakhon	Escherichia coli	361	NDM-5	none
<b>C049</b>	Udonthani	Escherichia coli	354	NDM-1	none
<b>C098</b>	Surin	Escherichia coli	48	NDM-1, OXA-232	blaOXA-1
<b>C150</b>	Mae Sot	Escherichia coli	448	NDM-7	none
<b>C153</b>	Mae Sot	Escherichia coli	448	NDM-7	none
<b>C155</b>	Suratthani	Escherichia coli	448	NDM-4	blaOXA-1
<b>C176</b>	Suratthani	Escherichia coli	1340	OXA-181,hugA	none
<b>C787B</b>	Surin	Escherichia coli	410	OXA-232	none
<b>C161</b>	Suratthani	Escherichia coli	410	OXA-181	blaOXA-1
<b>C179B</b>	Suratthani	Escherichia coli	448	NDM-4	blaOXA-1
<b>C214</b>	Suratthani	Escherichia coli	410	OXA-484	none
<b>C163</b>	Suratthani	Escherichia coli	410	NDM-1,OXA-181	blaOXA-1
<b>C149</b>	Surin	Escherichia coli	2144	NDM-1	none
<b>C168B</b>	Suratthani	Escherichia coli	410	OXA-181	blaOXA-1
<b>C497</b>	Surin	Escherichia coli	88	NDM-1	none
<b>C163</b>	Suratthani	Escherichia coli	410	NDM-1,OXA-181	blaOXA-1

## List of Klebsiella pneumoniae clinical bacterial

<b>Iso No.</b>	<b>Hospital</b>	<b>Specimen</b>	<b>KmerIden</b>	<b>ML ST</b>	<b>NGS Carbapenemase</b>	<b>NGS blaOXA</b>
<b>C001</b>	Sakon Nakhon	Abdomen	Klebsiella pneumoniae	<b>147</b>	NDM-1	blaOXA-1, blaOXA-9
<b>C002</b>	Sakon Nakhon	Sputum	Klebsiella pneumoniae	<b>340</b>	OXA-181	blaOXA-1
<b>C003</b>	Sakon Nakhon	Sputum	Klebsiella pneumoniae	<b>147</b>	NDM-1	blaOXA-1, blaOXA-9
<b>49</b>	C049	Udonthani	Escherichia coli	<b>354</b>	blaCTX-M-24, blaCTX-M-55	none
<b>C009</b>	Sakon Nakhon	Stump	Klebsiella pneumoniae	<b>336</b>	NDM-1	blaOXA-1
<b>C038</b>	Sakon Nakhon	pleural fluid	Klebsiella pneumoniae	<b>340</b>	OXA-181	blaOXA-1
<b>C074</b>	Sakon Nakhon	Urine	Klebsiella pneumoniae	<b>147</b>	NDM-1, OXA-181	blaOXA-1, blaOXA-9
<b>C045</b>	Udonthani	Blood	Klebsiella pneumoniae	<b>231</b>	NDM-1	none
<b>C054</b>	Udonthani	Sputum	Klebsiella pneumoniae	<b>15</b>	none	none
<b>C063</b>	Udonthani	Urine	Klebsiella pneumoniae	<b>1089</b>	NDM-5	none
<b>C073</b>	Sakon Nakhon	Sputum	Klebsiella pneumoniae	<b>16</b>	NDM-1, OXA-232	blaOXA-9
<b>C120</b>	Sakon Nakhon	Urine	Klebsiella pneumoniae	<b>340</b>	OXA-181	blaOXA-1
<b>C138</b>	Surin	Sputum	Klebsiella pneumoniae	<b>16</b>	NDM-1, OXA-232	blaOXA-9
<b>C143</b>	Surin	Sputum	Klebsiella pneumoniae	<b>231</b>	OXA-232	none
<b>C101</b>	Surin	pus	Klebsiella pneumoniae	<b>147</b>	NDM-1	none

## VITA

**NAME** Nindi Syahputri Lubis

**DATE OF BIRTH** 5 August 1996

**PLACE OF BIRTH** Medan, Indonesia

**INSTITUTIONS ATTENDED** Universitas Negeri Medan (State University of Medan)

**HOME ADDRESS** Charu Mueang Rd, Pathum Wan, Bangkok, Thailand, 10330

**AWARD RECEIVED** Asean-Non Asean Scholarship



จุฬาลงกรณ์มหาวิทยาลัย  
CHULALONGKORN UNIVERSITY